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 Literature Review: Molecular Chaperones; Regulation of signaling proteins in cells
Christian Antifsen and his colleagues concluded that “no special genetic 
information is required for the proper folding of the (protein) molecule and for the 
formation of ‘correct’ disulfide bonds” (1). The native conformation of a protein is 
postulated to be its most stable structure thermodynamically with the information 
specifying the structure coming from its primary amino acid sequences (1). A major 
driving force of folding non-native or intermediate polypeptides is the collapse of 
hydrophobic amino acid side chains away from an aqueous environment to form a 
hydrophobic molten globule core (2). 
For over a decade, the area of protein folding research has focused on 
understanding the function of the cell’s folding machinery in such processes as, the 
regulation of protein conformation and function, protein trafficking and degradation, and  
on the molecular basis of amyloid diseases [reviewed in (3-7)].  The cell’s folding or
chaperone machinery consists of several different conserved protein families and was 
classified originally by their approximate molecular weights and the environmental or 
physiological conditions that induced their synthesis.  While previously referred to as 
heat shock proteins (Hsp) or glucose-regulated proteins (Grp), these proteins are now 
known to be constitutively expressed in cells and to play a critical role in guiding proteins 
to their correct conformations in cells (8).
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However, macromolecules inside cells encounter a highly crowded environment 
that causes excluded volume effects, which can lead to increased aggregation of proteins 
(9). Cells appear to have evolved molecular chaperones to facilitate the folding of newly 
synthesized proteins, while protecting them from aggregation, and to rescue existing 
proteins that are partially denatured by stresses, such as heat shock and oxidative stress 
(10, 11). Molecular chaperones carry out their function to ensure that correct and efficient 
folding is achieved within the highly crowded environment of a living cell (6).   Thus, the 
correct conformation of a protein is essential for its proper function and the maintenance 
of a cell’s physiology, and defects in protein folding are now known to be factors in a 
number of human diseases, such as cystic fibrosis, cancer, and neurodegenerative 
diseases including Huntington’s, Alzheimer’s, and Parkinson’s diseases, and Creutzfeldt-
Jakob disease (12).
Several of the major molecular chaperone families have been well studied over 
the last decade.  However, I will review the properties and functions of Hsp90 and its co-
chaperones, as these proteins and their targets are the focus of the research described in 
my thesis.  Components of some of the major Hsp90 co-chaperones are listed in Table 1.
Hsp90 (Heat Shock Protein 90)
Hsp90 is an abundant and ubiquitous 90 kDa protein [reviewed in (13-15)].  It is a 
highly conserved chaperone that is required for folding and regulation of numerous signal 
transduction molecules, such as steroid hormone receptors, tyrosine and serine/threonine 
protein kinases, and other proteins like nitric oxide synthase and telomerase (13-15).  
Hsp90 is known to be critical for viability of eukaryotic cells and organisms, such as 
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Caenorhabditis elegans, Drosophila, and yeast (13-15).  While Hsp90 is dispensable for 
viability in Escherichia. coli, it is essential for thermotolerance in cyanobacteria (13-15).  
Members of the Hsp90 family are expressed and function in specific subcellular 
compartments.  There are two nuclear/cytoplasmic isoforms, α and β, of Hsp90 in 
vertebrate cells, but there are apparently four isoforms of Hsp90 in Arabidopsis thaliana.  
There is also an isoform of Hsp90 targeted to the endoplasmic reticulum (Grp94: 94 kDa 
glucose-regulated protein) (16), and the mitochondria (TRAP1, type- 1 tumor necrosis 
factor receptor-associated protein; or Hsp75) (17, 18).  However, while the functions of 
Hsp90 and Grp94 have been investigated, its function in other organelles is not well 
understood.
Structure and function of Hsp90 
Both biochemical and crystallographic studies indicate that the N-terminus of 
Hsp90 contains a nucleotide-binding pocket and is the most conserved region of Hsp90 
[reviewed in (14, 19)]. The N-terminus of Hsp90 binds to the inhibitors, geldanamycin 
(GA) (Fig. 1A and Fig. 3B) and radicicol. Unrelated in function to Hsp90, bacterial DNA 
gyrase (20), the DNA repair protein MutL (21), and histidine kinases (GHKL family)  
also share four common motifs with Hsp90 for binding ATP called the “Bergerat fold” 
(22, 23).  All require ATP binding and hydrolysis to carry out their function which 
requires dynamic conformational changes.  The binding and hydrolysis of ATP by Hsp90 
is proposed to drive the opening and closing of a ‘molecular clamp’ (24).  The jaws of the 
clamp are the N-terminal domains within the Hsp90 dimer, which associate upon binding 
ATP, and thus promote closing of the clamp (24) (See Fig. 2. model of Hsp90 ATPase 
cycle). 
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Recent studies suggest that the C-terminal region of Hsp90, which contains 
sequences responsible for Hsp90 dimer formation, has a second nucleotide-binding site 
(25).  Binding of the drug, novobiocin (26) (Fig. 1B), to the C-terminal site blocks 
binding of ATP to Hsp90’s N-terminal nucleotide binding site (27).  Thus, regulation of 
Hsp90 function may be coordinated by the two nucleotide-binding sites undergoing 
dynamic conformational changes, which regulate nucleotide binding at the other site.  
However, the specific function of the second nucleotide-binding site of Hsp90 remains 
uncharacterized.  Our recent study indicates that binding of nucleotide to the C-terminal 
site causes conformational changes in Hsp90, which may lead to client release (28).
The very C-terminus of Hsp90 contains a highly conserved MEEVD motif to 
which Hsp90 co-chaperones containing tetratricopeptide repeats (TPR), such as the 
immunophilins (FKBP52, FKBP51, cyclophilin-40/Cpr6/Cpr7), Hop/Sti1, and PP5, bind 
[reviewed in (29)] (See Fig. 3C). These TPR containing co-chaperones may regulate 
Hsp90 ATPase activity.  Prodromou and co-workers (30) showed that Sti1 inhibits Hsp90 
ATPase activity by binding to Hsp90 and blocking access to the ATP-binding site in the 
N-terminal domain of Hsp90.  On the other hand, Cpr6 can reactivate Hsp90 ATPase 
activity by displacing Sti1 from Hsp90 (30).
The middle domain of Hsp90 is thought to contain one of Hsp90’s client binding 
sites (31).  A charged linker region connects the N- and the middle domain of Hsp90 (14)
(Fig. 3A).  This charged linker region is the least conserved between bacterial and 
eukaryotic Hsp90, and may play a key role in regulating chaperone function of Hsp90 by 




Figure 1. Structures of Geldanamycin (A) and Novobiocin (B).
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Figure 2. Model of Hsp90 ATPase cycle. 1.)  Hsp90 in its default conformation with its 
N- and C-terminal ATP binding sites empty (speculative).  2.)  Hsp90 containing ATP 
bound to its N-terminal domain and weakly bound client (C) after Hsc70/ATP-dependent 
loading of client.  3.) The conformation of Hsp90 formed following ATP- and p23-
dependent clamping of Hsp90’s N-terminal domain about bound client molecule (C).  4.) 
The high-affinity client bound conformation of Hsp90 formed following p23-stimulated 
ATP hydrolysis, which results in the opening of the C-terminal ATP binding domain 
(NB, arrow).  It is currently postulated (? by arrow) that MoO4
- stabilizes this 
conformation of Hsp90 by occupying the binding site of the γ-phosphate hydrolyzed from 
the ATP bound to the N-terminal domain of Hsp90.  It is also uncertain a what step the γ-
phosphate hydrolyzed from the ATP bound to the N-terminal domain is released.  5.)  
Hsp90 containing ATP (or novobiocin) bound to its C-terminal nucleotide binding site.  
6.)  Conformation of Hsp90 formed after dissociation of nucleotide from its N-terminal 
domain, which is induced by saturation of its C-terminal nucleotide binding site with 
ATP (or novobiocin).  Novobiocin would arrest Hsp90 in this state, accounting for the 
absence of the association of p23 and Hsc70 with Hsp90 in the presence of novobiocin. 
1.) Regeneration of the default conformation of Hsp90 due to the dissociation of ATP 
from its C-terminal nucleotide-binding site.  It is uncertain whether the ATP bound to the 
C-terminal site is hydrolyzed (ATP or ADP+Pi?).  The presence of Cdc37 and TPR-
containing co-chaperones are indicated, but exact times and sites of interaction are 
generally, but not specifically, indicated to simplify the model.  The binding of Cdc37 
and Hop to Hsp90 appears to be mutually exclusive (or Cdc37).
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Figure 3.  Structural basis for the interaction of Hsp90 with nucleotides, ansamycin 
drugs, and TPR domain co-chaperones. (A) Domain organization of human Hsp90α. 
(B) Crystal structure of N-terminal domain of Hsp90 complexed with ADP and 
geldanamycin. (C) Crystal structure of the Hsp70-binding N-terminal TPR domain of 
Hop complexed with the Hsp70 C-terminal peptide (GPTIEEVD) (left) and the Hsp90 C-
terminal peptide (MEEVD) (right). Structures in the bottom panel are rotated 90° from 
the top panel. The peptides are oriented with the C-terminal carboxyl group at the bottom 
of the figure (top) and toward the viewer (bottom) [From Young et al. (14)].
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region (32).  However, a recent study suggests that both dimerization of the N-terminus 
and the association of the N-terminus with the middle domain are important for the 
efficiency of the ATPase cycle (33).  This hypothesis is supported by recent finding that  
Hsp90 co-chaperone AHA1 binds to middle domain of Hsp90 and enhances Hsp90’s 
ATPase activity (34).
Therefore, Hsp90’s function as a molecular chaperone seems to require all three 
of its domains, which interact to modulate the conformation of Hsp90 in response to ATP 
binding and hydrolysis.  Furthermore, Hsp90’s co-chaperones are also thought to 
modulate Hsp90 chaperone activity in response to stimuli. 
Hsp90 co-chaperones 
As indicated earlier, Hsp90 functions in conjunction with cofactors that are not 
client targets. These so called co-chaperones are listed in Table 1.  Here I will briefly 
explore the properties of these co-chaperones, and the current studies regarding possible 
regulation of Hsp90 by co-chaperones.
Cdc37 (p50)
Cdc37 was first identified as a 58 kDa protein product of a yeast gene, 
temperature-sensitive mutants of which arrested the cell division cycle at the 
nonpermissive temperature [reviewed in (35)].  Cdc37 is an essential protein known to be 
required for viability in yeast (36), Drosophila (37), and Caenorhabditis elegans (38). 
Recently, Cdc37 was discovered to be an Hsp90 co-chaperone that is required for 
the proper folding and function of Hsp90-dependent protein kinases, such as Raf-1 (39), 
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Table 1
    Hsp90 binding cohorts/co-chaperones. [adapted from Pratt et al. 2003 (13)]
Cohorts/Co-chaperones Properties  
P23 




       Hop
             Sti1 (yeast)
       Dpit47
Binds to form Hsp90-Hop/Sti1-Hsp70-
client complex, prior to transfer of 
client to Hsp90 heterocomplex 
Hsp90-Dpit47 complex bound to DNA 
polymerase α
Immunophilins
       FKBP52
       FKBP51
       CyP40
              Cpr6, Cpr7  (yeast) 
              Cns1            (yeast)
Bind to Steroid hormone receptor (SR)-
Hsp90 heterocomplex 
Binds to dynein
GR and v-Src signaling adversely 
affected by cpr7 null mutation, cns1 is 
essential for viability
Cdc37 (p50)
Harc ( Hsp90-associating relative of 
cdc37)




PP5 Binds Hsp90 via TPR, found in SR-
Hsp90 complexes and dynein
CHIP (C-terminus of Hsc70 interaction 
protein)
Interaction with Hsc70 causes 
proteasome-dependent degradation of 
substrate, binding to Hsp90 causes p23 
release 
UNC-45 Binds via N-terminal TPR to Hsp90 and 
via  C-terminal regions to myosin
ARA9(called XAP2 and AIP) Found in aryl hydrocarbon receptor 
(AHR)-Hsp90 heterocomplexes
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Cdk4 (40), and HRI (41).  Cdc37 is composed of three domains: an N-terminal kinase 
binding domain; a middle Hsp90-binding domain; and a C-terminal domain of unknown 
function (42). Although its precise role in regulating Hsp90 function still needs to be 
fully characterized, the binding of Cdc37 to Hsp90 inhibits Hsp90’s ATPase activity (43).  
Structural studies indicate that Cdc37 binds to the N-terminal domain of Hsp90 in its 
“relaxed” conformation, with the lid of the nucleotide-binding site open (44).  This is 
thought to be the conformation of Hsp90 that required for the binding of client targets.  
However, Cdc37 also interacts with Hsp90 in complexes containing stably bound kinase 
clients (41).   A C-terminally truncated Cdc37 mutant, which does not interact with 
Hsp90, stably binds kinase clients, and can inhibit their Hsp90-dependent folding (41).  
However, the binding of client protein to Hsp90-Cdc37 stabilizes the Hsp90-Cdc37 
complexes (45). Thus, it remains to be determined whether Cdc37 modulates the stability 
and activity of the protein kinase clients by docking them to Hsp90, or by having a direct 
action on the client molecules. 
Cdc37 may also have a chaperone function independent of Hsp90.  Cdc37 can 
stabilize denatured casein kinase II (CKII), maintaining it in a state competent for 
refolding by other chaperones (46).  Overexpression of Cdc37 in yeast can suppress the 
effects of Hsp90-deficiency (46).  In addition, a recent study indicated that mutant yeast 
containing deletion of Cdc37’s Hsp90 binding domain were viable under normal growth 
conditions (47).  Furthermore, not all endogenous Cdc37 is associated with Hsp90.
Recent studies have demonstrated that nucleotide-mediated conformational 
switching of Hsp90 regulates the capacity of Cdc37 to bind to protein kinases (41).  The 
Hsp90-inhibitor geldanamycin inhibits the ability of Cdc37 to bind the Hsp90-dependent 
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kinases, HRI and Lck, even though Cdc37 contains an independent protein kinase 
binding domain at its N-terminus (45).  However, in the case of protein kinase B (Akt) 
geldanamycin does not appear to disrupt the binding of Cdc37 to Akt, but it does shorten 
the half-life of the kinase (48).  Thus, Cdc37 appears to allosterically modulate the 
binding of Hsp90 to kinases, and acts in concert with Hsp90 to facilitate the folding and 
stabilization of protein kinases (42).
Co-chaperones containing tetratricopeptide repeat (TPR) domains
A number of Hsp90 co-chaperones, such as the immunophilins (FKBP51 and 52, 
and Cyclophilin 40), Hop (p60), and PP5, possess TPR domains. TPR domains are 
identified as degenerate consensus sequences of 34 amino acids that often are arranged in 
tandem repeat (49). These TPR domains are protein-protein interaction sites that are 
utilized to bind to the C-terminus of Hsp90, and possibly to client targets (49).
Immunophilins
The immunophilins are so named because they contain domains that bind to 
immunosuppressant drugs, such as FK506, rapamycin, and cyclosporin A.  These 
domains have peptidylprolyl isomerase (PPIase) activity, suggesting they could have 
chaperone function.  This family of co-chaperones is classified as two families: i) the 
FKBPs bind FK506 and rapamycin [as referenced by (50)], and ii) the cyclophilins 
(Cyps) bind cyclosporin A [as referenced by (50)]. These immunophilins contain 
additional TPR domains and FKBP52 contains a calmodulin-binding domain in its C-
terminal region (51, 52). 
FKBP52 was first identified as a component of Hsp90 complexes formed with 
steroid hormone receptors (SHR) [reviewed in (13, 50)].  Later, it was proposed that it 
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has a role in translocation of receptors to the nucleus (53, 54).  Expression of human 
FKBP52 in yeast, which lack genes coding for this family of proteins, increased 
glucocorticoid (GR) hormone-binding affinity and its ability to transactivate reporter 
genes, while expression of FKBP51, PP5, or Cpr7 (yeast homolog of Cyp40) did not 
(55).
Cytoplasmic FKBP52 localizes to microtubules and associates with dynein via its 
PPIase domain (56).  Binding of hormone has been shown to cause the exchange of 
FKBP51 for FKBP52, leading to the hypothesis that differential binding of TPR proteins 
to SHR complexes might be a switch regulating the subcellular trafficking of receptors 
(57).
Immunophilins may also have effects on the chaperone activity of Hsp90 that is 
required for SHR maturation and transactivation.  In vitro, FKBP52 modulates the 
ATPase activity of Hsp90 (30).  In yeast, Cpr6 (a homolog of Cyp40R) stimulates the 
ATPase activity by displacing Sti1 from Hsp90 (30). 
Protein Phosphatase 5(PP5)   
PP5 is a novel member of the serine/threonine (Ser/Thr) phosphoprotein 
phosphatase family that is expressed ubiquitously in mammalian cells (58).  PP5 is a 58 
kDa protein that is unique in that it posses three TPR motifs at its N-terminus (59).  
Polyunsaturated fatty acids, such as arachidonic acid, stimulate purified PP5 activity via 
disrupting the binding of its TPR domain to its catalytic domain, relieving its 
autoinhibition (60).  PP5 also associates with Hsp90 via its TPR domain (61).  PP5 has 
been identified in Hsp90 heterocomplexes containing SHRs (62), and HRI (21), and it 
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has been found bound to the atrial natriuretic peptide receptor, Cdc16p, and Cdc27p even 
in the absence of Hsp90 (63, 64). 
Recent studies suggest that PP5 itself can interact and regulate apoptosis signal-
regulation kinase-1 (ASK1) (65).  PP5 appears to negatively regulate the hypoxia-
induced ASK1/MKK4/JNK signaling cascade that promotes an apoptotic response (65).  
Interestingly, the C-terminal domain of Hsp90 stimulates the activity of PP5 in vitro (66). 
However, there is no evidence so far, indicating that PP5 may act to regulate Hsp90 
function.    
Hop (Hsp70-Hsp90 organizing protein, p60)
Hop was identified as a 60-kDa protein that interacted with complexes containing 
both Hsp90 and Hsp70 immunopurified from chick oviduct (as referenced by (50)).  The 
yeast homolog of Hop is the nonessential stress protein, Sti1 (67). Hop is required for the 
assembly of ‘early’ SHR-Hsp90 heterocomplexes that first contain Hsp70, and 
subsequently acts as an adaptor to link the SHR-Hsp70 complex to Hsp90 (68).  Hop 
possesses three distinct TPR domains, TPR1, TPR2A and TPR2B that allows Hop to bind 
both Hsp90 (via TPR2A) and Hsp70 (via TPR1), simultaneously (69, 70) [see Fig. 3C].  
Hop preferentially forms a complex with ADP-bound form of Hsp70, but does not affect 
Hsp70’s ATPase activity (71). On the other hand, Hop binds to ADP-bound Hsp90, and 
inhibits Hsp90’s ATPase activity in vitro (71).  Thus, Hop can modulate the function of 
Hsp90 by blocking the ATP dependent conversion of Hsp90 to a form capable of 
interacting with p23 (72).  Binding of Sti1 to Hsp90 can displace geldanamycin (GA) 
from Hsp90’s N-terminal nucleotide binding domain.  In vitro, Hop interacts with both 
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the N- and C- terminal domains of Hsp90, and inhibits the N-terminal dimerization of 
Hsp90 that is required for efficient hydrolysis of ATP (73).
p23
p23 was identified as a 23-kDa protein associated with the avian progesterone 
receptor (PR) (74) and the murine glucocorticoid receptor (GR) (75).  p23 has been 
shown to have passive chaperone activity, as it can prevent the aggregation of denatured 
protein in vitro [reviewed in(76)].  
The stable binding of p23 to Hsp90 requires hydrolysable ATP, suggesting that 
p23 function is coupled to the ATPase activity of Hsp90 (77).  Recently, p23 has been 
proposed to function in the release of Hsp90-bound client proteins (78).  Studies utilizing 
purified factors have demonstrated that p23, in conjunction with Hsp90, Hsp70, Hsp40 
and Hop, is required for the assembly of steroid receptor-Hsp90 heterocomplexes, and 
functional SHRs (79).  However, genetic studies in yeast indicate that while p23 
enhances Hsp90’s function, it is not essential for activation of Hsp90-dependent clients 
(80).  A recent study on p23 function has suggested that p23 may localize to the 
chromatin of hormone-responsive genes and facilitate the disassembly of transcriptional 
regulatory complexes (81).  
Regulation of signal transduction pathways by Hsp90
Hsp90 activity has been demonstrated to be required for the proper folding and 
function of numerous signal transduction molecules in cells.  A summary of known 
Hsp90 clients is shown in Table 2.  This review will focus on Hsp90-dependent 
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Table 2
       Identified Hsp90 clients. Bold Letter: Tested in this study. 
          Not all shown in this table adapted from (13, 82). 
Classes of Substrates Hsp90 substrates





p53, MyoD1, Heat shock factor
Mineralcorticoid receptor
Hypoxia-inducible factor-1α
Tyrosine Kinases v-Src, c-Src, Fyn
v-Fps, v-Yes, v-Fes, Frg, Hck, Lck
ErbB2, Senvenless RTK, p210bcr-abl
Wee1, Insulin receptor, Fak
Serine/Threonine Kinases HRI, Gcn2, PKR
eEF-2 kinase
MEK, MOK, c-MOS
Akt (PKB), PDK1, PI3K
Raf kinases, Casein kinase II
CDK4, CDK6, CDK9
Others Nitric oxide synthases (NOS): 
Endothelial, Neuronal, & inducible.
CFTR, ANPR, Apaf-1 
Telomerase
Hepatitis B virus reverse transcriptase
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regulation of protein kinases determined primarily through the pharmacological effects of 
Hsp90 inhibitors on their function and stability. Many signal transduction molecules 
involved in cancer progression require Hsp90 function for their maturation and/or 
stabilization.  These proteins include receptor tyrosine kinases, steroid hormone 
receptors, Src-family kinases, serine/threonine kinases, transcription factors, and cell 
cycle regulators, as summarized in Table 2.  Obviously, 
Hsp90 function is essential for cell proliferation and survival [reviewed in (10, 12-14)]. 
However, the function of many critical signal transduction molecules is altered by 
mutations, and in many cases the stability of the altered gene products have an 
exaggerated requirement for Hsp90. Thus, Hsp90 function becomes essential for these 
mutant proteins to cause the imbalance of signal transduction pathways that leads to the 
oncogenic transformation of normal cells.
For example, the receptor tyrosine kinase ErbB2 (also called Her-2/Neu) plays 
key roles in regulating cell proliferation [reviewed in (83)]. Recent studies have shown 
that overexpression or mutation of ErbB2 can cause malignancies, including ovarian 
cancer, cell carcinoma of the head and neck, glioblastoma, lung cancer, and breast cancer 
(84, 85).  ErbB2 requires Hsp90 function which is critical for its maturation, stabilization 
and regulation in signal transduction pathways (86, 87). Inhibition of Hsp90 function by 
geldanamycin (GA) or its derivative, 17allylamino-17-demethoxygeldanamycin (17-
AAG), destabilizes ErbB2 and induces proteasomal degradation of ErbB2 through its 
polyubiquitination and thus reduces tumor cell growth (86, 88). 
The Ras/Raf/Mek/MAPK signaling pathway regulates cell proliferation and 
survival by transducing cell signals from the cell surface to the transcriptional machinery 
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(89).  Dysregulation (constitutive activation) of Ras/Raf signal transduction pathways 
causes oncogenic transformation of cells, and has been identified to occur in various 
cancers (90).  Geldanamycin (GA) disrupts Raf-1-Hsp90 complexes, causes 
destabilization of Raf-1 and loss of Ras-Raf-1 association, which results in inhibition of 
Raf-1/Mek/MAPK signaling pathway (91, 92).  
PI3K/PDK/Akt signaling pathway plays central roles in cell proliferation, growth, 
and survival [reviewed in (93-96)].  Phosphatidylinositide-3-OH kinase (PI3K) and 3-
phosphoinositide-dependent kinase-1 (PDK1) are upstream signaling molecules of Akt.  
Akt regulates the phosphorylation of downstream effectors, such as GSK-3, Bad, 
Forkhead, NF-κB, mTOR, and MDM-2, that have been demonstrated to contribute to 
angiogenesis, cancers of the prostate and breast, and the hypertrophy of muscle cells 
[reviewed in (97)].  These signaling molecules are known Hsp90 clients.  Inhibition of 
Hsp90 function by geldanamycin (GA) leads to destabilization of these molecules and 
disruption of these signaling pathways (98). A recent study suggests that inhibition of 
Hsp90 binding to Akt, stimulates Akt dephosphorylation via PP2A, leading to the 
suppression of Akt’s kinase activity (99).  In ErbB2 overexpressing cancer cells, 17-AAG 
also stimulates Akt dephosphorylation prior to loss of Akt expression (98).
A recent study on Hsp90 inhibition by 17-AAG reported that Hsp90 derived from 
tumor cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from
normal cells (100).  They postulate that this higher binding affinity is due to Hsp90 being 
present in multi-chaperone client complexes with high ATPase activity in tumor cells, 
while in normal cells most of the cell’s Hsp90 appears to be in client free complexes 
(100).  This finding suggests an explanation for the observation that Hsp90 inhibitors are 
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selectively toxic to tumors cells, and why Hsp90 inhibitors appear to be efficient drugs 
for cancer treatment. 
My studies presented in the subsequent chapters will mainly focus on the function 
of Hsp90, using Hsp90 inhibitors, in particular novobiocin, to alter to Hsp90’s 
conformation, function and interaction with clients in reticulocyte lysate.  Additional 
studies examine the effect of Hsp90 inhibitors on signal transduction molecules and 
pathways in differentiating C2C12 myoblasts.
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CHAPTER II
Novobiocin induces a distinct conformation of Hsp90 and alters
                                       Hsp90-cochaperone-client interactions
Abstract
Hsp90 functions to facilitate the folding of newly synthesized and denatured 
proteins.  Hsp90 function is modulated through its interactions with co-chaperones and 
the binding and hydrolysis of ATP.  Recently, novobiocin has been shown to bind to a 
second nucleotide binding site located within the C-terminal domain of Hsp90.  In this 
report, we have examined the effect of novobiocin on Hsp90 function in reticulocyte 
lysate.  Novobiocin specifically inhibited the maturation of the heme-regulated eIF2α
kinase (HRI) in a concentration dependent manner.  Novobiocin induced the dissociation 
of Hsp90 and Cdc37 from immature HRI, while the Hsp90 co-chaperones p23, FKBP52 
and protein phosphatase 5 remained associated with immature HRI.  Proteolytic 
fingerprinting of Hsp90 indicated that novobiocin had a distinct effect on the 
conformation of Hsp90, and molybdate lowered the concentration of novobiocin required 
to alter Hsp90’s conformation by ten fold.  Recombinant C-terminal domain of Hsp90 
adopted a proteolytic resistant conformation in the presence of novobiocin, indicating that 
alteration of Hsp90/co-chaperone interactions was not the cause of the novobiocin-
induced protease resistance within Hsp90’s C-terminal domain.  The concentration 
dependence of this novobiocin-induced conformation change correlated with the 
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dissociation of Hsp90 and Cdc37 from immature HRI and novobiocin-induced inhibition 
of Hsp90/Cdc37-dependent activation of HRI’s autokinase activity.  The data suggest that 
binding of novobiocin to the C-terminal nucleotide-binding site of Hsp90 induces a 
change in Hsp90’s conformation leading to the dissociation of bound kinase.  The unique 
structure and properties of novobocin-bound Hsp90 suggests that it may represent the 
“client-release” conformation of the Hsp90 machine.
Introduction
Numerous proteins that are involved in the control of physiological processes 
within cells require the Hsp90 chaperone machine for their biogenesis and regulation 
[reviewed in (13, 82, 101, 102)]. While Hsp90 can function to facilitate the renaturation 
of misfolded proteins (103-107), it is not required for the biogenesis of most proteins 
synthesized in a cell.  Rather, Hsp90's specific clientele is primarily restricted to certain 
proteins involved in the regulation of signal transduction [reviewed in (13, 82, 101, 102)].  
Additionally, Hsp90 supports mutational drift in proteins (108, 109) that may be essential 
to the microevolution of transformed cell populations.  Thus, Hsp90’s essential function 
as a chaperone, which is required for regulation of cellular signal transduction makes it 
an attractive target for efforts to manipulate the growth and differentiation of normal and 
aberrant cell populations [reviewed in (8, 110, 111)].
Hsp90 functions through its interactions with numerous co-chaperone partners 
[reviewed in (13, 82, 101, 102)].  Some of Hsp90’s co-chaperone partners are thought to 
modulate the interaction of Hsp90 with specific families of clientele.  For example, 
Hsp90’s co-chaperone Cdc37 is required for the biogenesis of numerous Hsp90-
dependent protein kinases [reviewed in (35)].  Besides mediating the binding of Hsp90 to 
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specific client targets, Hsp90-associated co-chaperones also modulate Hsp90’s ATP-
driven reaction cycle and Hsp90’s nucleotide–modulated conformation switching.
Hsp90 binds and hydrolyzes ATP via a Bergerat fold (112, 113) within its N-terminal 
domain, which mediates global switching between at least two alternative Hsp90 
conformations [reviewed in (13, 82, 101, 102)].  The binding of ATP to Hsp90’s N-
terminus induces the N-terminal domains within the Hsp90 dimer to associate, forming a 
“molecular clamp” about its client target (24, 33, 114-116).  The Hsp90-specific inhibitor 
geldanamycin binds to this nucleotide-binding site and prevents the formation of the 
closed conformation of Hsp90 (117, 118), resulting in the destabilization of Hsp90-kinase 
complexes.  Geldanamycin, thus causes the accumulation of “intermediate” Hsp90 
complexes (119, 120) containing Hsc70 and the Hsp70-Hsp90 organizing protein 
p60/HOP (a homolog of the yeast protein, Sti1), as it prevents the progression of Hsp90 
through its ATP driven reaction cycle.  Sti1 appears to repress Hsp90’s ability to 
consume ATP (30, 73, 121), as does Cdc37 (43, 44).
The C-terminal region of Hsp90 mediates Hsp90’s stable dimerization (33, 116, 122, 
123) and contains a second nucleotide-binding site (26, 27, 124).  Novobiocin binds to 
this nucleotide-binding site and inhibits Hsp90 function (25-27).  The C-terminal region 
together with Hsp90’s middle domain mediates the interactions of Hsp90 with molybdate 
(27, 125), protein clients (126, 127) and modulates Hsp90’s ATPase activity (33, 128).  
Binding of ATP to Hsp90’s N-terminal domain is required for the second ATP site to 
become available for the binding of nucleotide (26, 27, 124), and for the ability of 
molybdate to stabilizes Hsp90-client complexes (77).  The ability of molybdate binding 
to “freeze” Hsp90’s ATPase cycle causes the accumulation of “late” Hsp90 complexes 
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containing the Hsp90 co-chaperone p23 and an assortment of other co-chaperones, such 
as Cdc37 and immunophilins (41, 77, 125, 129, 130).  Mutagenesis studies indicate that 
formation of stable complexes between p23, Hsp90 and client requires the N-terminal 
domain of Hsp90, the presence of hydrolysable ATP, and sequences within the C-
terminal domain of Hsp90 (24, 77, 114, 118, 128, 131-133).  The binding of p23 has also 
been proposed to stimulate the release of client substrate (78), and novobiocin appears to 
disrupt the interaction of p23 (26, 134) and Hsp70 (26) with Hsp90.  Thus, Hsp90 
function is regulated by a complex series of reactions that are modulated by the binding, 
hydrolysis and presumably exchange of ATP at two sites, and the interactions of Hsp90 
with co-chaperones and client target proteins.
While reports indicate that novobiocin treatment of cultured cells leads to the loss of 
Hsp90-dependent protein kinases (25), mutant p53 (25) and HIF-1α (135), and that 
novobiocin disrupts the binding of Hsp90 and Hsp70 to the glucocorticoid receptor in 
vitro (136), and the AKT kinase in cells (137), the effect of novobiocin on the interaction 
of Hsp90 with other clients and Hsp90-associated co-chaperones has yet to be studied in 
detail.  In this report, we have examined the effect of novobiocin on Hsp90-dependent 
maturation of the heme-regulated eIF2α kinase (HRI), Hsp90’s conformational switching 
and its interactions with other co-chaperone partners and HRI under quasi-physiological 
conditions in rabbit reticulocyte lysate.  The data indicate that novobiocin inhibits Hsp90
function by inhibiting Hsp90’s ATP-driven chaperone cycle at a distinct stage.  The 
properties and structure of novobiocin-bound Hsp90 distinguish this Hsp90 conformation 
from those it adopts when it is bound to geldanamycin or molybdate.
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Experimental Procedures
Analysis of the effects of novobiocin on the maturation and activation of HRI in 
rabbit reticulocyte lysate.  Untreated reticulocyte lysate was prepared by injecting New 
Zealand White rabbits with 1 mg/Kg of 1% N-acetylphenylhydrazine (w/v) in sterile 
water for 5 days.  After 4 days of recovery, blood was collected and washed four times 
with buffer containing 10 mM Hepes-KOH (pH 7.2), 134 mM NaCl, 5 mM KCl, 7.4 mM 
magnesium acetate and 5 mM glucose.  Reticulocytes were lysed in one volume of sterile 
deionized water, and lysate collected after centrifugation at 20,000 x g for 10 min.  
Normal untreated reticulocyte lysate used in maturational incubations was incubated 
under conditions for protein synthesis with or without the addition of 20 mM hemin as 
described previously (138).
[35S]-His-tagged HRI was synthesized for 30 min at 30 ºC by coupled 
transcription/translation in nuclease-treated rabbit reticulocyte lysate (TnT, Promega) as 
previously described (41, 129, 138-140).  Following inhibition of initiation by the 
addition of aurintricarboxylic acid (60 µM final), HRI was then incubated with drug for 
the times indicated in the figures, or aliquots (3 µl) of the reaction mixtures were 
transferred to untreated heme-deficient rabbit reticulocyte lysate protein synthesis 
mixtures (22 µl) containing drug or vehicle control.  Reaction mixtures were then 
incubated at 30 ºC for 65 min to determine the effects of the drugs on the maturation and 
activation (“transformation”) of HRI.
Immunoadsorption of complexes of HRI and components of the Hsp90 chaperone 
machine from rabbit reticulocyte lysate. [35S]-His-tagged HRI was synthesized as 
described above, then mixed with seven volumes of heme-deficient rabbit reticulocyte 
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lysate that was pretreated with drug or vehicle control for 5 min at 30 ºC, and further 
incubated for 60 min at 30 ºC.   Co-adsorption of Hsp90 and Cdc37 in chaperone-HRI 
heterocomplexes was analyzed by adsorption with anti-(His5) antibody (Qiagen) as 
described previously (41, 129, 138).  To analyze the effect of novobiocin on the 
interaction of HRI with other co-chaperones, HRI was synthesized and matured in the 
presence or absence of drug as described above.  Reaction mixtures were divided in half 
and incubated with mouse anti-His5 monoclonal antibody (Qiagen) for the adsorption of 
His-tagged HRI, or with mouse JJ3 anti-p23 monoclonal antibody (provided from Dr. 
David Toft), mouse EC1 anti-FKBP52 monoclonal antibody (SRA-1400, Stressgen), or 
mouse M2 anti- FLAG monoclonal antibody (Sigma).  Control reactions lacking template 
coding for His-tagged HRI (or FLAG-[35S]PP5 for experiments examining PP5 
interactions) were used as negative controls for nonspecific binding of chaperone and co-
chaperone components from reticulocyte lysate.  Unless specified in the figure legends, 
the immune pellets were washed once with PIPES buffer (10 mM, pH 7.2) containing 
150 mM NaCl with 0.5% Tween20, followed by 3 washes with PIPES buffer lacking 
Tween-20.  Samples were separated by SDS-PAGE, and analyzed by electrotransfer to 
polyvinylidene difluoride membrane (PVDF, Bio-Rad) followed by autoradiography to 
visualize [35S]-His tagged HRI or FLAG-[35S]PP5.  western blotting with polyclonal anti-
Hsp90 (41), polyclonal anti-Cdc37 (141), N27 anti-Hsp70 monoclonal (N27F3-4, 
StressGen), JJ3 anti-p23 monoclonal, F5 anti-HOP monoclonal, and EC1 anti-FKBP52 
monoclonal antibodies was used to detect chaperone components co-adsorbed with HRI 
or with basal Hsp90 complexes adsorbed from lysate using an anti-N-terminus Hsp90 
antibody (PA3-013 Affinity BioReagents).
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Analysis of the effect of novobiocin on the autokinase activity of HRI.  [35S]-His-
tagged HRI was synthesized and matured in heme-deficient reticulocyte lysate as 
described above.  After immunoadsorption of His-tagged HRI, its autokinase activity was 
assayed by incubation of the immune pellet in buffer containing 5 µCi of [γ-32P]-ATP 
(PerkinElmer) and 2 mM unlabeled ATP for 5 min at 30º C in the presence or absence of 
novobiocin, as described previously (138, 142).  Autophosphorylation of HRI was 
quantified by scanning densitometry of the autoradiogram screened to eliminate 35S-
emmissions. The band intensity of the [32P]-HRI was expressed as optical density 
(Ο.D.×mm2).
Proteolytic fingerprinting of Hsp90.  TnT reticulocyte lysate was incubated under 
conditions for protein synthesis in the absence of plasmid at 30 ºC in the presence of drug 
or vehicle control for 10 min.  For sequential drug treatments, the second drug was 
applied after the first 5 min of incubation.  Reaction mixtures were then chilled on ice 
and digested with the indicated amount of trypsin at the concentrations indicated in the 
figure legend as described previously (125).  Samples were separated by SDS-PAGE and 
western blotted using antibodies specific to the N-terminus of Hsp90 (PA3-013 Affinity 
BioReagents), or the C-terminus of Hsp90 (AC88: kindly provided by Dr. David Toft) 
(125).
To estimate the Hill coefficient for novobiocin binding, the intensity of the 78 
kDa band generated upon incubation of untreated lysate with 24 µg/ml of trypsin and 
detected by western blotting with the antibody specific for the N-terminus of Hsp90 was 
assume to represent 0% occupancy of Hsp90’s novobiocin binding sites.  The change in 
intensity of the 78 kDa with varying concentrations of novobiocin was used to estimate 
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the fraction of novobiocin-bound versus free Hsp90 from which the Hill plot was 
constructed.
Purification and proteolytic fingerprinting of the C-terminal domain of Hsp90 
(HSP90-CT).  To express Hsp90's C-terminal nucleotide-binding domain, a PCR product 
encoding amino acids Q531 to D732 of human Hsp90α was amplified using primers that 
included exogenous sequences to facilitate subcloning, and this PCR product was ligated 
into pQE32 (Qiagen).  The resultant gene product thus included human Hsp90α residues 
Q531-D732 fused to an N-terminal tag (MRGSHHHHHHGIRM) derived from the vector 
and linker sequences.  This gene product was purified to apparent homogeneity from E. 
coli lysates using metal-ion affinity chromatography on nickel affinity resin (Qiagen), 
wherein recombinant Hsp90 gene product was eluted from this resin with imidazole.  
After elution, peak fractions were pooled and dialyzed against 100 mM ammonium 
bicarbonate, 1 mM DTT.  After dialysis, aliquots were lyophilized and stored in liquid 
nitrogen until further use.
Purified Hsp90-CT was dissolved with 100 µl (~0.4 µg/ml) of 20 mM Tris HCl 
pH 7.4.  Aliquots of Hsp90-CT (10 µl) were used for each fingerprint assay.  Each 
sample was incubated on ice for 30 min with drug at the concentration indicated in the 
figure legend.  Each sample was digested for 6 min on ice with 25 µl of assay buffer (10 
mM Tris HCl pH 7.4, 150 mM NaCl, 4 mM CaCl2, 0.1 mM EDTA) containing trypsin at 
the concentrations indicated in the figure legend.  Reactions were terminated with boiling 
SDS sample buffer, and analyzed by SDS-PAGE and western blotting with the AC88 
antibody which detects an epitope in the C-terminus of Hsp90 (AC88).
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Results
Effect of novobiocin on the interaction of Hsc70 and p23 with Hsp90.  Hsp90 
function is modulated through its interaction with other co-chaperones.  Consistent with 
results reported by Marcu and coworkers (25), novobiocin reduced the amount of Hsc70 
and p23 co-immunoadsorbed with Hsp90 from reticulocyte lysate in a concentration 
dependent manner (Fig. 4A).  While the concentration required to reduce the interaction 
of Hsc70 and p23 with Hsp90 was somewhat higher than those reported by Marcu et al
(25), these results confirm the ability of novobiocin to alter Hsp90’s default interactions 
with its co-chaperone partners.
Effect of novobiocin on the maturation and activation of HRI.  The maturation and 
activation of HRI in heme-deficient reticulocyte lysate (HRI “transformation”) requires 
its interaction with Hsp90 and its co-chaperone Cdc37 (41, 138).  Under normal 
conditions in reticulocyte lysate, Hsp90 and Cdc37 form a high-affinity complex with 
protein kinases after their release from the ribosome that is stable in the presence of high 
salt (41, 141).  Geldanamycin inhibits Hsp90-facilitated transformation of newly 
synthesized HRI in reticulocyte lysate (41, 138), prevents the formation of salt-stabile 
high-affinity complexes between Hsp90 and HRI, and blocks the incorporation of Cdc37 
into complexes formed between Hsp90 and newly synthesized HRI (41, 141). On the 
other hand, molybdate in the presence of ATP, “freezes” Hsp90-client complexes, 
renders Hsp90-client complexes stable to washing with high salt, but also blocks the 
transformation of HRI (41, 141).  Therefore, we investigated whether novobiocin had the 
capacity to inhibit the ability of Hsp90 to facilitate the transformation of newly
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Figure 4. Effect of novobiocin on protein folding and Hsp90/co-chaperone 
interactions in rabbit reticuocyte lysate.  (A) Nuclease-treated reticulocyte lysate was 
incubated on ice in the absence of an ATP-regenerating system with 0, 2 or 5 mM 
novobiocin for 1 h.  Samples were immunoadsorbed with anti-Hsp90 antibody and 
analyzed by SDS-PAGE and western blotting for Hsp90, and co-adsorbed Hsc70 and 
p23. (B) [35S]-His-tagged HRI was synthesized in TnT reticulocyte lysate and then 
matured in normal heme-deficient lysate in the presence or absence (buffer control) of 
0.5, 0.75, 1.0 mM novobiocin as described under “Experimental Procedures”.  His-tagged 
HRI was immunoadsorbed and samples were analyzed by SDS-PAGE, and 
autoradiography ([35S]HRI and [32P]HRI, upper two panels) and western blotting (Hsp90 
and Cdc37).  His-tagged HRI was assayed for autokinase activity as described under 
“Experimental Procedures”.   NS: Analysis of sample lacking template coding for His-
tagged HRI as a control for nonspecific binding of Hsp90 and Cdc37 to the immune resin 
(B, left hand panels).  Band densities of [32P]HRI (open triangles) from the 
autoradiogram, and Hsp90 (open circles) and Cdc37 (open squares) from the western 
blots were quantified by densitometry (O.D.×mm2) and plotted as percent of the buffer 
control versus novobiocin concentration (average of three experiments ± standard 
deviation) (B, right hand panel). (C) His-tagged HRI was synthesized and matured in 
heme-deficient reticulocyte lysate as described above.  Immunoadsorbed HRI was 
assayed for autokinase activity in the presence (1 mM, lane 3) or absence (0 mM, lane 2) 
of novobiocin as described under “Experimental Procedures”. Band intensity of [32P]-
HRI was quantified by densitometry, and expressed as OD×mm2. NS: Analysis of sample 
lacking template coding for His-tagged HRI as a control for nonspecific binding of any 
endogenous HRI.  Autoradiogram of [35S]-HRI (lower panel) and autophosphorylated 
[32P]-HRI (upper panel).
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synthesized HRI, and whether it similarly altered the interactions of Hsp90 and Cdc37 
with HRI.
[35S]-His-tagged HRI was synthesized in reticulocyte lysate and subsequently 
matured in heme-deficient lysate in the presence or absence of novobiocin.  The 
Hsp90/Cdc37-dependent transformation of HRI resulted in the autophosphorylation of 
HRI and the appearance of a species of HRI with slower electrophoretic mobility during 
SDS-PAGE [Fig. 4B, and (41, 138)].  Novobiocin inhibited the “transformation” of HRI 
in a dose dependent fashion, as evidence by the decrease in amount of [35S]-HRI that 
exhibited slower electrophoretic mobility (Fig. 4B).
The effect of novobiocin on the co-immunoadsorption of Hsp90 and Cdc37 with 
HRI was examined to determine whether novobiocin disrupted the interactions of Hsp90 
and Cdc37 with HRI.  Western blotting indicated that there was a dose dependent 
decrease in the amounts of Hsp90 and Cdc37 that were co-adsorbed with His-tagged HRI 
from heme-deficient lysates (Fig. 4B).  Consistent with our previous work (138), 
reciprocal co-immunoadsorptions of HRI with anti-Hsp90 or anti-Cdc37 antibodies from 
novobiocin-treated lysate indicated that only the faster migrating species of HRI (e.g., 
untransformed HRI) was associated with Hsp90 and Cdc37 (not shown).
Hsp90/Cdc37-dependent transformation of HRI in heme-deficient lysate is accompanied 
by the activation of HRI’s autokinase activity.  Therefore, we measured the effect of 
novobiocin on the autophosphosphorylation of HRI (Fig. 4B, left panel).  Again 
novobiocin inhibited the activation of HRI’s autokinase activity in a concentration 
dependent manner.  Quantification of the degree of novobiocin-induced inhibition of 
HRI’s autophosphorylation indicated that it correlated closely with the extent of
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novobiocin-induced reduction of the interaction of Hsp90 and Cdc37 with HRI (Fig. 4B): 
the concentrations of novobiocin that were required to inhibit the interaction of Hsp90 
and Cdc37 with HRI and to inhibit HRI’s autokinase activity by 50% were both between 
0.75 and 1 mM (Fig. 4B).
Effect of novobiocin on the autophosphorylation of HRI.  Autophosphorylation of 
HRI is required for its transformation into an active Hsp90-independent kinase (41, 138).  
Because novobiocin inhibits DNA gyrase through its ability to bind at or near DNA 
gyrases’s ATP binding pocket, we examined the effect of novobiocin on the 
autophosphorylation of transformed HRI in vitro at quasi-physiological ATP 
concentrations (e.g., 2 mM).  Addition of 1 mM novobiocin to HRI autokinase assays had 
little direct effect on HRI’s autokinase activity in vitro (Fig. 4C), indicating that 
novobiocin did not compete with ATP for binding to HRI.  Thus, there appears to be a 
good correlation between the ability of novobiocin to reduce the interaction of Hsp90 and 
Cdc37 with newly synthesized HRI, and its ability to inhibit the Hsp90/Cdc37-dependent 
activation of HRI’s autokinase activity.
Effect of novobiocin on the stability of the interaction of Hsp90/Cdc37 with HRI.  
The strength of the interactions between Hsp90, Cdc37 and newly synthesized HRI is 
regulated through nucleotide-modulated conformational switching of Hsp90 (41, 141).  
To further characterize the effect of novobiocin on the interactions of Hsp90 and Cdc37 
with HRI, we examined the effect of novobiocin on the salt-stability of complexes 
formed between Hsp90, Cdc37, and HRI.  Newly synthesized His-tagged HRI was 
immunoadsorbed from control and drug-treated reticulocyte lysate, and immunoresins 
were washed with buffer containing a low or high concentration of NaCl (Fig. 5).                            
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Western blot analysis indicated that in the absence of drug, high affinity complexes were 
formed between Hsp90/Cdc37 and newly synthesized HRI, which were stable in the 
presence of high salt concentrations  (Fig. 5A, 0).  Consistent with previous results (41, 
141), the presence of molybdate similarly led to the formation of salt-stable 
Hsp90/Cdc37-HRI complexes  (Fig. 5A, MoO4), while geldanamycin blocked the 
interaction of Cdc37 with Hsp90-kinase complexes, and rendered the interaction of 
Hsp90 with HRI salt-labile (Fig. 5A, GA).  In contrast, both Hsp90 and Cdc37 were co-
adsorbed with HRI from reticulocyte lysate treated with 1 mM novobiocin, and their 
association with HRI was not affected upon washing with buffer containing high salt.  
However, neither Hsp90 nor Cdc37 were co-adsorbed with HRI from lysate treated with 
2 mM novobiocin, indicating that novobiocin can completely disrupt the interaction of 
Hsp90 with a client target at concentrations > 2 mM.  These results suggest that 
novobiocin has effects on Hsp90/Cdc37/kinase interactions that are distinct from those 
induced by molybdate and geldanamycin.
Effect of novobiocin on molybdate-induced stabilization of Hsp90-Cdc37-kinase 
complexes.  As noted above, newly synthesized protein kinases form high-affinity 
complexes with Hsp90 and Cdc37 that are stabile to washing in buffers containing high
salt (e.g., 0.5 M NaCl) immediately after their release from the ribosome (129, 141).  
Furthermore, addition of molybdate in the presence of ATP “freezes” these high affinity 
complexes preventing kinase maturation and activation, while the addition of 
geldanamycin prevents the formation of these high-affinity Hsp90-Cdc37-kinase 
complexes (129, 141).  Order-of-addition experiments have indicated that pre-incubation
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Figure 5.  Effects of pharmacological agents on the salt stability of the interaction of 
Hsp90-Cdc37 with HRI.  (A) [35S]-His-tagged HRI was synthesized in TnT reticulocyte 
lysate as described under “Experimental Procedures”.  Ten minutes after arresting 
initiation of translation, HRI was matured in the absence (0 mM, lanes 1 and 7) or 
presence of 1 mM (lanes 2 and 8) or 2.0 mM (lanes 3 and 9) novobiocin, 10 µg/ml:18 µM 
geldanamycin (GA, lanes 4 and 10), or 20 mM sodium molybdate (MoO4, lanes 5 and 11) 
for 1 h.  His-tagged HRI was immunoadsorbed, followed by washing of the 
immunoresins with 10 mM PIPES buffer (pH 7.2) containing no salt (lanes 1 – 6) or 500 
mM NaCl (lanes 7 – 12).  (B) [35S]-His-tagged HRI was synthesized in TnT reticulocyte 
lysate and subsequently matured in normal heme-deficient lysate that had been pre-
treated with buffer (lane 1), 1.0 mM novobiocin (NB(1), lanes 2 and 4), 2.0 mM 
novobiocin (NB(2), lane 6), or 20 mM sodium molybdate (MoO4, lanes 3, 5 and 7) for 5 
min.  After 5 min of incubation at 30 °C, samples were supplemented with buffer (lanes 
1-3), 1.0 mM novobiocin [NB(1), lane 5], 2 mM novobiocin [NB(2), lane 7] or 20 mM 
sodium molybdate (MoO4, lanes 4 and 6).  After incubation for 60 min, His-tagged HRI 
was immunoadsorbed, and samples were washed as described under “Experimental 
Procedures”.  Samples were separated by SDS-PAGE, and analyzed by autoradiography 
([35S]HRI) and western blotting (Hsp90, middle panel;  Cdc37, lower panel).    NS: 
Analysis of sample lacking template coding for His-tagged HRI as a control for 
nonspecific binding of Hsp90 and Cdc37 to the immune resin (A: lanes 6 and 12; B: lane 
8).
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of reticulocyte lysate with either geldanamycin or molybdate blocks the pharmacological 
effect of the other upon its subsequent addition to lysate (141).  The ability of novobiocin 
to induce dissociation of Hsp90-Cdc37 from immature HRI molecules suggests that the 
binding of novobiocin to Hsp90 induces Hsp90 to adopt a conformation distinct from the 
conformation Hsp90 adopts in the presence of ATP and molybdate.  Thus, we carried out 
order-of-addition experiments to determine whether molybdate or novobiocin had a 
dominant effect to the other upon its pre-incubation in reticulocyte lysate (Fig. 5B).  
While the presence of molybdate stabilized the interaction of Hsp90 and Cdc37 with 
HRI, a reduction in the binding of Hsp90 and Cdc37 to HRI was apparent in the presence 
of 1 mM novobiocin and molybdate, and a marked reduction in the interaction between 
these proteins occurred in the presence of 2 mM novobiocin.  Furthermore, this reduction 
in binding was observed whether molybdate was present in the initial pre-incubation (Fig. 
5B, lane 7) or whether it was added to lysate after pre-incubation with novobiocin (Fig. 
5B, lane 6).  Thus, binding of novobiocin and molybdate to Hsp90 does not appear to be 
mutually exclusive and may occur concurrently.  In addition, it was quite clear that 
novobiocin inhibited the ability of molybdate to stabilize the binding of Hsp90 and 
Cdc37 to its client target, HRI.
Effect of novobiocin on the basal interaction of co-chaperones with Hsp90.  
Marcu and co-workers have reported that Hsp70 and p23 are not co-adsorbed with Hsp90 
from novobiocin-treated reticulocyte lysate (26).  However, their experiment was carried 
out on ice and it was not apparent from the description of the experimental protocol 
whether an ATP-regenerating system was present.  Therefore, we further characterized 
the effect of novobiocin on basal complexes formed between Hsp90 and its 
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co-chaperones in reticulocyte lysate.  Anti-Hsp90 immunoadsorptions were carried out 
on ice, or at 30 ºC in the presence of an ATP regenerating system and analyzed for co-
adsorbing Hsc70, HOP, FKBP52, Cdc37 and p23.  On ice, 4 and 10 mM novobiocin 
significantly reduced the interaction of Hsc70, FKBP52 and p23 with Hsp90, while it 
suppressed the interaction of HOP with Hsp90 to a small degree and had little effect on 
the amount of Cdc37 that was co-adsorbed with Hsp90 (Fig. 6A).
In the presence of an ATP-regenerating system, Hsp90 is a mixture of molecules in their 
default conformation, and those that are actively cycling after binding to cryptic client 
substrates.  In the absence of molybdate, 5 mM novobiocin markedly reduced the binding 
of Hsc70 to Hsp90, with 10 mM novobiocin blocking their interaction completely (Fig. 
6B).  Both concentrations of novobiocin inhibited the interaction of p23 and Hsp90.  The 
interaction Cdc37 with Hsp90 was affected very little in the presence of 5 mM 
novobiocin, while 10 mM novobiocin reproducibly caused a slight increase in the binding 
of Cdc37 to Hsp90.  On the other hand, the interaction of HOP with Hsp90 was decreased 
by 13 ± 9% and 44 ± 19% (mean ± s.d. of three experiments) in the presence of 5 and 10 
mM novobiocin, respectively, but was unaffected by 2 mM novobiocin (not shown). 
Addition of molybdate to reticulocyte lysate in the presence of the ATP regenerating 
system caused a significant decrease in the amount of Hsc70 that bound
Hsp90 and caused a 27 ± 6% (mean ± s.d. of three experiments) decrease in the 
regenerating system caused a significant decrease in the amount of Hsc70 that bound
Hsp90 and caused a 27 ± 6% (mean ± s.d. of three experiments) decrease in the 
interaction of HOP with Hsp90 (Fig. 6B, lane 4 versus 1).   In contrast, molybdate
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Figure 6. Effects of novobiocin on the basal interaction of co-chaperones with 
Hsp90.  (A) Nuclease-treated TnT reticulocyte lysate was incubated without the addition 
of an ATP-regenerating system in the absence (lane 1) or the presence of 5 mM (lane 2) 
or 10 mM (lane 3) novobiocin on ice for 1 h.  (B) Nuclease-treated TnT reticulocyte 
lysate was incubated under conditions for coupled transcription-translation for 10 min at 
30 °C with no additions (lane 1), 5 mM (lane 2) or 10 mM (lane 3) novobiocin, 20 mM 
molybdate (lane 4), or 20 mM molybdate  and 5 mM (lane 5) or 10 mM (lane 6) 
novobiocin, or 10 µg/ml geldanamycin (GA, lane 7).  Hsp90 was immunoadsorbed (IP: 
boxed panel) and samples were separated by SDS-PAGE, and analyzed by western 
blotting for Hsp90, Hsc70, HOP, FKBP52, Cdc37 and p23.  NS: Sample prepared using a 
non-specific IgG as a control for nonspecific binding of proteins to the immune resin (A: 
lane 4; B: lane 8).  Boxed panels indicates the target protein for the immunoadsorption.
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increased in the amounts of FKBP52 and p23 bound to Hsp90 (Fig. 6B).  This is 
consistent with molybdate’s ability to stabilize late Hsp90 heterocomplexes that lack 
Hsc70 and HOP, but contain p23 and FKBP52.  In the presence of molybdate, 
novobiocin eliminated the binding of both Hsc70 and FKBP52 to Hsp90.  The 5 mM and 
10 mM concentrations of novobiocin further decreased the interaction of HOP with 
Hsp90 by approximately 23 ± 14% and 55 ± 9%, respectively (mean ± s.d. relative to the 
molybdate control of three experiments).  In contrast, novobiocin at concentrations of 5 
mM and 10 mM had only a slight inhibitory effect on the interaction of Cdc37 with 
Hsp90 (Fig. 6B).  Furthermore, in the presence of molybdate, novobiocin had little effect 
on the interaction of p23 with Hsp90, with 10 mM novobiocin causing a slight but 
reproducible reduction in the interaction of p23 with Hsp90.  Again the effects of 
novobiocin on the basal interactions of Hsp90 with its co-chaperones were distinct from 
those of geldanamycin:  geldanamycin blocked the association of p23 with Hsp90, 
reduced the amount of HOP that was co-adsorbed with Hsp90, but had little effect on the 
interactions of Hsc70, FKBP52 and Cdc37 with Hsp90 (Fig. 6B, GA).
Effect of novobiocin on the interaction of p23, FKBP52 and PP5 with newly 
synthesized HRI.  FKBP52, protein phosphatase 5 (PP5) and p23 are co-chaperones that 
interact with Hsp90-client complexes that are formed “late” in the ATP-driven reaction 
cycle of Hsp90 [reviewed in (13, 82, 101)].  Recently, we have demonstrated that co-
chaperone components containing tetratricopeptide repeat (TPR) motifs (i.e. FKBP52 and 
PP5), which interact with the C-terminal EEVD motif of Hsp90 (49, 60, 61, 69, 70, 143, 
144), can be present as components of Hsp90-Cdc37 complexes containing bound kinase 
(129, 141).  Thus, to characterize further the step in the reaction cycle that is affected by 
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novobiocin, we examined the effect of novobiocin on the interactions of the co-
chaperones p23, PP5 and FKBP52 with client, HRI, and the results were compared with 
the effects of molybdate and geldanamycin on these interactions.
Newly synthesized His-tagged-HRI was immunoadsorbed from heme-replete reticulocyte 
in the presence and absence of drug treatments (Fig. 7A), and the co-adsorption of 
Hsp90, Cdc37. FKBP52, and p23 with HRI were assessed by western blotting.  
Consistent with previous results (129, 141), geldanamycin completely disrupted the 
interaction of Cdc37 with HRI, while a weak interaction of Hsp90 with HRI was 
maintained (Fig. 7A: GA).  Geldanamycin also inhibited the co-adsorption of p23 and 
FKBP52 with His-tagged HRI.  In contrast, 2 mM novobiocin completely disrupted the 
binding of both Hsp90 and Cdc37 to HRI (Fig. 7A).  Interestingly, western blotting 
indicated that 2 mM novobiocin reproducibly increased the amount of FKBP52 that was 
co-adsorbed with His-tagged HRI (Fig. 7A).  In addition, p23 (Fig. 7A, lane 1) was 
detected to co-adsorb with His-tagged HRI.  In the presence of 2 mM novobiocin, 
however, the amount of p23 that was co-adsorbed with HRI was reduced to a nearly 
imperceptible level (not readily visible on scanned data: Fig 4A, lane 2).  Co-adsorption 
of p23 with HRI was readily detectable in the presence of molybdate, and the level of co-
adsorbed p23 was decreased markedly in the presence of 2 mM novobiocin (Fig. 7A, lane 
3 versus 4).  Currently, antibodies available to PP5 do not have sufficient sensitivity to 
detect PP5.Immunoadsorptions of His-tagged HRI (Fig. 7B, C and D) from heme-
deficient lysate were also carried out.  Novobiocin and geldanamycin both inhibited the 
transformation of HRI in heme-deficient lysate as evidenced by the lack of an [35S]-HRI
exhibiting slower electrophoretic mobility on SDS PAGE (Fig. 7B, C and D: left panels).
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Figure 7. Effects of novobiocin on the interaction of HRI with Hsp90 co-chaperones.
(A) [35S]-His-tagged HRI was synthesized in TnT reticulocyte lysate.  After inhibition of 
initiation by the addition of aurintricarboxylic acid, the lysate was incubated for 1 h at 30 
°C with no additions (lane 1), 2 mM novobiocin (lane 2), 20 mM molybdate (lane 3), 2 
mM novobicin plus 20 mM molybdate (lane 4), or 10 µg/ml geldanamycin (GA, lane 5). 
(B) [35S]-His-tagged HRI was synthesized in TnT reticulocyte lysate and then matured in 
normal heme-deficient lysate in the absence (B-D: lane 1) or presence of 2 mM 
novobiocin (B-D: lane 2 ) or 10 µg/ml geldanamycin (B-D: GA, lane 3), as described 
under “Experimental Procedures”.  For the experiment shown in part D of the figure, 
sample containing His-tagged HRI was mixed with an equal volume of lysate containing 
newly synthesized FLAG-[35S]PP5 prior to dilution of the sample into heme-deficient 
lysate.  Samples for (A) were immunoadasorbed with anti-His-tag antibody, while 
samples for B-D) were divided in half and immunoadsorbed with anti-His-tag (B-D, left 
panel), JJ3 anti-p23 (B: right panel), EC1 anti-FKBP52 (C: right panel) or M2 anti-FLAG 
(D: right panel) antibody.  After washing, the samples were separated by SDS-PAGE, 
and analyzed by autoradiography (A-D: [35S]HRI, upper panel; D, [35S]PP5) and western 
blotting (Hsp90, FKBP52, Cdc37 and p23). Boxed panels indicates the target protein for 
the immunoadsorption.  NS: Analysis of sample lacking template coding for His-tagged 
HRI as a control for nonspecific binding of Hsp90 and Cdc37 to the immune resin (A: 
lane 6; B-D lane4, all panels).
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The effects of novobiocin and geldanamycin on the co-adsorption of Hsp90 and Cdc37 
(Fig. 7B, C, And D: left panels) were the same as those observed for the experiments 
carried out in heme-replete lysate (Fig. 7A).  However, the amount of HRI 
immunoadsorbed in these experiments was not sufficient to detect co-adsorption of either 
p23 or FKBP52.
Immunoadsorptions of p23 (Fig. 7B: right panel), FKBP52 (Fig. 7C: right panel) 
and [35S]-FLAG-PP5 (Fig. 7D: right panel) from heme-deficient reaction mixes were 
carried out in parallel to overcome the poor detection sensitivity of antibodies directed 
against these proteins on western blots.  Geldanamycin markedly reduced the amount of 
Cdc37 that was co-adsorbed with basal complexes containing p23 (Fig. 7B: right panel), 
FKBP52 (Fig. 7C: right panel) or PP5 (Fig. 7D: right panel).  While geldanamycin 
blocked the basal interaction of p23 with Hsp90 (Fig. 7B: right panel), it had little effect 
on the basal interaction of FKBP52 (Fig. 7C: right panel) and PP5 (Fig. 7D: right panel) 
with Hsp90.  Furthermore, while little HRI was co-adsorbed with p23 from 
geldanamycin-treated lysate, geldanamycin only partially reduced the amount of HRI that 
was co-adsorbed with FKBP52 and Flag-PP5.  The co-adsorption of HRI with Flag-PP5 
in the presence of geldanamycin is consistent with our previous work (45, 129).
In contrast to the effects of geldanamycin, HRI was co-immunoadsorbed in 
conjunction with p23, FKBP52 and Flag-[35S]-PP5 from lysates treated with 2 mM 
novobiocin.  Western blotting of samples from anti-co-chaperone immunoadsorptions 
(Fig. 7B, C and D: left panels) indicated that 2 mM novobiocin markedly reduced the 
amount of Cdc37 present in basal complexes with p23, and nearly completely blocked the 
interaction of Cdc37 with basal complexes containing FKBP52 or PP5.  In addition,
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2 mM novobiocin brought about a reduction in the amount of Hsp90 present in basal 
complexes with FKBP52 and PP5, but had only a marginal effect on the basal interaction 
of p23 with Hsp90.  Data presented in Figure 4 suggests that novobiocin concentrations 
of greater than 2 mM may be required to quantitatively disrupt the basal interaction of 
p23 with Hsp90.  Thus, the data suggests that the p23, FKBP52 and PP5 co-chaperone 
components of the Hsp90 chaperone machine can maintain their interaction with HRI 
after novobiocin-induced dissociation of Hsp90 and Cdc37 from this client target.  Since 
these co-chaperones are components of “late” complexes formed between the Hsp90 
chaperone machine and client targets, the data suggest that novobiocin may bind Hsp90 
during or subsequent to the formation of these late complexes.
Effect of novobiocin on the conformation of Hsp90.  Hsp90 gives different 
proteolytic fingerprints in its geldanamycin-bound and its molybdate-bound states (141). 
The proteolytic fingerprint of Hsp90 in the presence of geldanamycin is the same as the 
fingerprint of Hsp90 in its default conformation.  Order-of-addition experiments have 
indicated that the geldanamycin-bound and molybdate-bound conformations are not 
freely interchangeable, such that Hsp90 adopts the conformation induced by the first 
agent added, and does not convert to the alternate conformation upon the subsequent 
addition of either geldanamycin or molybdate (141).  The biochemical properties of 
geldanamycin-bound Hsp90 suggest that Hsp90 is in its “open” conformation and poised 
to bind client, while the properties of molybdate-bound Hsp90 formed in the presence of 
ATP, suggest that Hsp90 is in its “closed” conformation: a conformation equivalent to the 
salt-stabile high affinity conformation Hsp90 adopts with bound client [e.g., with newly 
synthesized HRI (141)] in the presence of hydrolysable ATP (77, 118, 125, 131) .
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Proteolytic fingerprinting of Hsp90 in situ in reticulocyte lysate was carried out to 
determine whether the binding of novobiocin induces Hsp90 to adopt a conformation that 
differs from the conformation it assumes upon binding of geldanamycin or molybdate 
(Fig. 8).  Membranes were blotted with antibodies directed against N-terminal residues of 
Hsp90 or C-terminal residues of Hsp90 (AC88) (145) to determine the position of the 
major cut sites (141).  The trypsinolytic fingerprint of Hsp90 generated in the presence of 
2 mM novobiocin was indistinguishable from the fingerprints of Hsp90 generated from 
untreated lysate (its default conformation, Fig. 8A).  Addition of geldanamycin either 
before or after incubation of lysate with 2 mM novobicin also had no effect on Hsp90’s 
fingerprint (data not shown).  However, novobiocin concentrations of greater than 5 mM 
had significant effects on Hsp90’s proteolytic fingerprint.  At high novobiocin 
concentrations, a 50 kDa C-terminal fragment was detected by western blotting with the 
AC88 antibody (Fig. 8A right panel).  This fragment is also generated when molybdate 
alone is added to reticulocyte lysate (Fig. 8B).  In addition, the 30, kDa, 50 kDa doublet 
and the 78 kDa N-terminal fragments of Hsp90 were lost with increasing novobiocin 
concentrations and a new 73 kDa fragment appeared (Fig. 8A left panel). Consistent with 
our previously published results (141), addition of molybdate altered the fingerprint of 
Hsp90, with the binding of molybdate protecting Hsp90 from cleavage by trypsin at a site 
around amino acid 400 and decreasing the rate of cleavage at a site around amino acid  
600, such that a major stable 50 kDa fragment representing the C-terminal half of Hsp90
was detected on western blots with the AC88 anti-Hsp90 antibody (Fig. 8B: right panel).  
Addition of 0.5 to 5 mM novobiocin in the presence of molybdate lead to a concentration 
dependent protection of Hsp90 from trypsinolytic cleavage at the site near amino acid
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Figure 8.  Proteolytic mapping of structural changes in Hsp90 induced by 
novobiocin.  TnT reticulocyte lysate was incubated under conditions for protein synthesis 
in the absence of plasmid for 10 min at 30 ºC in the presence of the indicated 
concentrations of novobiocin (A: 0, 2, 5, 10 and 20 mM) or in the presence of 20 mM 
molybdate plus the indicated concentrations of novobiocin (B: 0, 0.5, 0.75, 1, 2 and  5 
mM).  Reactions were chilled on ice and incubated for 6 min in the presence of the 
indicated concentration of trypsin and analyzed as described under “Experimental 
Procedures”. Western blot with AC88 anti-Hsp90 antibody which recognizes an epitope 
within the C-terminal region of Hsp90 [AC88(α-CT): A and B- right panel].  Western 
blot with anti-Hsp90 antibody raised to sequence at the N-terminus of Hsp90 [ABR(α-
NT): A and B- left panel].
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600, leading to the disappearance of the 78 kDa Hsp90 fragment detected by the anti-N-
terminal Hsp90 antibody (Fig. 8B: left panel) and an increase in the amount of 50 kDa C-
terminal fragment detected by the AC88 anti-Hsp90 antibody (Fig. 8B: right panel).  
Furthermore, a 30 kDa N-terminal fragment disappeared from Hsp90 fingerprints 
generated in the presence of molybdate and increasing concentrations of novobiocin (Fig. 
8B: left panel).  Consistent with data presented in Figure 5, the order of addition of 
molybdate and novobiocin had no effect on the trypsinolytic fingerprints of Hsp90 (data 
not shown).  Thus, in the presence of molybdate and novobiocin, only the major cleavage 
site near amino acid 280 and two minor sites around amino acid 230 of Hsp90 were 
cleaved, generating 40 kDa and 22/24 kDa bands detected by blotting with antibody 
specific to the N-terminus of Hsp90 (Fig. 8B: left panel).  Cleavage near amino acids 
around 230 and 280 represent cutting of Hsp90 near the beginning and the end of the 
charged linker region that separates the N-terminal ATP binding domain of Hsp90 from 
its middle domain (146).
Results presented in Figure 4 indicated that novobiocin-induced inhibition of 
HRI’s Hsp90/Cdc37 dependent acquisition of autokinase activity correlated directly with 
disruption of the binding of Hsp90 and Cdc37 to HRI.  Therefore, the decrease in the 
intensity of the 78 kDa N-terminal fragment and the increase in the intensity of the 50 
kDa C-terminal fragment was quantified and used to estimate the change in Hsp90 
conformation induced by increasing concentrations of novobiocin (Fig. 9A).  The 
concentration of novobiocin required to induce a 50% changed in the cleavage of Hsp90 
was approximately10 mM.  A Hill plot, constructed assuming that the change in intensity 
of the 78 kDa band induced by novobiocin was proportional to the amount of novobiocin-
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bound Hsp90, yielded a Hill coefficient of 1.7 (R = 0.98) suggesting that the binding of 
novobiocin is highly cooperative.
However, in the presence of molybdate, only ~1 mM novobiocin was required to 
induce a 50% change in the cleavage of Hsp90 (Fig. 9A). Thus, the conformational 
change in Hsp90 that is induced by the binding of molybdate in the presence of ATP 
increased the binding affinity of Hsp90 for novobiocin by ten fold.  The change in Hsp90 
conformation induced by novobiocin in the presence of molybdate correlated well with 
novobiocin-induced disruption of the interaction of Hsp90 and Cdc37 with HRI and 
inhibition of HRI’s autokinase activity (Fig. 4B).  These results suggest that there may be 
a relationship between the conformational change induced in Hsp90 upon the binding of 
novobiocin to molybdate- bound Hsp90 and the dissociation of Hsp90-Cdc37 from 
complexes containing client kinase.  It should be noted that in the presence of molybdate 
and 5 mM novobiocin, approximately 20% of the 78 kDa band remained relative to the 
molydate control, suggesting that there may be a population of Hsp90 molecules present 
in reticulocyte lysate that may not be capable of interacting with molybdate. 
To further investigate the effect of novobiocin on the conformation of Hsp90, we 
examined the ability of the AC88 anti-Hsp90 antibody to immunadsorb Hsp90 from 
reticulocyte lysate.  AC88 does not appear to adsorb Hsp90 present in complexes 
containing bound client (147), and molybdate decreases the ability of the AC88 antibody
to immunoadsorb Hsp90 from reticulocyte lysate (125).  The AC88 anti-Hsp90 antibody 
quantitatively adsorbed Hsp90 from control, geldanamycin-treated, and novobiocin-
treated (2 mM) lysate (Fig. 9B).  In the presence of molybdate, approximately 50% of the 
Hsp90 present in reticulocyte lysate was adsorbed by the AC88 antibody, while in the
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Figure 9. Structural changes in Hsp90 induced by novobiocin. (A) The amount of the 
50 kDa band in the right panels, and the 78 kDa band in left panels from Figure 8A (open 
circles) and Figure 8B (open triangles) were quantified by scanning densitometry, and 
plotted as percent of the no novobiocin control (from Figure 8, A and B: 78 kDa band; 
left panel, lane 2 = 100%), or percent of the maximum observed change (from Figure 8, 
A and B: 50 kDa band, right panel, lane 15 = 100%).  Values are the average of two 
experiments with the error bars indicating the range of the two points.  (B) Ability of the 
AC88 anti-Hsp90 antibody (I) or non-immune control antibody (N) to immunadsorb 
Hsp90 from rabbit reticulocyte lysate was determined.  Briefly, TnT reticulocyte lysate 
was incubated under conditions for protein synthesis in the absence of plasmid for 20 min 
at 30 °C, followed by a 10 min incubation in the presence of no additions (lanes 1 and 2), 
20 mM sodium molybdate (lanes 3 and 4), 20 mM sodium molybdate and 2 mM 
novobiocin (lanes 5 and 6), 2 mM novobiocin (lanes 7 and 8), 10 µg/ml geldanamycin 
(lanes 9 and 10), or 10 mM novobiocin (lanes 11 and 12).  After immunoadsorption of 
Hsp90, the amount of unadsorbed Hsp90 remaining in the unbound fraction was analyzed 
by SDS-PAGE and western blotting. 
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presence of both molybdate and novobiocin or high concentrations of novobiocin alone 
(10 mM) only about 5 to 15% of the Hsp90 was immunoadsorbed.  Thus, overall these 
results suggest that novobiocin interacts with Hsp90 complexes after Hsp90 adopts its 
molybdate-bound conformation: a conformation with properties similar to those exhibited 
by Hsp90 after it has formed salt-stabile high-affinity complexes with kinase client.
Novoboicin directly protects the C-terminal domain of Hsp90 from cleavage by trypsin.
The effect of novobiocin on the sensitivity of Hsp90 to proteolytic cleavage could result 
from a direct effect of the binding of novobiocin to Hsp90, or it could be due to 
novobiocin altering the interaction of co-chaperones with Hsp90.  To distinguish between 
these two possibilities, we examined the effect of novobiocin on the proteolysis of 
Hsp90’s C-terminal domain (amino acids 584-730).  The C-terminal domain of 
recombinant Hsp90 binds novobiocin in the absence of the N-terminal domain of Hsp90 
(26).  Thus, use of His-tagged recombinant Hsp90-CT domain avoids potential problems 
caused by the allosteric regulation of the novobiocin binding site via the binding of 
nucleotide to the N-terminal domain of Hsp90 (27). The recombinant Hsp90-CT was 
highly sensitive to digestion with trypsin in the absence of novobiocin (Fig. 10A).  As 
expected, geldanamycin, which binds to the N-terminal, but not to the C-terminal domain 
of Hsp90, had no effect on the protease sensitivity of the domain. Furthermore, 
molybdate did not protect the Hsp90-CT from cleavage by trypsin.  However, novobiocin 
alone protected recombinant Hsp90-CT from trypsin cleavage, and molybdate had no 
additional effect on this protection.  The ability of MgATP to similarly protect 
recombinant Hsp90-CT from trypsinolytic cleavage (Fig. 10B) supports the hypothesis
that novobiocin inhibits Hsp90 function by binding to a nucleotide binding site present in 
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Figure 10.  Proteolytic mapping of C-terminal domain of Hsp90. Purified 
recombinant C-terminal domain was incubated for 10 min at 30 ºC in the presence of (A) 
no additions, 20 mM sodium molybdate (MoO4), 2 mM novobiocin (NB), 20 mM sodium 
molybdate and 2 mM novobiocin (MoO4/NB) or 20 µg/ml geldanamycin (GA), or (B) no 
additions or 5 mM MgATP.  Reactions were chilled on ice and incubated 6 min in the 
presence of the indicated concentration of trypsin and analyzed by SDS-PAGE and 
western blotting with AC88 anti-Hsp90 antibody.
the C-terminal domain of Hsp90 and altering the structure near its binding site.
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Discussion
In this manuscript, we demonstrate that novobiocin inhibits Hsp90-dependent 
maturation of newly synthesized client target (e.g., the maturation and activation of the 
Hsp90-Cdc37-dependent kinase HRI) in a dose dependent manner.  In addition, 
novobiocin-induced inhibition of the Hsp90/Cdc37-dependent activation of HRI’s 
autokinase activity correlated well with its ability to disrupt the interaction of Hsp90 and 
Cdc37 with newly synthesized HRI.  The concentration range required to inhibit HRI’s 
Hsp90-dependent transformation was similar to the range of novobiocin concentrations 
that Kanelakis and co-workers found was required to inhibit Hsp90-dependent restoration 
of steroid hormone binding to the glucocorticoid receptor in vitro using purified proteins 
(136).
The mechanism by which novobiocin inhibits Hsp90 function appears to be 
distinct from that of geldanamycin and molybdate, as novobiocin has effects distinct from 
those of geldanamycin and molybdate both on the basal interaction of co-chaperones with 
Hsp90, and on the interactions of Hsp90/Cdc37 and co-chaperones with the Hsp90 client
kinase, HRI.  Of further interest is the observation that the binding of novobiocin to 
Hsp90’s C-terminal domain decreased the interaction of Hsp90 with co-chaperones 
containing TPR domains, which interact with Hsp90’s C-terminal EEVD motif.  This 
suggests that novobiocin-binding may alter the conformation of Hsp90’s C-terminus 
leading to the dissociation of TPR containing co-chaperones.  Of note is that while 
novobiocin markedly reduced or eliminated the interaction of Hsp90 with PP5 and 
FKBP52, it had less of an inhibitory effect on the basal interaction of HOP with Hsp90.  
This difference probably reflects the fact that HOP interacts with Hsp90 early in its ATP 
cycle at a point when the C-terminal nucleotide binding site may be inaccessible, or more 
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likely in a low affinity conformation.  In contrast, FKBP52 and PP5 are present in late 
complexes in which the C-terminal nucleotide-binding site would be open and readily 
accessible for novobiocin binding.  These results are also consistent with the observations 
that the binding of HOP versus PP5 or FKBP52 to Hsp90 is mutually exclusive, and that 
HOP interacts with Hsp90 when its N-terminal domain is in its “open”, possibly 
nucleotide-free conformation (29).  
Novobiocin had effects on the interactions of Hsp90 with co-chaperones and 
client kinase that were dominant to the effects of molybdate.  Novobiocin altered the co-
chaperone composition of basal Hsp90 complexes, destabilized the binding of 
Hsp90/Cdc37 to HRI, and changed the interactions of co-chaperone with HRI even when 
lysate was pre-incubated with molybdate.  The dominance of the effect of novobiocin 
over molybdate and the ability of novobiocin to quantitatively dissociate Hsp90/Cdc37-
kinase complexes suggests that novobiocin may bind to Hsp90 subsequent to molybdate 
and induce kinase release. The notion that novobiocin may bind to Hsp90 after molybdate 
is supported by observations which suggest that the interaction of novobiocin with Hsp90 
occurs after the formation of “late” Hsp90-client complexes.  Geldanamycin induces 
accumulation of intermediate Hsp90 complexes that contain Hsc70 and weakly bound 
client, while molybdate stabilizes Hsp90/Cdc37-client complexes that contain “late” 
components of the Hsp90 machine (119, 120).  Nucleotide-modulated switching of 
Hsp90’s conformation establishes Hsp90’s and Cdc37’s high-affinity salt-stabile binding 
to kinase (41, 141).  Molybdate and p23 stabilize Hsp90 binding to client, and the binding 
of molybdate and p23 to Hsp90 in the absence of client is thought to induce a similar 
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Hsp90 conformation.  Thus, the observation that p23, FKBP52 and PP5 (“late” co-
chaperone components of the Hsp90 machine) remain associated with HRI client after 
novobiocin-induced dissociation of Hsp90 and Cdc37 from HRI supports the hypothesis 
that novobiocin binds Hsp90 subsequent to the formation of late Hsp90/co-chaperone 
client complexes.  This notion would be consistent with the observed absence of Hsc70 (a 
component of intermediate Hsp90 heterocomplexes) and p23 (a component of late Hsp90 
heterocomplexes) from basal Hsp90 complexes isolated from lysate incubated in the 
presence of novobiocin [Fig. 6 and (26)].  Again, the dominance of the effects of 
novobiocin over molybdate-induced stabilization of Hsp90-client complexes suggests 
that the novobiocin-bound conformation of Hsp90 may be responsible for client release.
The observation that p23, FKBP52, and PP5 interact directly with HRI after 
novobiocin-induced dissociation of Hsp90 and Cdc37 suggests that these co-chaperones
may play a role in chaperoning client folding or communicating changes in client 
conformation in some manner to Hsp90.  While we had previously demonstrated a direct 
interaction of PP5 with HRI (129), past data had not allowed us to deduce whether
FKBP52 or p23 had any direct interaction with HRI or whether they were present in 
Hsp90-kinase complexes simply due to their binding affinity for Hsp90 (141).  The direct 
interaction of p23 and FKBP52 with HRI is consistent with the chaperone activity that 
these two proteins display in assays in vitro (107, 148, 149), and the observation that p23 
is present in stable complexes with some client proteins, presumably after their 
dissociation from Hsp90 (81, 150, 151).  This observation also invites the speculation that
the interaction of these proteins with HRI may play a role in the reassembly of Hsp90 
complexes with immature HRI, as reiterative cycles of Hsp90 action are required for 
kinase maturation (42, 141).  Furthermore, the interactions could play additional roles in 
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regulating HRI function, such as the proposed role of FKBP52 in intracellular 
localization of Hsp90-dependent clients (13, 152).  This latter possibility is of interest, as 
novobiocin-treatment appears to enhance the interaction of FKBP52 with HRI, and some 
“matured and activated” HRI, which exhibits a slower electrophoretic mobility, was co-
immunoadsorbed with FKBP52 from heme-deficient lysate (Fig. 7C).
It has been suggested, however, that novobiocin might affect the function of the 
Hsp90 chaperone machine by affecting Hsc70 as well (136).  While our data cannot 
conclusively rule out this possibility, the work presented here (which is discussed below) 
clearly demonstrates that novobiocin binds Hsp90 and directly alters its structure and
dynamic, such that at any given time basal heterocomplexes containing Hsp90 can be in 
the process of assembly or disassembly.  Thus, we favor a model in which novobiocin 
compromises Hsc70’s function indirectly through altering Hsp90’s structure at a specific 
point in its reaction cycle and subsequently compromising Hsc70’s ability to interact 
productively with the Hsp90 chaperone machine.
The notion that novobiocin can affect the function of co-chaperone components 
‘indirectly’ through its effects on Hsp90 function is supported by additional observations.  
Addition of molybdate reproducibly caused an approximate 30% decrease in the 
interaction of HOP with Hsp90, and a significant decrease in the binding of Hsc70.  The 
presence of molybdate would stabilize “late” complexes formed from intermediate 
Hsp90/HOP/Hsc70 heterocomplexes and cryptic clients present in the reticulocyte lysate.  
These complexes would lack Hsc70 and HOP, but be sensitive to novobiocin-induced 
dissociation of cryptic substrate.  On the other hand, Hsp90/HOP complexes are thought 
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to be nucleotide-free prior to the association of Hsc70 containing bound client (30, 71, 
131).  As such, Hsp90’s C-terminal nucleotide-binding site in these complexes would be 
in its low affinity conformation, and only be sensitive to novobiocin at very high 
concentrations, as we have observed.  In addition, since nucleotide bound to Hsp90’s N-
terminus appears to be required for molybdate-induced effect on Hsp90’s 
conformation(77, 118), the C-terminal nucleotide binding site of nucleotide-free 
Hsp90/HOP would remain in its low affinity conformation, which is consistent with the 
observation that high concentrations of novobiocin are still required to cause a decrease 
in Hsp90/HOP complexes in the presence of molybdate.  The observation that the 
intensity of the 78 kDa N-terminal tryptic fragment generated in the presence of 
molybdate and 5 mM novobiocin is only reduced by approximately 80% (Fig. 8B, 
discussed below), suggests that about 20% of the Hsp90 molecules present in reticulocyte 
lysate may be in a nucleotide-free form under our assay conditions.  Approximately 30% 
of the Hsp90 in reticulocyte lysate appears to be bound to HOP (1). Consistent with its 
unique effects on the interactions of Hsp90 with client and co-chaperones, novobiocin 
also had distinct effects on the conformation of Hsp90 as assessed by proteolytic 
fingerprinting of Hsp90 in situ.  Fingerprinting of Hsp90 indicated that addition of 
novobiocin had little effect on the default conformation of Hsp90 at concentrations (1-2 
mM) that significantly inhibited HRI transformation and induced the dissociation of 
Hsp90 and Cdc37 from newly synthesized HRI (Fig. 4).  Similarly, 1-2 mM novobiocin 
had little effect on the proteolytic fingerprint of Hsp90 generated in the presence of 
geldanamycin.  However, very high concentrations of novobiocin (10 to 20 mM) were 
found to alter the proteolytic fingerprint of Hsp90 both in the presence2 and absence of 
geldanamycin.  Results from other laboratories indicates that occupancy of the N-
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terminal ATP binding site is required for the accessibility of the second C-terminal ATP 
binding site to novobiocin (26, 27).  Our results suggest that the default and 
geldanamycin-bound conformations of Hsp90 maintain the C-terminal nucleotide-
binding site in a low-affinity conformation, but that novobiocin- induced switching of 
Hsp90’s conformation can occur in the presence of a sufficiently high concentration of 
novobiocin.  The conformational change induced by the binding of novobiocin appears to 
be highly cooperative with a Hill coefficient of 1.7, suggesting that both novobiocin-
binding sites within an Hsp90 dimer must be occupied for the conformational switching 
to occur.
The molybdate-induced switching of Hsp90’s conformation dramatically 
enhances the binding affinity of Hsp90’s C-terminal nucleotide binding site for ligand. 
This hypothesis is supported by the observation that 2 mM novobiocin has a dramatic 
effect on the proteolytic fingerprint of Hsp90 when added to reticulocyte lysate in the
presence, but not in the absence of molybdate.  The interaction of Hsp90/Cdc37 with 
newly synthesized HRI was also markedly reduced both in the presence or absence of
molybdate when 2 mM novobiocin was added to reticulocyte lysate (Fig. 5 and 7).  
Furthermore, 2 mM novobiocin blocked the Hsp90/Cdc37-dependent transformation of 
HRI in heme-deficient lysate (Fig. 5B, 6B, and 7B).  Binding of molybdate to Hsp90 
stabilizes Hsp90 in a conformation that mimics the properties of salt-stabile high-affinity 
complexes formed between Hsp90/Cdc37 and bound client following nucleotide 
modulated conformation switching of Hsp90 (125, 141).  Thus, ATP-induced “clamping” 
of Hsp90’s N-terminal domain and the subsequent hydrolysis of this ATP may markedly 
enhance to accessibility or the affinity of Hsp90’s C-terminal nucleotide binding site.  
Since molybdate markedly enhanced the binding affinity of Hsp90 for novobiocin, it is 
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likely that the release of bound phosphate [of which molybdate has been proposed to be a 
high affinity binding mimetic (77)] is an important step kinetically in the regulation of the
Hsp90 reaction cycle (125). Past work identifying the location of the major sites in Hsp90
that are cleaved by trypsin (145, 146) now allows us to accurately identify the sites within
Hsp90 whose cleavage is altered upon the binding of molybdate and novobiocin (Fig. 
11). Relative to the amino acid sequence of human Hsp90α, Hsp90 has major trypsin 
cleavage sites at residues 288, 399 and 614/619, and minor cleavage sites near residues 
228, 250 and 573 (145, 146).  The sites at residues 228, 250 and 288 represent cleavage 
of Hsp90 near the N-terminus, the middle and the C-terminus of the highly charged linker 
region that connects the N-terminal nucleotide binding domain and the middle domain of 
Hsp90 [Fig. 3A, 11, and (145, 146)].  K573 is located at the C-terminal end of a highly 
charged sequence that is present between the middle and C-terminal domains of Hsp90 
(145).  The site at 399 is within the region of Hsp90 that has been proposed to interact 
with (27) and catalyze the hydrolysis of (31) the γ-phosphate of ATP bound to the 
N-terminal domain of Hsp90, as well as being adjacent to the site that has been proposed 
to be the client binding pocket (31).  The site at residue 614/619 is adjacent to the region. 
that binds novobiocin (26, 27), and the site at 573 is just upstream from this region.
Consistent with its ability to inhibit Hsp90 proteolysis at residue 399, molybdate 
is thought to act as a phosphate mimetic which binds to the site occupied by the γ-
phosphate of the ATP bound to the N-terminal domain of Hsp90 after its hydrolysis (77).
Our previous work also indicates that molybdate reduces cleavage of Hsp90 at residue
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Figure 11.  Summary of effects of pharmacological agents on the proteolytic 
fingerprint of Hsp90.  (A) 1) Trypsin cleavage sites of Hsp90 in its default and 
geldanamycin-bound conformations. 2) Trypsin cleavage sites of Hsp90 in its molybdate-
bound conformation. 3) Trypsin cleavage sites of Hsp90 in its novobiocin-bound 
conformation.  4) Trypsin cleavage sites of Hsp90 in the presence of molybdate and 
novobiocin.  Large arrow, major cleavage site; small arrow, minor cleavage site; presence 
or absence of arrow, or altered size indicates change in susceptibility to cleavage by 
trypsin.  (B) Origin of N- and C-terminal Hsp90 fragments.  Note that N-terminal 
fragments containing the charge linker region (CL) have abnormal electrophoretic 
mobility.  ATP, nucleotide binding sites; γ-PO4, putative site of interaction of the γ-
phosphate of the ATP bound to Hsp90’s N-terminus.
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614/619 (125).  Our current work demonstrates that novobiocin (and MgATP) 
quantitatively protects Hsp90 from cleavage at the 614/619 site independent of 
molybdate.  Thus, the ability of molybdate to retard cleavage at this site may represent 
molybdate’s ability to enhance interaction of endogenous nucleotide with the C-terminal 
nucleotide-binding site of Hsp90.  In addition, the observation that novobiocin and 
MgATP protect Hsp90-CT from proteolytic cleavage indicates that the binding of 
novobiocin or nucleotide to the C-terminal site is directly responsible for the altered 
Hsp90 conformation, and that the protection from proteolysis is not caused by altering the 
binding of a co-chaperone to the site that would render the site inaccessible to protease.  
However, it cannot be excluded at this time that the changes in protease sensitivity of 
Hsp90 at other sites might be due to alterations in the interactions of co-chaperones with 
Hsp90 as opposed to direct changes in structure. Because dissociation of client kinase 
from Hsp90/Cdc37 complexes in all likelihood requires the “unclamping” of the N-
terminal nucleotide binding domains within the Hsp90 dimer, the data suggest that the 
binding of novobiocin to Hsp90 may induce this event.  Since the N-terminal domain of 
Hsp90 does not bind novobiocin (26, 27), occupancy of the C-terminal nucleotide-
binding site of Hsp90 by novobiocin would need to be communicated to Hsp90’s N-
terminal domain through its effects on the conformation of Hsp90 at its C-terminus (26, 
27).  This proposed communication between the N- and C-terminal domains of Hsp90 is 
consistent with several observations: 1) occupancy of the N-terminal ATP binding site of 
Hsp90 is required for the C-terminal nucleotide binding site to become accessible (27, 
124); 2) binding of novobiocin to the C-terminal nucleotide binding site disrupts 
nucleotide binding at the N-terminus (27); 3) sequences in the C-terminus of Hsp90 
regulate the hydrolysis of ATP bound to the N-terminal domain of Hsp90 (33, 128), 
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which is required for the ATP-dependent formation of stable Hsp90-client complexes 
containing p23 (77, 116, 118, 128, 131); and 4) our proteolytic fingerprints indicate that 
novobiocin causes structural changes (and/or altered co-chaperone/client interactions) in 
the C-terminal domain, the middle domain, and the linker region between the N-terminal 
and middle domains of Hsp90. In toto, the data presented in this paper suggest that the 
binding of novobiocin to the C-terminal nucleotide-binding site of Hsp90 stimulates the 
dissociation of Hsp90 from client protein.  Since the binding of novobiocin to Hsp90 
inhibits binding of nucleotide to the N-terminal domain of Hsp90 (26, 27), and N-
terminally bound nucleotide is required to stabilize Hsp90 in its “closed”, high-affinity 
client binding conformation (24, 116, 118), we propose that novobiocin binding induces 
the dissociation of nucleotide from the N-terminal domain of Hsp90, the destabilization 
of p23 binding and kinase release.  The questions of whether this model will apply to 
other or all Hsp90 client targets,  as well as what stimulates the recycling of Hsp90 from 
its novobiocin bound state remain to be explored.
58
                                                       CHAPTER III
Hsp90 Functions to Balance the Phosphorylation State of Akt during C2C12 
Myoblast Differentiation: a potential anti-apoptotic effect of Hsp90 inhibitors
Abstract
Hsp90 function is essential for the regulation of a myriad of signal transduction 
cascades that control all facets of a cell’s physiology.  Akt (PKB) is an Hsp90-dependent 
serine-threonine kinase that plays critical roles in the regulation of muscle cell 
physiology, including roles in the regulation of muscle differentiation and anti-apoptotic 
responses that modulate cell survival.  In this report, we have examined the role of Hsp90 
in regulating the activity of Akt in differentiating C2C12 myoblasts.  While long-term 
treatment of differentiating C2C12 cells with the Hsp90 inhibitor geldanamycin led to the 
depletion of cellular Akt levels, pulse-chase analysis indicated that geldanamycin 
primarily enhanced the turnover rate of newly synthesized Akt. Hsp90 maintained an 
interaction with mature Akt, while Cdc37, Hsp90’s kinase-specific co-chaperone, was 
lost from the chaperone complex upon Akt maturation.  Geldanamycin partially disrupted 
the interaction of Cdc37 with Akt, but had a much less significant effect on the 
interaction of Hsp90 with Akt.  Surprisingly, short-term treatment of differentiating 
C2C12 with geldanamycin increased the phosphorylation of Akt on Ser473, an effect 
mimicked by treatment of C2C12 cells with okadaic acid or the Hsp90 inhibitor 
novobiocin.  Furthermore, Akt was found to interact directly with PP2Ac in C2C12 cells,
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and this interaction was not disrupted by geldanamycin.  Our findings indicate that Hsp90 
functions to modulate PP2A action on Akt during C2C12 myoblast differentiation.  
While previous studies have indicated that PP2A plays a role in regulating Akt activation, 
our data suggests that Hsp90 modulates the ability of Akt to be dephosphorylated when it 
is bound in an Akt-PP2A complex.
Introduction
The Akt (PKB) serine-threonine protein kinase plays a major role in regulating 
signal transduction pathways that are activated by cellular growth factors [reviewed in 
(153)].  Akt function is integrated with pathways that control cell proliferation, size, 
differentiation and viability.  Since altered Akt function has been associated with the 
etiology of a number diseases states, including cancer and diabetes, a better 
understanding of Akt regulation is needed to develop adequate therapies for treatment of 
diseases associated with its dysregulation (153).
Akt plays important roles in regulating muscle cell physiology [reviewed in (154-
159)].  Stimulation of Akt has hypertrophic effects on skeletal and cardiac muscle (160-
163).  In addition to playing a positive role in stimulating myoblast proliferation, Akt 
function is required for muscle cell differentiation (164-168).  Subsequently, Akt has 
positive effects on cell growth and viability of myotubules (111, 153, 155, 157-159).  
Thus, Akt function contributes to the regulation of the number, size and survival of 
mature muscle cells.
Regulation of Akt activity is complex and not yet thoroughly understood 
[reviewed in (153, 159)].  Akt is activated upon stimulation of growth factor and integrin 
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receptors.  Akt activation in response to growth factors occurs primarily through 
receptor-mediated activation of PI3-kinase.  Direct binding of the N-terminal pleckstrin 
homology domain of Akt to PI3-kinase generated phospholipids causes the translocation 
of Akt to the plasma membrane and leads to Akt activation via its phosphorylation by 
PDK1 (Thr308) and PDK2 (Ser473).  Additional protein kinases (153), such as integrin-
linked kinase-1 (169),  also modulate Akt activity through their ability to phosphorylate 
Akt on Ser 473.  Once activated, maintenance of Thr308 phosphorylation does not appear to 
be required for Akt to remain active (170), and Akt may be capable of maintaining its 
activity through its autophosphorylation at Ser473 (171).
Akt activity is also modulated through regulation of its dephosphorylation (137, 
172-179).  Protein phosphatase 2Ac is the principal phosphatase that has been implicated 
in regulation ot Akt activity (137, 172, 174-176, 178, 179).  The best characterized 
example of phosphatase-modulated regulation of Akt is the ability of integrin-α2β1 
receptor stimulation to activate PP2Ac and induce the dephosphorylation of Akt (179).
The molecular chaperone Hsp90, together with its co-chaperone partner Cdc37, 
functions to facilitate the folding and activation of numerous protein kinases that regulate 
signal transduction pathways in cells [reviewed in (13, 29, 35, 101, 110, 180)].  Hsp90 
contains two nucleotide binding sites and it carries out its function through the binding 
and hydrolysis of ATP, which is modulated in part through the interactions of Hsp90 with 
its co-chaperone partners and its target clientele (13, 29, 101, 181-183).  Geldanamycin 
and novobiocin inhibit Hsp90 function by binding to nucleotide-binding sites located in 
the N-terminal and C-terminal domains of Hsp90, respectively, and thus, blocking 
Hsp90’s ATP-driven reaction cycle.  
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An interaction of Hsp90 (48, 99) and Cdc37 (48) with endogenous Akt has been 
documented in cancer cell lines, and Akt function is known to be dependent upon Hsp90 
and Cdc37 (48, 99, 184, 185).  Treatment of cultured cells with geldanamycin-derivative, 
17-allylaminogeldanamycin (17-AAG) leads to a depletion of Akt protein (48).  
Treatment of cells with 17-AAG did not appear to disrupt the interaction of Cdc37 with 
Akt, and the 17-AAG-induced decrease in the interaction of Cdc37 with Akt occurred in 
parallel with the loss of Akt protein from cells (48).  However, no direct data 
documenting the effect of geldanamycin or its derivatives on the interaction of Hsp90 
with endogenous cellular Akt has been presented.  In addition, HA-tagged Akt was found 
in complexes with Hsp90 only when Cdc37 was co-transfected and overexpressed (48).
Most studies attribute geldanamycin-induced loss of Hsp90-dependent protein 
clientele, including Akt (48), to its ability to disrupt the productive interaction of Hsp90 
with its client targets, leading to the destabilization of Hsp90 clients, their ubiquitination, 
and subsequent proteolysis by the proteasome (110, 180). In contrast, Tsuruo and co-
workers have suggested that Hsp90 dependence of Akt activity is the result of Hsp90 
protecting Akt from dephosphorylation by PP2A (99), in conjunction with the 
dependence of the Akt-activating kinase, PDK1 on Hsp90 function (185).  However, their 
experimental paradigms utilized Akt overexpressed in cells by transfection, which does 
not allow one to assess the effect of prolonged Hsp90-inhibition (24 h) on the activity, 
stability or turnover of previously matured Akt molecules (99, 185).  Thus, the effect of 
Hsp90 inhibition on the interaction of Hsp90 and Cdc37 with endogenous cellular Akt, 
and its maturation and stability warrants further investigation
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The process of skeletal muscle differentiation is regulated by contact-inhibition of 
cell growth, cell growth factors and cytokines (160, 166, 181-183, 186).  C2C12 
myoblasts proliferate in medium containing serum with high growth factor concentrations 
(fetal serum), but are induced to differentiate upon incubation of confluent cells in 
medium containing low growth factor concentrations (horse serum).  During this 
processes, myoblasts withdraw from the cell cycle, express a number of muscle specific 
genes, and fuse into multinucleated myotubes.  Akt has been shown to play a critical role 
in regulating the differentiation and survival C2C12 myoblasts/myotubules (166, 186, 
187).
In this report, we have examined the effects of inhibition of Hsp90 on Akt protein 
stability and activity in differentiating C2C12 myoblasts.  Contrary to conclusions drawn 
in previous reports utilizing cancer cell lines (48, 99), geldanamycin primarily 
destabilized newly synthesized Akt, while only marginally affecting the stability of 
mature Akt kinase molecules.  Of particular interest was the observation that short-term 
treatment with Hsp90 inhibitors enhanced Akt activation, apparently through their ability 
to disrupt the ability of PP2Ac to dephosphorylate Akt present in Akt/Hsp90 complexes.
Experimental Procedures
Cell culture.  C2C12 myoblast (from ATCC) cells were grown in DMEM 
(BioWhitaker) containing 10% fetal calf serum (Hyclone) and streptomycin/penicillin 
(100 units/mL, Sigma) at 37ºC, in the presence of 5% CO2 and 95% air.  For induction of 
differentiation, confluent cells were maintained in DMEM containing 5% equine serum 
(Hyclone) (differentiation media, DM).
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Analysis of effects of pharmacological treatment of C2C12 cells.  Confluent cells 
were maintained in DM for 40 h, and then treated with the given pharmacological agent 
or solvent control for 0 to 24 h as indicated in the legend to the figures.  After washing 
the cells briefly with phosphate-buffered saline (PBS), the cells were lysed with SDS 
sample buffer.  Samples were boiled in a water bath for 5 min, separated by SDS-PAGE, 
and electro-transferred to PVDF membrane (Bio-Rad).  Proteins were analyzed by 
western blotting with anti- Akt, anti-phospho-Ser473 or Thr308 specific Akt (Cell 
Signaling), anti-GSK3β, or anti-Hsp90 antibodies. 
Pulse-chase analysis of Akt expression.  Confluent cells were maintained in DM 
for 40 h, followed by metabolic labeling with [35S]methionine (100 µCi/mL, 
PerkinElmer).  For experiments analyzing the turnover of newly synthesized Akt kinase, 
geldanamycin (5 µg/mL) or vehicle control (DMSO) was added to the DM during the 30 
min labeling period with [35S]methionine.  After 30 min, the cells were washed and 
maintained in fresh DM containing geldanamycin (5 µg/mL:9 µM) for 0 to 4 h.  For 
experiments analyzing the turnover of mature kinase, cells were incubated with 
[35S]methionine for 30 min. The cells were then washed and maintained in fresh DM 
medium for 3h.  Geldanamycin (5 µg/mL) or DMSO was then added for 0 to 24 h. At the 
time points indicated in the figure legends, cells were washed with phosphate-buffered 
saline (PBS), and then lysed with RIPA lysis buffer (50 mM HEPES pH 7.5, 150 mM 
NaCl, 0.25% deoxycholic acid, 1% SDS, 2mM EDTA, 1mM EGTA and protease 
inhibitor cocktail (Sigma)).  Samples were clarified by centrifugation for 15 min at 
maximum speed in a microcentrifuge (~12000 rpm), and Akt was immunoadsorbed with 
anti-Akt antibody (Cell Signaling) at 4ºC for 2 to 3 h.  Samples were washed 3 times with 
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lysis buffer, boiled in SDS sample buffer and analyzed by SDS-PAGE on 8% gels.  
Proteins were electro-transferred to PVDF membrane, and total Akt in each sample was 
determined by western blotting with anti-Akt antibody.  [35S]-labeled Akt was visualized 
by autoradiography.
Co-immunoadsorption of Akt with Hsp90/Cdc37 or PP2Ac.  Confluent cells were 
maintained for 40 h as described previously.  Cells were treated with geldanamycin (5 
µg/mL) or DMSO for 30 min and then lysed with lysis buffer (50 mM HEPES pH 7.5, 
100 mM NaCl, 0.1% deoxycholic acid, 0.1% Triton X-100, 20 mM sodium molybdate, 
50 mM NaF, 2 mM EDTA, 1 mM EGTA, and protease inhibitor cocktail (Sigma)).  Cell 
lysate was clarified by centrifugation for 20 min at ~ 12000 rpm.  Akt or PP2A was 
immunoadsorbed with anti-Akt or anti-PP2Ac (Upstate Biotechnology) antibody at 4º C 
for 2 to 3 h.  Samples were washed 4 times with washing buffer (10 mM PIPES pH 7.2, 
150 mM NaCl) and then analyzed by western blotting with anti-Hsp90, anti-Cdc37, anti-
Akt or anti-PP2Ac as indicated in the figure legends. 
To assay PP2Ac activity present in cell extracts, immunoadsorbed PP2Ac was 
washed 2 times with wash buffer containing 20 mM NaF and then 2 times with 
phosphatase assay buffer (50 mM Tris-HCl pH 7.0, 100 µM CaCl2).  Samples were 
assayed as described as protocol of the manufacturer’s PP2A assay kit (Upstate 
Biotechnology).  To determine the effect of geldanamycin on PP2A activity in vitro, 
samples were mixed with phosphatase substrates in the presence of 10 µg/mL 
geldanamycin or DMSO and then incubated at 30º C for 10 min.  The assay was 
terminated by addition of a Malachite Green mixture solution and samples were analyzed 
using a Microplate autoreader (Bio-TEK Instruments) at 660 nm.
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In vitro transcription/translation of Akt in rabbit reticulocyte lysate.  The coding 
sequence of Akt was excised from a plasmid containing HA-tagged mouse Akt1 (kindly 
provided by Dr. Phillip Dennis, NCI) using HindIII and XbaI restriction enzyme sites, 
and cloned into pSP64T, as described previously (140), to construct pSP64T encoding 
Akt with a His6-tag at its N-terminus.  His-tagged Akt was synthesized in rabbit 
reticulocyte lysate (Promega) by coupled transcription/ translation (28, 138, 140) in the 
presence of (5 µg/mL) geldanamycin or DMSO and then matured for the times indicated 
in the figure legends.  Protein synthesis was determined to terminate at approximately 25 
min in this lot of lysate.  Akt was immunoadsorbed with anti-His5 monoclonal antibody 
(Qiagen) bound to anti-mouse agarose resin at 4ºC for 1 to 2 h as previously described 
(28, 138, 140). Samples were washed with 4 times with wash buffer and analyzed by 
SDS-PAGE on 8% gels. [35S]-labeled Akt was visualized by autoradiography and co-
adsorbed Hsp90 and Cdc37 were detected by western blotting. 
Results 
Effects of geldanamycin on Akt expression in differentiating C2C12 myoblasts.  
While the effect of Hsp90 inhibition on the fate of Hsp90-dependent protein kinases has 
been extensively studied in proliferating cancer cells, few studies have examined the 
effects of geldanamycin on cells that have withdrawn from the cells cycle.  Upon 
reaching confluence and withdrawal of serum containing high levels of growth factors, 
C2C12 myoblasts enter into G0, and proceed to differentiate and fuse into multinucleated 
myotubules.  Akt, a well-characterized Hsp90-dependent protein kinase (48, 99, 173), is 
known to play an essential role in regulating C2C12 myoblast differentiation (165, 166, 
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168).  Therefore, we examined the effect of geldanamycin on Akt expression in 
myogenic C2C12 cells during their differentiation. 
Two days after induction of differentiation, C2C12 cells were treated with 
geldanamycin for 0 to 24 h.  Western blot analysis of cell extracts indicated that the level 
of Akt was reduced gradually over the course of the 24 h geldanamycin treatment 
compared to control cells, while the level of Hsp90 expression was maintained (Fig 12A).  
Addition of the protease inhibitor ALLN or the proteasome-specific inhibitor lactacystin 
to geldanamycin-treated cells protected Akt from geldanamycin-induced turnover (Fig. 
12B).  The partial reduction of Akt observed in the presence of geldanamycin and 
protease inhibitors was likely due to accumulation of polyubiquitinated Akt species 
which would not have been detected under our western blot conditions.   These results 
suggest that Akt is degraded via a proteasome-dependent pathway in geldanamycin-
treated cells, which is consistent with the effects of geldanamycin on Akt levels reported 
in a previous study using a different cell line (48). 
Subsequently, pulse-chase analysis was utilized to determine the mechanism by 
which geldanamycin-treatment led to the depletion of Akt levels in differentiating C2C12 
cells.  Newly synthesized Akt was pulse-labeled with [35S]-Met in the presence or 
absence of geldanamycin for 30 min.  Cells were then incubated in fresh media for 0 to 
4 h in the presence or absence of geldanamycin.  The turnover rate of the newly 
synthesized [35S]-labeled Akt was determined by immunoadsorption of Akt from cell 
extracts, SDS-PAGE and autoradiography (Fig. 12C).  Newly synthesized Akt turned 
over rapidly within 1 h of “chasing” the cells into fresh media.  At the 0 h time point, the
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Figure 12.  Effects of geldanamycin on Akt protein levels and turnover.  (A) 
Confluent C2C12 cells were maintained in differentiation medium (DM) for 40 hrs and 
then treated with geldanamycin (+) or DMSO (-) for 0 to 24 h as indicated. (B) Cells 
were treated with DMSO (-/-, lane 1), 5 µg/mL:9 µM geldanamycin (GA/-, lane 2), 10 
µM ALLN (AN/-, lane 3), 10 µM lactacystin (LC/-, lane 4), 10 µM ALLN plus 5 
µg/mL:9 µM geldanamycin (AN/GA, lane 5) or 10 µM lactacystin plus 5 µg/mL 
geldanamycin (LC/GA, lane 6) for 24 hrs.  Cells were washed and lysed directly with 
SDS buffer, and analyzed by SDS-PAGE and western blotting with anti-Hsp90 and anti-
Akt antibodies.  Pulse-chase experiments to determine the turnover rates of newly 
synthesized (C) or mature (D) [35S]-Akt were carried out as described under 
“Experimental Procedures”.  Briefly, Cells were pulsed labeled with [35S]Met for 30 min.  
DMSO (lanes 1-5) or 5 µg/mL geldanamycin (GA; lanes 7-11) were present during the 
labeling period and chase (C), or added 3 h after the initiation of the chase (D). Akt was 
immunoadsorbed with anti-Akt agarose resin from cell extracts prepared at the times (h) 
indicated after the initiation of the chase.  Akt was detected by autoradiography 
([35S]Akt) or western blotting (WB:Akt) after analysis of samples by SDS-PAGE.  NS: 
non-immune IgG as a control for non-specific binding (C and D, lane 6).
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[35S]-Akt in extracts from control cells appeared as a doublet that shifted to a single band 
with slower electrophoretic mobility at later time points.  In contrast, most of the [35S]-
Akt present in extracts from geldanamycin treated cells co-migrated with the band from 
the control cell extracts that had the faster electrophoretic mobility.  Furthermore, the 
minor amount [35S]-Akt that was present in extracts from geldanamycin-treated cells that 
had slower electrophoretic mobility did not turnover during the time course of the 
experiment.  These observations suggested that Akt was undergoing phosphorylation 
(commonly associated with acquisition of slower electrophoretic mobility (48, 138)
during its maturation, and that the little Akt that had “matured” in geldanamycin-treated 
cells had attained a stable conformation.
Work with other cell lines has suggested that geldanamycin-induced depletion of 
Akt protein (48, 188, 189) is due to accelerated turnover of Akt (48).  To test this 
hypothesis, Akt was pulsed labeled in differentiating C2C12 cells for 30 min, and then 
matured for 3 h prior to exposure of the cells to geldanamycin.  In three independent 
experiments, geldanamycin-treatment caused little significant change in the turnover rate 
of Akt during the first 8 h of exposure of the cells to the drug (Fig. 12D).  However, 
between 8 and 12 h of treatment of the cells with geldanamycin, the turnover of Akt was 
clearly accelerated relative to the control, and near complete turnover of the Akt was 
noted after 24 h of treatment. Thus, while the data clearly indicate that newly synthesized 
Akt requires geldanamycin-inhibitable Hsp90 function for its folding and stability, the 
requirement of mature Akt for Hsp90 function is more subtle, as little impact on Akt 
protein levels were noted for the first 8 h of incubation with geldanamycin. 
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Effect of geldanamycin on the interaction of Hsp90 and Cdc37 with Akt.  In 
previous studies, we have utilized coupled transcription/ translation in rabbit reticulcyte 
lysate to model interaction of Hsp90 and Cdc37 with the Src-family tyrosine kinases, Lck 
and Hck, and the heme-regulated eIF2α kinase (HRI) (138-141, 190-192).  Hsp90 and 
Cdc37 were observed to dissociate from Hsp90/Cdc37-kinase complexes as newly 
synthesized kinases matured into their active conformations (41, 138, 139, 141, 190).  
Furthermore, these studies indicated that geldanamycin-inhibitable Hsp90 function was 
obligate for these protein kinases to attain an active conformation, and that 
geldanamycin-treatment prevented the formation of Hsp90-kinase complexes that were 
stable to washing in buffers containing high salt concentrations (41, 45, 138, 139, 141, 
190).  In addition, geldanamycin blocked the interaction of Cdc37 with the salt-labile 
Hsp90-kinase complexes that form in its presence in rabbit reticulocyte lysate (41, 45, 
129, 141).
Therefore, His-tagged [35S]-Akt was synthesized and matured in reticulocyte 
lysate.  Both Hsp90 and Cdc37 were co-immunoadsorbed with His-tagged Akt after its 
synthesis was terminated at 25 min (Fig. 13B, lane 1).  Relative to the amount of Cdc37 
bound to Akt immediately after termination of its synthesis, the interaction of Akt with 
Cdc37 was reduced by 70 % and >95% after maturation of the kinase for 60 and 90 min, 
respectively.  In contrast, interaction of Akt with Hsp90 was reduced by only 25% and 
40% after the 60 and 90 min maturation, respectively, after normalization to the amount 
of His-tagged [35S]-Akt immunoadsorbed from the reticulocyte lysate (Fig. 13B).  Thus, a 
stable interaction of Hsp90 with a population of Akt molecules appears to be maintained 
after a maturation period that results in nearly the complete loss of associated Cdc37.
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Figure 13.  Effects of geldanamycin on the interaction of Akt with Hsp90 and Cdc37.
(A) [35S]-labeled His-tagged Akt was synthesized for 30 min in the presence of DMSO (-, 
lane 1) or 10 µg/mL geldanamycin (GA) (+, lane 2) in reticulocyte lysate. The samples 
were immunoadsorbed with anti-His antibody and analyzed by western blotting with anti-
Hsp90 (Hsp90) and anti-Cdc37 (Cdc37) antibodies and autoradiography (IP: 
His6[
35S]Akt). (B) [35S]-labeled His-tagged Akt was synthesized for 25 min (lane 1) and 
then matured for an additional 35 (lane 2, 60) or 65 (lane 3, 90) min as indicated. [35S]-
labeled His-tagged Akt was immunoadsorbed and analyzed as described above. NS (A. 
lane 3 & B. lane 4): Analysis of sample lacking template coding for His-tagged Akt as a 
control for nonspecific binding of Hsp90 and Cdc37 to the immune resin.  (C) C2C12 
cells were maintained in DM for 40 hrs, and then treated with DMSO (lane 1 and 2) or 5 
µg/mL geldanamycin (GA; lane 3 and 4) for 3 h.  Cell lysates were prepared as described 
under “Experimental Procedures”.  Akt was immunoadsorbed with anti-Akt antibody 
resin (lanes 2 and 4) or a nonspecific IgG antibody resin (lanes 1 and 3), and Hsp90, 
Cdc37 and Akt were detected by western blotting.
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Subsequently, the effect of geldanamycin on the interaction of Hsp90 and Cdc37 with the 
newly synthesized Akt was assessed (Fig. 13A).  Western blot analysis of samples 
prepared by immunoadsorption with anti-His tag antibodies using buffers with a 
moderate salt concentration (150 mM NaCl) indicated that Hsp90 and Cdc37 co-adsorbed 
with newly synthesized Akt, and that geldanamycin quantitatively blocked the interaction 
of Cdc37 with Akt.  In contrast, geldanamycin reduced the interaction of Hsp90 with Akt 
by only 25% relative to the amount of His-tagged [35S]-Akt immunoadsorbed from the 
reticulocyte lysate.
We next examined the effect of geldanamycin on the interaction of Hsp90 and Cdc37 
with Akt in differentiating C2C12 cells.  Western blot analysis of protein that co-
adsorbed with Akt from C2C12 extract indicated that the interaction of Hsp90 with Akt 
was not disrupted by geldanamycin.  However, the interaction of Cdc37 with Akt was 
decreased ~50 % relative to the DMSO-treated control cells (Fig. 13C).
Effect of short-term geldanamycin treatments on Akt phosphorylation-state in 
proliferating and differentiating C2C12 cells.  The results describe above indicate that 
short-term treatments of C2C12 cells with geldanamycin have little effect on the turnover 
rate of mature Akt molecules and does not disrupt the interaction of Hsp90 with Akt over 
the period of drug treatment.  Therefore, we examined the effect of geldanamycin 
treatment on the phosphorylation state of Akt in proliferating and differentiating C2C12 
cells.  Phosphorylation of Akt on Thr308 and Ser 473 is associated with its activation, 
which occurs through a number of pathways as described in the introduction (153, 159).
Short-term (30 min) treatment of proliferating C2C12 with geldanamycin caused 
no loss of Akt protein, and did not affect the level of Akt phosphorylation on Thr308 (Fig. 
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14A).  However, an approximate doubling of Akt phosphoryation on Ser473 was noted in 
the presence of geldanamycin, which correlated with an increase in the level of 
phosphorylation of glycogen synthase kinase-3β (GSK3) (Fig. 14A), a well characterized 
target of Akt (153).  Thus, short-term treatment of actively growing C2C12 cells with 
geldanamycin appeared to be causing the activation of Akt.
Subsequently, we compared the effect of geldanamycin on Akt activity and 
phosphorylation state in proliferating versus differentiating C2C12 cells.  Again, 
geldanamycin-treatment of growing C2C12 cells (GC) caused no decrease in Akt protein, 
caused a slight increase in the phosphorylation of Thr308, and clearly increased the level 
of Akt phosphorylation on Ser473 (Fig. 14B).  On the higher resolution gel used in this 
experiment, the increase in Akt phosphorylation on Ser473 correlated with the appearance 
of a distinct doublet on the western blot used for the detection of total Akt protein. 
Short-term treatment of differentiated C2C12 cells (DF) with geldanamycin also 
did not cause any decrease in Akt protein levels and increased the level of Akt 
phosphorylation on Ser473 (Fig. 14B). However, phosphorylation of Akt on Thr308 was 
not observed in either control or geldanamycin-treated differentiating C2C12 cells.  Thus, 
Akt activity in differentiated C2C12 cells appears to be regulated at the level of Ser473
phosphorylation and not through changes in the phosphorylation state of Thr308.
Effect of Hsp90 inhibition on Akt phosphorylation-state in differentiating C2C12 
cells.  To determine whether C2C12 activation was a specific effect of geldanamycin, or 
was a general effect of the inhibition of Hsp90, we compared the effects of geldanamycin 
to those of novobiocin, an Hsp90 inhibitor which binds to the C-terminus of Hsp90 (26-
28). 
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Figure 14. Differential phosphorylation states of Akt in proliferating and 
differentiating C2C12 cells. (A) Cells were grown to 50 to 70% confluence and treated 
with DMSO (-) or 5µg/mL geldanamycin (GA, +) for 30 min. (B) C2C12 were grown to 
50 to 70% confluence (growing cells, GC: lanes 1 and 2), or induced to differentiate 
(differentiating cells, DF: lanes 3 and 4) as described in Figure 12.  Cells were treated 
with DMSO (-, lanes 1 and 3) or 5 µg/mL geldanamycin (GA, +, lanes 2 and 4).  Cell 
lysates were prepared as described under “Experimental Procedures”, and samples were 
analyzed by western blotting with anti-Akt (Akt), anti-Akt/phospho-Thr308 (p-T308Akt), 
anti-Akt/phospho-Ser473 (p-S473Akt) Akt, or anti-GSK3- phospho-S21/9 (p-GSK3) 
specific antibodies.
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Again, treatment of C2C12 cells with geldanamycin led to enhanced phosphorylation of 
Akt on Ser 473, which increased as early as 30 min after initiation of the drug treatment 
compared to the DMSO treated control cells (Fig. 15A).  Novobiocin similarly enhanced 
the phosphorylation of Akt on Ser 473 (Fig. 15B), and the enhancement of Ser 473
phosphorylation in C2C12 cells occurred in a concentration dependent manner.  Thus, 
inhibition of Hsp90 function with either geldanamycin or novobiocin treatment led to 
enhancement of Akt phosphorylation.  This enhanced phosphorylation of Akt correlated 
with increased Akt activity, as evidenced by enhanced phosphorylation state of GSK3β in 
C2C12 cells (Fig. 14A and 15B).
Previous studies have indicated that activation of Akt by phosphorylation on 
Ser 473 may occur in the absence of PDK1 activation (99, 153).   PP2Ac has been 
proposed to be the most likely candidate for regulating the rate of Akt dephosphorylation 
(99, 137, 175, 177).  To test this hypothesis, differentiating C2C12 cells were treated with 
okadaic acid or geldanamycin.  Okadaic acid treatment enhanced Akt phosphorylation on 
Ser 473 in a concentration dependent manner, similar to the effect observed for 
geldanamycin (Fig. 15C).  Again, enhanced Akt phosphorylation on Ser473 correlated 
with enhanced GSK3β phosphorylation (Fig. 15C).  These results suggest that Akt 
activation in response to geldanamycin and novobiocin may be occurring through their 
capacity to inhibit the ability of PP2Ac to dephosphorylate Akt via some as yet 
uncharacterized mechanism.
Interaction of PP2Ac with Akt in C2C12 cells.  While PP2A has been proposed to 
play a role in regulating the activity of Akt, only one previous study has demonstrated a 
direct interaction between the two proteins (179).  To further characterize the effect of
75
Figure 15.  Effects of short-term treatments with geldanamycin, novobiocin, and 
okadaic acid on Akt phosphorylation and activity.  Cells were maintained in DM for 
40 hrs and then treated with DMSO (lane 1 & 2) or 5µg/mL geldanamycin (GA, lane 3 & 
4) for 30 or 60 min (A); or cells were treated with DMSO (lane 1) or 1 mM (lane 2), 2 
mM (lane 3), 5 mM (lane 4) or 7.5 mM (lane 5) novobiocin (NB) for 30 min (B); or cells 
were treated with DMSO (lane 4), or 5 µg/mL:9 µM geldanamycin (GA, lane 5), or 1000 
nM (lane 1), 500 nM (lane 2), or 100 nM (lane 3) okadaic acid (OA) for 30 min (C). Cells 
were lysed with SDS buffer and analyzed by western blotting with anti-Akt (Akt), anti-
Akt/phopho-Ser473 (pAkt) Akt, or anti-GSK3- phospho-S21/9 (pGSK3) specific antibodies.
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geldanamycin on Akt activation, we examined whether Akt and PP2Ac were associated 
in C2C12 extracts.  PP2Ac was found to be co-immunoadsorbed with Akt from C2C12 
extracts (Fig. 16A).  Geldanamycin-treatment had no effect on the interaction of the two 
proteins and did not have an effect on the amount of Hsp90 that was co-adsorbed with 
Akt from the cell extracts.  Furthermore, Akt co-immunoadsorbed with PP2Ac in the 
reciprocal experiment (Fig. 16B).  Thus, PP2Ac interacts directly with Akt in C2C12 
cells and inhibition of Hsp90 function with geldanamycin had no effect on this 
interaction.
Discussion
Our results indicate that inhibition of Hsp90 function by geldanamycin results in 
the progressive loss of Akt protein from differentiating C2C12 cells.  However, the effect
of geldanamycin was only reproducibly observed after 8 h of drug treatment.  While our 
results are consistent with previously published studies noting a loss in Akt protein levels 
after 9 h of treatment with 17-AAG (48, 184), the previously published pulse-chase study 
only examine mature Akt levels after treatment of cells with 17-AAG for 12 h or longer 
(48).  Since we observed little effect of geldanamycin on the interaction of Hsp90 with 
Akt, and geldanamycin-treatment results in the inhibition of a myriad of Hsp90-
dependent proteins, it is difficult to conclude that the geldanamycin-induced decrease in 
Akt levels is a direct effect of geldanamycin on Akt stability via Hsp90-inhibition.
On the contrary, our data indicate that the geldanamycin-induced decrease in Akt 
levels may be primarily the result of inhibition of Hsp90-facilitated maturation of Akt.  
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Figure 16. Interaction of Akt with PP2Ac.  Confluent C2C12 cells were maintained in 
DM for 40 h (A and B), and were untreated (B) or were treated with DMSO (A: lane 1) 
or 5 µg/mL geldanamycin (A: GA, lane 2) for 30 min. Cell lysates were prepared as 
described under “Experimental Procedures” and (A) Akt was immunoadsorbed with anti-
Akt agarose resin (IP:Akt) or (B) PP2A was immunoadsorbed with anti-PP2Ac antibody 
(IP:PP2Ac).  Samples were analyzed by western blotting with anti-PP2Ac, anti-Akt, or 
anti-Hsp90 antibodies.  Nonspecific IgG agarose resin used as a control for nonspecific 
binding of proteins to the immune resin (A, NS: lane 3; and B, lane 1).
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Geldanamycin-treatment nearly quantitatively blocked the maturation of newly 
synthesized Akt in differentiating in C2C12 cells.  Furthermore, newly synthesized 
immature Akt molecules were completely degraded within 1 h of their synthesis in 
geldanamycin treated cells.  Thus, the slow progressive loss of Akt in the presence of 
geldanamycin correlates with the inability of the cells to mature newly synthesized Akt 
molecules into a stable conformation.  However, as discussed below, the geldanamycin-
induced enhancement of the turnover of mature Akt molecules may result from its ability 
to cause the activation of Akt.  
The geldanamycin-induced inhibition of Akt maturation probably results from its 
ability to inhibit Cdc37 from productively interacting with newly synthesized Hsp90-
bound Akt molecules in cultured C2C12 cells, rather than geldanamycin affecting the 
interaction of Hsp90 and Cdc37 with mature Akt molecules.  Both Hsp90 and Cdc37 are 
required to facilitate the maturation and activation of numerous protein kinases in cells 
(35), and consistent with the results reported here, both Hsp90 (48, 99) and Cdc37 (48, 
193) interact with endogenous Akt in cells.  Previously, we have shown that while
geldanamycin treatment does not block the interaction of Hsp90 with protein kinases, it 
does, however, cause Hsp90-kinase binding to become labile to washing in high salt 
buffers (28, 41, 45, 129, 141, 194).  On the other hand, geldanamycin blocks the 
interaction of Cdc37 with their newly synthesized target kinases (28, 41, 45, 129, 141, 
194).  In our current studies, short-term treatment with geldanamycin had little effect on 
the interaction of Hsp90 with Akt in differentiating C2C12 cells, while geldanamycin 
reduced the interaction of Cdc37 with Akt by ~50%.  In a previous study, treatment of 
MCF-7 cells with 17-AAG had little effect on the interaction of Cdc37 with Akt, but data 
relative to the effect of 17-AAG on Hsp90-Akt interactions was not shown (48) .  In the 
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reticulocyte lysate model system, geldanamycin blocked the interaction of Cdc37 with 
newly synthesized Akt, while it had much less of an effect on the interaction of Hsp90 
with Akt.  Thus, geldanamycin-induced inhibition of Akt maturation is likely the result of 
its ability to inhibit the binding of Cdc37 to complexes formed between Hsp90 and newly 
synthesized Akt molecules.
Our data suggest that turnover of Akt occurs via the proteasome.  Treatment of 
C2C12 cells with lactacystin, a proteasome-specific inhibitor, and ALLN, a more 
generalized protease inhibitor, prevented the complete loss of mature Akt molecules from 
differentiating C2C12 cells treated with geldanamycin.  The partial loss of Akt observed 
in the presence of the inhibitors is likely due to accumulation of ubiquitinated Akt, which 
would not have been detected under our western blot conditions.  Again, these results are 
consistent with conclusions drawn from another study examining the Hsp90-dependence 
of Akt stability in tumor cell lines (48), which clearly indicated that inhibition of Hsp90 
by ansamycins leads to a loss of Akt protein from cells via the ubiquitination/proteasome 
pathway.  While alterations of PP2A activity (99) or PDK1 levels (185) could 
undoubtedly play additional roles in the decline of cellular Akt activity observed upon 
Hsp90-inhibition, as proposed by Tsuruo and co-workers, the loss of total Akt activity 
observed upon long-term (24 h) inhibition of Hsp90 function is most simply accounted 
for by the loss of mature Akt protein.
Akt activity appears to be regulated differently in proliferating versus 
differentiating C2C12 cells.  Akt was phosphorylated on Thr308 and Ser473 in pre-
confluent C2C12 cells, but was only phosphorylated on Ser473 in differentiating cells.  
Phosphorylation of Akt at Thr308 has been shown to be stimulated through growth factor 
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receptor (e.g., insulin-like growth factor-1 receptor) mediated pathways [reviewed in 
(153, 155-157, 159)].  Phosphorylation of Thr308 is then thought to enhance 
phosphorylation of Akt at Ser473.  Our results appear to indicate that differentiating 
C2C12 cells are able to maintain the ability to regulate Akt activity via changes in Ser473
phosphorylation after withdrawal of growth factors from the serum and in the absence of 
phosphorylation of Thr308.  These results are consistent with previous studies indicating 
that after its initial activation, phosphorylation of Thr308 is not required to maintain the 
activity of Akt (153, 170). 
Our results indicate that Akt activity is modulated both by positive and negative 
signaling pathways in differentiating C2C12 myoblasts.  Akt function is required for 
muscle cell differentiation, and in maintaining the viability and size of differentiated 
muscle cells [reviewed in (154-159)].  As noted in the introduction, Akt activity is 
regulated through multiple mechanisms, and can involve mechanisms leading to 
stimulation of Akt’s phosphophorylation or dephosphorylation (153, 159, 169, 176, 179, 
189).  Stimulation of Akt leads to skeletal and cardiac muscle hypertrophy, while down-
regulation of its activity leads to muscle cell atrophy and apoptosis (160-163).  Treatment 
of differentiating C2C12 cells with okadaic acid leads to enhanced phosphorylation of 
Akt on Ser473 and increased GSK3β phosphorylation.  Thus, positive signals that lead to 
Akt phosphorylation on Ser473 in C2C12 cells are being balanced by negative signals, 
which stimulate Akt dephosphorylation.  While this manuscript was in preparation, 
geldanamycin was also reported to enhance Akt phosphorylation in IGF-1 (or insulin) 
stimulated neuroblastoma and embryonic kidney cells, possibly through a mechanism 
involving inhibition of Akt dephosphorylation (178).  Our results are consistent with this 
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hypothesis, and identify PP2Ac as the phosphatase responsible for Akt dephosphorylation 
modulated by geldanamycin- and novobiocin-inhibitable Hsp90 function in C2C12 cells.  
Hsp90 appears to play a role in balancing the phosphorylation state of mature Akt 
molecules in response to signaling pathways.  As opposed to the long-term effects of
Hsp90 inhibitors on Akt stability and protein levels, short-term treatment of 
differentiating C2C12 cells with geldanamycin or novobiocin led to enhanced Akt 
activity, as measured by Akt phosphorylation at Ser473 and enhanced phosphorylation of 
GSK3β.  The effect of the Hsp90 inhibitors on Akt phosphorylation appears to be 
through their action on Hsp90, as the inhibitors had no direct inhibitory effect on PP2Ac 
activity in vitro (not shown).  Furthermore, PP2A appears to interact directly with Akt, 
rather than Hsp90, since no detectable amounts of Hsp90 or PP2Ac were co-
immunoadsorbed with anti-PP2Ac or anti-Hsp90 antibodies, respectively.  Thus, 
inhibition of Hsp90 function in C2C12 cells appears to alter Akt structure in a manner 
that interferes with the ability of PP2A to dephosphorylate Akt at Ser473, as geldanamycin 
does not interfere with the interaction of Akt with PP2A or Hsp90.  Alternatively, 
geldanamycin could cause the inhibition of an Hsp90-dependent protein whose activity is 
required for PP2Ac activity.
Geldanamycin-induced activation of Akt may also account for the reduced half-
life of mature Akt molecules in differentiating C2C12 cells.  Activated mutants of Src-
family kinases, v-Src, Lck/Y505F and Hck/Y499F have an increased dependence upon 
Hsp90 function to maintain their stability and function in their mature state, and 
geldanamycin enhances the rate of turnover of these proteins in cells relative to their wild 
type counterparts.  Thus, mutations that lead to hyperactivation of Hsp90-dependent 
kinases appear to generate a greater dependence of these kinases on Hsp90 to maintain 
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their function.  The enhanced turnover rate of mature Akt in geldanamycin treated cells 
may similarly be a function of its enhanced state of activation.
As alluded to above, the results presented here also suggest an additional 
mechanism by which inhibition of Hsp90 function can enhance cell survival and protect 
against apoptosis in certain cell populations.  Depending on cell context, geldanamycin
can promote or impede apoptosis [reviewed in (195)].  Treatment of both rat neonatal 
cardiomyocytes and myogenic H9c2 cells with Hsp90 inhibitors, herbimycin A or 
geldanamycin induced resistance of these cells to apoptosis stimulated by ischemia (196).  
Geldanamycin also protects brain cells from damage induced by ischemia (189, 197).  
While the anti-apoptotic effect of Hsp90 inhibitors has been attributed primarily to their 
ability to induce the elevation of Hsp70 levels, our results suggest an additional 
mechanism may also play a role, at least during short-term treatment with these drugs: 
the potential anti-apoptotic effect of Akt stimulation induced by short-term inhibition of 
Hsp90.
The hypothesis that Hsp90 functions to balance the phosphorylation state, and 
therefore, attenuate the activation of the Akt kinase may be relevant to the regulation of 
other protein kinase systems.  After their Hsp90-dependent maturation, geldanamycin has 
been shown to activate the double-stranded RNA-activated eIF2α kinase, and the Raf-
MAPK pathway in cells (198).  The maturation of the HRI kinase activity has been 
shown to involve a balance between the stimulatory effects of Hsp90-Cdc37 on HRI’s 
autophosphorylation, and the inhibitory effects of HRI’s Hsp90- and PP5-dependent 
dephosphorylation (41, 129).  Thus, the capacity of Hsp90 to modulate a protein’s 
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activation state by integrating the signals from both positive and negative effectors may 
be paradigm applicable to other Hsp90-dependent signal transduction proteins.
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CHAPTER IV
           Differential effects of Hsp90 inhibition on protein kinases regulating signal 
transduction pathways required for myoblast differentiation
Abstract
Several protein kinases whose functions are required for the development and 
homoeostasis of muscle cells are dependent upon Hsp90 to acquire and maintain an 
active conformation.  These protein kinases not only regulate pathways involved in 
myoblast differentiation, they also regulate growth and viability of differentiated 
myotubules.  In this study, we examined the effect of geldanamycin-induced inhibition of 
Hsp90 function on the differentiation of C2C12 myogenic cells.  Geldanamycin treatment 
of differentiating C2C12 myoblasts, blocked myotubule formation, and led to the 
depletion of three Hsp90-dependent protein kinases, ErbB2, Fyn, and Akt, and induction 
of apoptosis.  Geldanamycin caused ErbB2 levels to drop rapidly (absent within 8 h), 
while Fyn and Akt levels decreased at a slower rate (absent after 24 h).  Geldanamycin 
blocked the interaction of Hsp90 and Cdc37 with Fyn, an interaction that has not been 
previously documented.  Pulse-chase experiments with metabolically [35S]-labeled 
proteins indicated that newly synthesized Akt and Fyn were degraded rapidly in the 
presence of geldanamycin.  However, geldanamycin had little effect on the turnover rate 
of mature Fyn and Akt.  Curiously, total cellular Src (c-Src) protein levels and the 
turnover rate of newly synthesized [35S]-c-Src were not affected by geldanamycin.
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Geldanamycin blocked the expression of myogenin in differentiating C2C12 cells 
without affecting the level of MyoD expression.  However, MyoD was found to interact 
with Cdc37, and geldanamycin disrupted this interaction. Thus, inhibition of Hsp90 
disrupts signal transduction networks that are involved in regulating myoblast 
differentiation, and muscle cell homeostasis.  Our findings indicate that protein kinases 
can have a differential dependence on Hsp90 for maintenance of their function, and that 
Hsp90-inhibitors could potentially have both beneficial and adverse effects on muscle 
cell populations depending upon the physiology of the system.
Introduction
Muscle cell differentiation is a highly complex and tightly regulated process that 
requires multiple steps to occur in an ordered progression [reviewed in (199-204)].  
Myoblasts must withdraw from the cell cycle, elongate and then fuse into multinucleated 
myotubes.  This program of differentiation requires the function of a number of signal 
transduction cascades that regulate the activation of muscle-specific regulatory factors, 
and the expression of muscle specific genes, which promote the development of mature 
muscle tissue.  In addition, signal transduction pathways subsequently function to 
regulate the size and sustain the viability of the mature muscle cell (reviewed in (153, 
155-159)).
The proto-oncogene product ErbB2 (a.k.a., HER2) encodes a receptor tyrosine 
kinase that acts as a co-receptor for growth factors through hetero-dimerization with other 
members of the erbB-family [reviewed in (205, 206)].  Signaling pathways regulated by 
ErbB2 play critical roles in numerous developmental processes.  ErbB2 function is 
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required for the proper development and differentiation of cardiac and skeletal muscle.  
Furthermore, ErbB2 function is also required for cardiac and skeletal muscle cell 
homoeostasis, and for the survival of myoblasts (207).  Disruption of ErbB2 function 
leads to apoptosis of differentiated myofibrils, with ensuing defects in skeletal muscle 
regeneration due to a reduction in the number of muscle spindles (208).  ErbB2 is also 
required to maintain normal heart physiology, and defects in ErbB2 function result in 
cardiomyopathy and heart failure (205, 206, 208, 209).
While insulin-like growth factors (e.g., IGF-1) act in concert with other growth 
factors to promote myoblast proliferation, they are also potent stimulators of muscle cell 
differentiation (160, 164, 167, 210, 211).  IGFs act in part through stimulation of the 
PI3K/Akt signal transduction pathway (153, 161, 167, 168, 210, 212).  Akt1 activation is 
required for the expression of Akt2, and subsequent Akt2-dependent activation of MyoD-
MEF2 transcriptional activity and induction of myogenin expression (161, 165, 166, 168, 
186, 210).  Activation of Akt also promotes muscle cell growth and increase in muscle 
mass, while Akt deficiency leads to atrophy of muscle tissue (155, 157-163, 172, 187, 
212-217).
Cell adhesion also plays a part in the highly orchestrated multi-step process of 
muscle cell differentiation (reviewed in (153, 218)).  Integrins are hetero-dimeric 
transmembrane receptors composed of alpha- and beta- subunits that interact with 
components of the extracellular matrix and regulate cell adhesion.  Different isoforms of 
these subunits are expressed in a developmentally regulated fashion, are localized to 
different sites in cells, and carry out distinct functions (183, 219-225).  Signaling via 
integrin receptors modulates cell cycle progression, migration and proliferation of 
developing myoblasts.  Integrin receptors are also involved in regulating the 
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differentiation of myoblasts.  Integrins play roles in myotubule formation via cell fusion, 
the formation and the maintenance of the integrity of neuromuscular and myotendinous 
junctions, and the adhesion of muscle fibers that is essential for generation of contractile 
force (218, 222, 224-227).  Signaling pathways activated by integrin receptors both 
promote and impede the differentiation of myoblasts.  The PI3K/Akt pathway is both 
activated and inhibited by this receptor family via changes in the activities of protein 
kinases and phosphatases that promote the phosphorylation or dephosphorylation of Akt 
(169, 176, 179, 182, 211, 221, 222, 228-230).  Dysregulation of intergrin-mediated 
signaling is associated with both skeletal and cardiac muscle hypertrophy and atrophy 
(219, 220, 223). 
Recent studies have indicated that non-receptor Src-family kinases are also 
involved in the regulation of muscle cell proliferation, differentiation and survival (231-
233).  c-Src stimulates myoblast proliferation, and also appears to play a role in clustering 
of acetylcholine receptors during development of the neuromuscular junctions (234-237). 
Expression of the Src-family kinase Fyn is up-regulated during myoblast differentiation 
and myotube formation (234, 238, 239).  Fyn expression is required for cell fusion 
leading to the formation of multi-nucleated muscle cells and neuromuscular junctions.  
Promotion of myofiber survival and suppression of anoikis (apoptosis induced by 
disruption of cells adhesion to the extracellular matrix) also involves Fyn signaling 
modulated through the merosin-integrin cell adhesion system (238).
The integration of signals generated through the pathways described above leads 
to changes in the expression or activity of gene products that regulated the expression of 
muscle-specific genes and cell differentiation.  Skeletal muscle differentiation can be 
induced by the overexpression of myogenic factors, such as MyoD, myogenin, Myf5 and 
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MRF4 in non-muscle cells [reviewed in (200-203, 240)].  Inhibition of the expression or 
function of these myogenic factors can arrest the formation of multi-nucleated cells 
during differentiation of C2C12 myoblasts, indicating that these factors regulate the 
expression of a distinct subset of muscle-specific genes at the onset of cell differentiation 
(166, 182, 186, 210, 234). 
Hsp90 (heat shock protein 90) is an ATP dependent molecular chaperone, which 
facilitates the folding and activation of numerous proteins involved in signal transduction 
in cells [reviewed in (13, 29, 101)].  Hsp90 signal transduction clients carry out functions 
that are involved regulation of cell proliferation, differentiation, and survival.  Included in 
this myriad of Hsp90-dependent protein clients are [reviewed in (13, 29, 101)] 
transcription factors, such as steroid hormone receptors, hypoxia-inducible factor-alpha, 
and MyoD (241, 242); protein kinases, including ErbB2, Akt, and Src family kinases; and 
others proteins, such as nitric oxide synthase and telomerase.
Drugs that bind to the N-terminal ATP-binding domain of Hsp90, such as the 
ansamycin-derivative geldanamycin, and radicicol, inhibit Hsp90 function (reviewed in 
(13, 29, 101, 110, 180).  Inhibition of Hsp90 can prevent the maturation of Hsp90-
dependent clients, and induce the destabilization and degradation of Hsp90 clients.  
Tumor cell populations are particularly sensitive to apoptotic cell death induced by these 
Hsp90-inhibitors (100, 243-246).  
Most studies on the physiological effects of Hsp90-inhibition have been carried 
out on cancer cell populations.  The geldanamicin derivative 17-allylamino-geldanamycin 
is currently in phase-I and -II clinical trials (110, 180, 243, 244, 246).  Considering the 
fact that inhibition of Hsp90 function interferes with numerous signal transduction 
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pathways that regulate the proliferation, differentiation and survival of other cell 
populations, a greater understanding of the potential adverse effects of Hsp90-inhibition 
on normal cells, tissues and organs is needed.  In this report, we have examined the effect 
of inhibition of Hsp90 on myoblast differentiation.  Our results indicate that Hsp90 
function is essential for the cellular processes involved in myoblast differentiation, as it is 
required for the expression of the muscle regulatory factor (e.g. myogenin), and for the 
maturation and/ or stability of the ErbB2, Akt, and Fyn kinases.
Experimental Procedures
Cell culture – C2C12 myoblast (from ATCC) cells were grown in DMEM 
(BioWhitaker) containing 10% fetal calf serum (Hyclone) and streptomycin/penicillin 
(100 units/mL, Sigma) at 37ºC, in the presence of 5% CO2 and 95% air.  For induction of 
differentiation, confluent cells were maintained in DMEM containing 5% equine serum 
(Hyclone) (differentiation media, DM).  Cells were photographed (100X magnification) 
at 50-70% confluence, at confluence, 40 h after induction of differentiation, and 24 h 
after treatment of the 40 h differentiating cells with DMSO or 5 µg/mL geldanamycin.
Analysis of the effects of geldanamycin on differentiating C2C12 myoblasts –
Confluent cells were maintained in DM for 40 h, and then treated with the given 
pharmacological agent or solvent control for 0 to 24 h as indicated in the legend to the 
figures.  After washing the cells briefly with phosphate-buffered saline (PBS), the cells 
were lysed with SDS sample buffer. Samples were boiled in a water bath for 5 min, 
separated by SDS-PAGE, and electro-transferred to PVDF membrane (Bio-Rad).  Protein 
concentration for SDS-PAGE was determined with a BCA assay kit (Pierce).  Cell 
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protein levels were analyzed by western blotting with anti-ErbB2 (Oncogene Research), 
anti-Hsp90, anti-Akt, anti-cleaved poly (ADP-ribose) polymerase (PARP) (Asp214) (Cell 
Signaling), anti-Fyn and c-Src (Santa Cruz Biotechnology) antibodies.
Pulse-chase analysis of Fyn, Akt and c-Src expression – Confluent cells were 
maintained in DM for 40 h, followed by metabolic labeling with [35S]methionine (100 
µCi/mL, PerkinElmer).  For experiments analyzing the turnover of newly synthesized 
kinases, geldanamycin (5 µg/mL) or vehicle control (DMSO) was added to the DM 
during the 30 min labeling period with [35S]methionine.  After 30 min, the cells were 
washed and maintained in fresh DM containing geldanamycin (5 µg/mL) for 0 to 4 h.  
For experiments analyzing the turnover of mature kinases, cells were incubated with 
[35S]methionine for 30 min. The cells were then washed and maintained in fresh DM 
medium for 3h.  Geldanamycin (5 µg/mL) or DMSO was then added for 0 to 24 h.  At the 
time points indicated in the figure legends, cells were washed with phosphate-buffered 
saline (PBS), and then lysed with RIPA lysis buffer (50 mM HEPES pH 7.5, 150 mM 
NaCl, 0.25% deoxycholic acid, 1% SDS, 2mM EDTA, 1mM EGTA and protease 
inhibitors cocktail (Sigma)).  Samples were clarified by centrifugation in a 
microcentrifuge for 15 min at maximum speed (~12000 rpm), and each kinase was 
immunoadsorbed with anti-Akt, anti-Fyn, or anti-c-Src antibodies at 4ºC for 2~3 h.  
Samples were washed 3 times with lysis buffer, boiled in SDS sample buffer and 
analyzed by SDS-PAGE on 8% gels.  Proteins were electro-transferred to PVDF 
membrane, and total level of kinase in each sample was determined by western blotting
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with anti-Akt, anti- Fyn, and anti-c- Src antibodies.  [35S]-labeled Akt, Fyn, and c-Src were 
visualized by autoradiography.
Co-immunoadsorption of Fyn or MyoD with Hsp90/Cdc37 complex–  Confluent 
cells were maintained in DM for 40 h as described above.  Cells were treated with 
geldanamycin (5 µg/mL) or DMSO for 3 h and then lysed in buffer containing 50 mM 
HEPES pH 7.5, 100 mM NaCl, 0.1% deoxycholic acid, 0.1% Triton X-100, 20 mM 
sodium molybdate, 50 mM NaF, 2 mM EDTA, 1 mM EGTA, and protease inhibitor 
cocktail (Sigma).  Cell lysate was clarified by centrifugation for 20 min at ~ 12000 rpm.  
Fyn or MyoD was immunoadsorbed with anti-Fyn or anti-MyoD antibodies at 4º C for 
2~3h.  Samples were washed 4 times with washing buffer (10 mM PIPES pH 7.2, 150 
mM NaCl) and then analyzed by western blotting with anti-Hsp90, anti-Cdc37, anti-Fyn 
or anti-MyoD antibodies as indicated in the figure legends.
Analysis of the effects of geldanamycin on the expression of myogenic factors in 
differentiating C2C12 cells – Confluent cells were maintained in DM and treated with 5 
µg/mL geldanamycin for 20 h at 0, 15, 24 h after induction of differentiation.  After 
briefly washed with phosphate-buffered saline (PBS), cells were lysed in SDS sample 
buffer and then analyzed by SDS-PAGE on 8% gels.  Protein concentration for SDS-
PAGE was determined with a BCA assay kit. The levels of proteins were determined by 
western blotting with anti- myogenin and anti-Akt1 (Santa Cruz biotechnology), anti-Akt2 
(Upstate Biotechnology), and anti-MyoD antibodies.
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Results
The effects of Hsp90 inhibition on signal transduction molecules in differentiating 
C2C12 cells - Upon reaching confluence, C2C12 cells undergo differentiation in response 
to lowering serum growth factors by the replacement of fetal calf serum in the growth 
medium with horse serum (181, 183, 199, 225, 247).  Upon changing medium, cells 
withdraw from the cell cycle and either differentiate and fuse into multinucleated 
myotubules or become quiescent “reserve cells” (199, 223, 248) that share several 
characteristics of muscle pioneer cells.  As noted in the introduction, two known Hsp90-
dependent client molecules, ErbB2 (173, 184, 188, 249, 250) and Akt (48, 99, 184, 185), 
play critical roles in the regulation of signaling cascades that control muscle cell 
proliferation, survival, and differentiation. 
Since inhibition of Hsp90 function has been demonstrated to block the function of 
Hsp90-dependent clients, either through inhibition of the client’s maturation or through 
their destabilization and subsequent depletion from cells (13, 101, 110, 180), we 
examined the effect of geldanamycin-induced inhibition of Hsp90 function on signal 
transduction molecules that are involved in myoblast differentiation and the development 
of skeletal muscle: ErbB2, Akt, c-Src and Fyn. 
Differentiation of confluent C2C12 cells was induced for 48 h, followed by treatment of 
the cells with geldanamycin or its vehicle solvent DMSO.  At the times indicated, cell 
extracts were prepared for analysis of ErbB2, Akt, c-Src, and Fyn levels by western 
blotting.  Consistent with previous studies in proliferating cancer cells (188, 189, 249), 
the amount of ErbB2 present in differentiating C2C12 was decreased rapidly, with ErbB2 
becoming undetectable after 8 h of treatment of cells with geldanamycin (Fig 17).
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Figure 17.  Effects of geldanamycin on signal transduction molecules in 
differentiating C2C12 myoblasts.  Confluent cells maintained in DM were treated with 
DMSO or 5 µg/mL geldanamycin for the time indicated in the figure (0 to 24 h). Cells 
were lysed directly with SDS sample buffer.  The level of each protein was determined 
by western blotting with anti- Hsp90, anti-ErbB2, anti-Akt, anti- Fyn, and anti-c-Src 
antibodies.
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In contrast, the amounts of Akt and Fyn protein declined gradually, becoming 
undetectable after 12 to 24 h of treatment with geldanamycin.  Interestingly, the level of 
c-Src was maintained in cells even after 24 h of geldanamycin treatment.  Thus, over a 
period of 24 h, inhibition of Hsp90 function lead to the depletion of multiple cellular 
protein kinases that are known to play critical roles in regulating muscle cell 
differentiation and survival.
Microscopic examination of control C2C12 cells indicated that they had an 
elongated morphology 48 h after culturing the cells in media containing horse serum, 
indicating that the cells were in the first stages of differentiation (Fig 18C).  After an 
additional 24 h treatment with DMSO, wide and elongated multi-nucleated cells were 
observed, indicative of the initial stages of myotubule formation (Fig. 18D).  In contrast, 
24h after treatment of C2C12 cells with geldanamycin, the majority of the cells remained 
thin and spindle-like (Fig. 18E).  The multi-nucleated cells that were present were shorter 
and thinner than those grown under control conditions.  In addition, areas rich in rounded 
cells populations, suggestive of cells that were undergoing apoptosis, were readily 
apparent.  Western blotting of cell extracts prepared from the control and geldanamycin 
treated cells with anti-cleaved PARP antibody, a marker for the initial stage of 
programmed cell death, confirmed that the geldanamycin-treated cells were undergoing 
apoptosis (Fig. 18F).
Inhibition of Hsp90 function destabilizes newly synthesized Fyn and Akt -
Previous studies have documented that inhibition of Hsp90 function causes the 
accelerated turnover of both newly synthesized and mature ErbB2 via proteasome-
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Figure 18.  Effects of geldanamycin on differentiation of C2C12 myoblasts.  C2C12 
cells were photographed: at 50-70% confluence (A: Growing cells); at confluence (B: 
Confluent cells); 2 days after induction of differentiation (C: Before treatment); and after 
24 h of treatment of C2C12 cells, previously induced to differentiate for 2 days, with 
DMSO (D) or or 5 µg/mL geldanamycin (E: Treated with GA).  (F) western blot (WB) 
analysis of extracts prepared from the cells shown in panel D and E of the figure with 
anti-cleaved PARP antibody.
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mediated degradation (87, 188, 189, 249, 251, 252).  The rapid depletion of ErbB2 from 
cells is a consequence of the dependence of mature ErbB2 on Hsp90-function. The data 
presented above suggest that the Src-family kinase Fyn is likely an Hsp90-dependent 
kinase, but c-Src appeared to be Hsp90-independent, as geldanamycin treatment did not 
reduced c-Src levels in differentiating C2C12 cells.
Pulse-chase experiments were therefore carried out to determine the Hsp90-
dependence of the maturation and stability of newly synthesized Fyn, c-Src and Akt 
kinases.  C2C12 cells were pulse-labeled with [35S]-Met in the presence or absence of 
geldanamycin for 30 min, followed by incubation in fresh media with or without the 
addition of geldanamycin for 0 to 4 h.  Fyn, Akt and c-Src were immunoadsorbed from 
cell extracts prepared at the indicated times after the initiation of the chase, and samples 
were then analyzed by SDS-PAGE and autoradiography to determine the effects of 
Hsp90 inhibition on the turnover rate of each kinase.
While newly synthesized [35S]-Fyn was stabile in control cells, newly synthesized 
[35S]-Fyn was nearly completely degraded within 3 h when matured in the presence of 
geldanamycin (Fig. 19A). Similarly, newly synthesized [35S]-Akt was nearly completely 
degraded in cells within 1 h of chase in the presence of geldanamycin (Fig. 19C).  In 
contrast geldanamycin appeared to have no effect on the turnover of newly synthesized c-
Src in differentiating C2C12 cells (Fig. 19E).  These observations indicate that Hsp90 
function is required for folding and stability of newly synthesized Fyn and Akt molecules 
in differentiating C2C12 myoblasts.  Consistent with the absence of an effect of 
geldanamycin on the total cellular levels of c-Src observed in Figure 17, the turnover rate 
of newly synthesized c-Src did not appear to be affected by treatment of the cells with
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Figure 19.  Pulse-chase analyses of the effects of geldanamycin on [35S]-labeled 
protein kinases in differentiating C2C12 myoblasts.  Pulse-chase experiments were 
carried as described under “Experimental Procedures”. Briefly, cells maintained in DM 
were pulsed with [35S]Met in the presence of DMSO or 5µg/mL geldanamycin (GA) for 
30 min, and then chased with fresh DM containing DMSO (A & E: lanes 1-4 and C: lanes 
1-5) or geldanamycin (GA; A & E: lanes 6-9 and C: lanes 7-11) for 0 to 4 h as indicated 
(A, C, & E).  Cells maintained in DM were pulsed for 30 min with [35S]Met, transferred 
to fresh DM for 3hrs, and then treated with DMSO (B: lanes 1-4; and D: lanes 1-5) or 5 
µg/mL geldanamycin (GA; B: lanes 6-9; and D: lanes 7-11) for 0 to 24 h as indicated (B 
& D).   Fyn (A & B), Akt (C & D), and c-Src (E) were immunoadsorbed with anti-Fyn, 
anti-Akt, or anti-c-Src agarose resin and analyzed by SDS-PAGE. [35S]-labeled proteins 
were detected by autoradiography ([35S]) or western blotting (WB) with kinase specific 
antibodies.  NS: non-immune IgG resin for non-specific binding of proteins (A, B, & E: 
lane 5, and C & D: lane 6).
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geldanamycin. These data suggest that geldanamycin-inhibitable Hsp90 function may not 
be required for folding and stability of c-Src in differentiating C2C12 myoblasts.
To determine the effect of Hsp90-inhibition on the stability of mature Fyn, and 
Akt molecules, C2C12 cells were pulse-labeled with [35S]-Met for 30 min, and then 
subsequently incubated with fresh media for 3 h.  Cells were then incubated with or 
without geldanamycin for 0 to 24 h.  The stability of mature [35S]-Fyn appeared to be 
unaffected in the presence of geldanamycin (Fig 19B), as mature [35S]-Fyn turned over at 
a rate comparable to that of mature Fyn in control cells.  On the other hand, 
geldanamycin appeared to moderately accelerate the turnover of mature [35S]-Akt, 
leading to its nearly complete degradation after 24 h, compared to only a 50% reduction 
of mature [35S]-Akt in control cells at 24 h (Fig. 19D).  This result suggests that Hsp90 is 
not required to maintain the stability of mature Fyn molecules in differentiating C2C12 
myoblasts.  Furthermore, the gradual geldanamycin-induced depletion of Fyn and Akt 
from differentiating C2C12 cells appears to be primarily due to the inability of the cells 
to mature newly synthesized kinase molecules, and thus, replenish mature kinase 
molecules that are slowly degraded in the cells.  
Interaction of Fyn with Hsp90 and Cdc37-  Previously, we have demonstrated 
that the Src-family kinases, Lck and Hck are Hsp90-dependent clients that interact with 
Hsp90 and its “kinase-specific” co-chaperone Cdc37 (139, 141, 190-192, 253).  
Therefore, we examined whether Fyn similarly interacts with Hsp90 and Cdc37, and 
whether this interaction was disrupted by geldanamycin-induced Hsp90 inhibition.  
C2C12 cells were treated with geldanamycin for 3 h, followed by immunoadsorption of 
Fyn from cell extracts.  Consistent with results obtained with the other Src- family 
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kinases, Hsp90 and Cdc37 were co-adsorbed in a complex Fyn, and inhibition of Hsp90 
by geldanamycin resulted in the dissociation of Hsp90 and Cdc37 from Fyn (Fig 20A).  
These results demonstrate that Fyn interacts directly with Hsp90 and Cdc37.  However, 
in similar experiments carried out with c-Src, we could not reproducibly demonstrate an 
interaction of Hsp90 with c-Src, while an interaction of Cdc37 with c-Src was 
consistently observed (data not shown). 
The effects of Hsp90 inhibition on the expression of myogenic markers during 
C2C12 differentiation-   As discussed in the introduction, ErbB2, Akt, and Fyn are 
known to play critical roles in regulating signal transduction pathways during myoblast 
differentiation.  The data presented above indicate that Hsp90 function is required for the 
maturation and/or stability of these kinases during C2C12 myoblast differentiation. The 
myogenic markers, MyoD and myogenin, are transcription factors that regulate the 
expression of muscle-specific genes during myoblast differentiation and the formation of 
myotubules (166, 182, 186, 200-203, 210, 234, 240).  Recent studies indicated that 
expression of Akt2 is required for myogenin expression, and that the expression of these 
two proteins correlated with the developmental processes that are involved in myoblast 
differentiation (160, 166, 168, 186). 
Therefore, we examined whether inhibition of Hsp90 function influenced the 
stability or expression of the myogenic markers, MyoD and myogenin.  C2C12 myoblasts 
constitutively express the myogenic marker MyoD (166, 182, 210, 223).  At confluence 
C2C12 cells were treated (or not) with geldanamycin for periods of 20 h at 0, 15, and 24 
h, respectively, after induction of differentiation.  
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Figure 20.  Interaction of Fyn with Hsp90 and Cdc37.  Confluent cells maintained in 
DM for 40 h were treated with DMSO or 5 µg/mL geldanamycin (GA) for 3 h.  Cell 
extracts were prepared as described under “Experimental Procedures”. Fyn (A) and 
MyoD (B) were immunoadsorbed with anti-Fyn and anti- MyoD agarose resin, 
respectively. Proteins were analyzed by western blotting with anti-Hsp90, anti-Fyn, anti-
Cdc37, and anti-MyoD antibodies. A, lane 1 & B, lane 3: non-immune IgG resin for non-
specific binding of proteins.
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While previously published data suggest that MyoD function may be dependent on 
Hsp90 (241, 242), geldanamycin-induced inhibition of Hsp90 had little, if any, effect on 
the amount of MyoD expressed in differentiating C2C12 cells (Fig. 20 and 21).  
Interestingly, Cdc37 was found to co-immunoadsorb with MyoD, while Hsp90 was not 
detectable on western blots of the co-immunoadsorption experiments (Fig 20B).  
However, the interaction of MyoD with Cdc37 was disrupted by geldanamycin, 
suggesting that the interaction of Cdc37 with MyoD may be an Hsp90-dependent event.  
Myogenin expression is dependent upon the functions of Akt1, Akt2, and MyoD 
(166).  The expression level of myogenin was increased in C2C12 cells, 24 h after 
induction of differentiation (Fig. 21A, DMSO).  Addition of geldanamycin at the 
beginning or after 15 h of the induction of differentiation blocked myogenin expression 
(Fig 21A, GA).  Addition of geldanamycin to cells 24 h after induction of differentiation, 
only partially suppressed myogenin expression, as myogenin was already being 
expressed prior to treatment of cells with geldanamycin.  Geldanamycin-induced 
suppression of myogenin expression correlated with geldanamycin-induced depletion of 
Akt1 and Akt2 from the differentiating C2C12 cells (Fig. 21B): an observation consistent 
with previous work indicating that the function of both Akt1 and Akt2 is required for the 
induction of myogenin expression (166).  Thus, the data indicate that Hsp90 function is 
essential for the expression of the myogenic regulatory factor, myogenin, which is critical 
for myoblast differentiation.
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Figure 21.  Effects of geldanamycin on the expression of myogenin in C2C12 cells.  
(A) Confluent C2C12 cells were treated with DMSO or 5 µg/mL geldanamycin (GA) for 
20 h at 0, 15, and 24 h after induction of differentiation. (B) Cells were treated with 
DMSO or 5 µg/mL geldanamycin for 24 h after maintained in DF for 48 hr.  Cells were 
lysed directly with SDS sample buffer and then analyzed by western blotting with anti-
Akt (detecting both Akt1 & Akt2), anti-Akt1, anti- Akt2 anti- MyoD and anti-myogenin 
specific antibodies.  
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DISCUSSION
Our data indicate that Hsp90 function is essential for the survival and 
differentiation of C2C12 myoblasts.  Previously, we have demonstrated a temporal and 
spatial requirement for Hsp90 function within somatic cells of zebrafish, which is 
necessary for the formation and possibly the survival of eng-2-expressing muscle pioneer 
cells and possibly other striated muscle fiber types (254).  Furthermore, functional 
ErbB2, Akt and Fyn have been demonstrated to be required for myoblast differentiation 
and for the survival of mature muscle cells and muscle satellite cells (155, 156, 187, 205, 
208, 231, 232, 234, 238, 255). Treatment of differentiating C2C12 cells with 
geldanamycin caused the depletion of ErbB2, Akt and Fyn from the cells.  Thus, multiple 
signal transduction pathways are impaired upon treatment of differentiating C2C12 cells 
with geldanamycin, and consistent with the requirement of these kinases for cell survival, 
inhibition of Hsp90 with geldanamycin in C2C12 cells appeared to lead to the induction 
of apoptosis.
The selective tumoricidal effects of ansamycins are believed to be due to their
ability to interfere with Hsp90-dependent pro-growth and anti-apoptotic signaling 
pathways that fuel the proliferation of cancer cells, leading to the arrest of the cell cycle 
and apoptosis (110, 180, 195, 243, 246).  The cytotoxic effect of geldanamycin on 
differentiating myoblasts suggest that geldanamycin can also adversely affect the 
viability of cells that have escaped from the cell cycle, but are still dependent on anti-
apoptotic or pro-growth signaling pathways for cell survival.  
Cancer cells that overexpress ErbB2 are highly susceptible to the tumoricidal 
effects of geldanamycin (173, 184, 188).  ErbB2 is also the target for 
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Trastuzumab/Herceptin, a novel and effective antibody-based therapy used for the 
treatment of mammary carcinomas.  Mice specifically expressing a mutated form of 
ErbB2 in ventricular cardiomyocytes, develop a severe dilated cardiomyopathy (207).  
Compared to wild-type myoblasts, ErbB2-null myoblasts were also found to be much 
more sensitive to apoptotic cell death during differentiation (208).  Cardiomyopathies 
have also been observed to develop in a proportion of patients treated with 
Trastuzumab/Herceptin (205, 209).  Thus, ErbB2 appears to play an important role in 
maintaining the differentiation, function or survival of cardiomyocytes (206).
Activation of Akt in cardiomyocytes also leads to an increase in cell size and 
prevents apoptosis (153, 154, 157, 159, 163).  Mice overexpressing a constitutively active 
Akt mutant in the heart show improved cardiac function with concomitant cardiac 
hypertrophy (157, 163).  Thus, the ability of geldanamycin to deplete muscle cells of both 
ErbB2 and Akt suggests that certain regimens of geldanamycin treatment could 
potentially have adverse effect on cardiac muscle and cardiovascular function.  
In addition to their roles in regulating the growth and survival of cardiac muscle 
cells, ErbB2, Akt and Fyn similarly regulate the growth and survival of skeletal muscle 
cells (153, 155, 158, 161, 162, 208, 234, 238, 255).  Overexpression or hyperactivation of 
these kinases leads to hypertrophy of skeletal muscle, while the down-regulation or 
inhibition of their function leads to skeletal muscle atrophy.  Thus, loss of skeletal muscle 
mass may also be a possible side effect of certain regimens of geldanamycin.  
However, increases in cell mass can also have adverse effects on cardiac function.  
Hypertrophy of cardiac cells induced by an increased load on the heart as a consequence 
of hypertension, ultimately leads to cell death and congestive heart failure (159, 205, 216, 
105
256).  Loss of cardiac tissue occurs, at least in part, through induction of apoptosis.  Thus, 
therapies designed to inhibit Hsp90 function with the aim of preventing the hypertrophy 
of smooth muscle cells in the vasculature (164, 167, 211, 214, 257), and thus the 
development of hypertension, or the consequent increase in cardiac muscle cell mass that 
occurs in response to elevated blood pressure may have some benefit in the deterrence of 
events that lead to congestive heart failure.
The activity of the Src-family kinase Fyn is required for fusion of differentiated 
muscle cells and the survival of differentiated myotubules (234, 238, 239).  Like its Src-
family relatives, Lck and Hck, Fyn was demonstrated to interact with Hsp90 and Cdc37, 
and its protein levels were depleted from cells treated with geldanamycin.  These results 
identify Fyn as a new Hsp90-dependent client.  Similar to Lck and Hck (191, 253), 
geldanamycin-induced inhibition of Hsp90 function led to the depletion of Fyn levels in 
differentiating C2C12 cells due to the inhibition of its folding and maturation:  inhibition
of Hsp90 function by geldanamycin had little effect on the rate of turnover of mature Fyn 
molecules.  Thus, loss of functional Fyn from differentiating myoblasts also likely 
contributes to the subsequent death of these cells in the presence of geldanamycin.
Curiously, geldanamycin treatment of differentiating C2C12 cells had no affect 
on the stability of either newly synthesized or mature forms of c-Src.  Similar to studies 
carried out in the 1980’s in other cell lines (258, 259), we failed to detect an interaction 
between Hsp90 and c-Src in differentiating C2C12 cells.  However, an interaction 
between newly synthesized c-Src and Hsp90 has been reconstituted in situ in reticulocyte 
lysate (260), and B.T. Scroggins, S.D. Hartson & R.L. Matts, unpublished observations), 
and Hsp90 is required for the activity of c-Src expressed in yeast (261).  On the other 
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hand, while Bijlmaker and Marsh (262) observed that geldanamycin led to the complete 
destabilization of newly synthesized c-Src overexpressed in transfected 3T3 fibroblasts, 
we observed that geldanamycin had no effect on the stability of either newly synthesized 
or mature c-Src endogenously expressed in C2C12 cells.  Bijlmaker and Marsh (262)
similarly observed that geldanamycin had no effect on the stability of mature c-Src 
expressed by transfection in 3T3 cells.  Cdc37 was consistently observed to co-
immunoadsorb with c-Src from C2C12 extracts, suggesting that Cdc37 may be able to 
interact with and/ or stabilize c-Src independently of Hsp90 in C2C12 myoblasts.  While 
our failure to document an interaction of Hsp90 with c-Src might result from the 
instability of their interactions in the present of detergents, the absence of any effect of 
geldanamycin on c-Src stability in C2C12 cells suggests that the dependence of c-Src on 
Hsp90 for its maturation and stability may be dependent upon the particular cell type in 
which it is expressed. 
Myogenin is one of the earliest molecular markers for commitment to myogenic 
differentiation, and the transcriptional activity of myogenin, in conjunction with other 
members of the MyoD family of transcription factors, is required for the expression of 
muscle-specific genes induced during muscle differentiation (201-203, 263, 264).  Akt2 
activity is required for the trans-activation of the transcriptional activity of MyoD-MEF2, 
and the upregulation of myogenin expression in differentiating muscle cells (165, 166, 
186, 210).  The ability of geldanamycin to deplete C2C12 cells of Akt2 likely explains 
the capacity of geldanamycin to block the expression of myogenin.  The mechanism by 
which the absence of Akt2 blocks the trans-activation of MyoD-MEF2 remains to be 
determined.
107
MyoD has been postulated to be a target of Hsp90 (241, 242).  However, this 
hypothesis is based on in vitro studies demonstrating the ability of a C-terminal fragment 
of Hsp90 to activate the DNA-binding activity of a fragment MyoD (241, 242).  No 
interaction of Hsp90 with the MyoD present in differentiating C2C12 cells was observed 
using antibody pull-down assays, and geldanamycin treatment had no effect on the level 
of expression of MyoD in differentiating C2C12 cells.  These observations suggest that 
MyoD stability is not dependent on its interaction with Hsp90.  However, an interaction 
of MyoD with Cdc37 was observed, and this interaction was inhibited by geldanamycin.  
A functional interaction of the androgen receptor with Cdc37 has been shown to be 
required for its transcription activation, in addition to its interaction with Hsp90 (265).  
Reverse transcriptase has also been identified as a non-kinase client of Cdc37 [reviewed 
in (35)]. 
The Hsp90-dependent interaction of Cdc37 with MyoD suggests a number of 
potential mechanisms by which geldanamycin could indirectly inhibit the function of 
MyoD and block myogenin expression.  MyoD is a phospho-protein and changes in its 
phosphorylation state have been correlated with its hetero-dimerization with other factors 
and its transcriptional activation (266-271).  Thus, geldanamycin-induced inhibition of 
any of these Hsp90-dependent protein kinases could block MyoD’s trans-activation or 
alter its function[reviewed in(13, 101)].  Furthermore, the kinase-binding activity of 
Cdc37 requires its phosphorylation by casein kinase 2 (272), an Hsp90-dependent kinase 
(273).  In the absence of phosphorylation, Cdc37 may not be capable of binding MyoD, 
or MyoD-associated Cdc37 may not be able to bind kinase and act as a scaffold to 
facilitate MyoD phosphorylation.
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The data presented in this report demonstrate that the inhibition of Hsp90 function 
leads to depletion of ErbB2, Akt1, Akt2 and Fyn from C2C12 myoblasts, and thus the 
impairment of a number of signal transduction cascades critical for orchestrating the 
differentiation C2C12 cells.  This study indicates, not unexpectedly, that the impairment 
of the function of no single Hsp90-dependent protein client can necessarily account the 
overall effect of geldanamycin on a cell’s physiological state.  In addition, further studies 
are clearly required to determine how inhibition of Hsp90-dependent signal transduction 
cascades interferes with trans-activation of transcription factors in differentiating muscle 
cells, as well as in other cell systems.
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CHAPTER V
Interdomain interactions regulating the activation of the
heme-regulated eIF2α kinase
Abstract
The heme-regulated inhibitor of protein synthesis (HRI) regulates translation in 
reticulocytes through its ability to phosphorylate the α-subunit of the eukaryotic initiation 
factor 2 (eIF2).  The structure of HRI consists of an N-terminal heme-binding domain 
(NT-HBD) followed by its kinase domain.  While HRI is best known for its activation in 
response to heme deficiency, we recently showed that the binding of NO and CO to the 
NT-HBD of HRI activates and suppresses the activity of HRI, respectively.  To further 
study the structure/function relationships between the NT-HBD and the catalytic domain 
of HRI (HRI/∆HBD), we examined the effect of hemin, NO and CO on the interactions 
of the two domains expressed separately in reticulocyte lysate.  In the presence of hemin, 
HRI/∆HBD interacted with His-tagged NT-HBD, and NO, but not CO, disrupted the 
domain-domain interaction.  When transferred to heme-deficient lysate, the interaction of 
the HRI/∆HBD with His-tagged NT-HBD decreased by approximately 75%.  In heme-
deficient lysate, the interaction between the two domains was disrupted by NO, but was 
stabilized by CO.  A deletion mutant of HRI (∆H-HRI), lacking a helix inside the
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NT-HBD predicted to be structurally equivalent to the H-helix of hemoglobin, was 
markedly less sensitive to heme-induced inhibition.  Furthermore, mutant NT-HBD, 
lacking the H helix did not bind HRI/∆HBD, suggesting that the deleted region is critical 
for regulation of HRI activity.  HRI/∆HBD and ∆H-HRI, unlike wild type HRI, 
underwent nearly complete transformation into its active form: a result consistent with a 
change in the heme-binding activity of these two mutant constructs.  Thus, the kinase 
activity of HRI appears to be regulated through an interaction between its NT-HBD and 
its catalytic domain, as the activation of HRI by heme deficiency or NO correlated with 
an alteration in the interaction between these two domains.
Introduction
The heme-regulated inhibitor of protein synthesis (HRI) is a member of a family 
of protein kinases that regulate initiation of protein synthesis in eukaryotic cells through 
the phosphorylation of the α-subunit of eukaryotic initiation factor-2 (eIF2α) [reviewed 
in (274, 275)].  The primary function of HRI is thought to be the coordination of the 
synthesis of globin chains in reticulocytes with heme availability.  Heme is required for 
the assembly of α- and β-globin chains into hemoglobin.  Thus, a deficiency of heme 
induces the activation of HRI, which subsequently phosphorylates the α-subunit of eIF2, 
leading to the inhibition of polypeptide chain initiation and the arrest of protein synthesis.  
This prevents the accumulation of unassembled globin chains, the aggregation of which 
is toxic to red blood cells. 
HRI is a multidomain protein that appears to contain two distinct heme-binding 
sites (276-278).  The heme-binding site that is thought to regulate HRI activity in 
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response to changes in heme concentration, has been tentatively localized to the “kinase 
insertion domain” of HRI (277).  The N-terminal domain of HRI contains the second 
heme-binding site (NT-HBD), which consists of approximately 165 amino acids (277, 
278).  This domain contains the heme, which is stably bound and co-purifies with HRI 
(276-278).  The NT-HBD appears to be the site for the binding of the diffusible gas 
second messengers, nitric oxide (NO) and carbon monoxide (CO), which enhance and 
suppress the activation of HRI, respectively, as HRI lacking most of the NT-HBD has 
kinase activity that does not respond to the presence of NO or CO (279).  However, while 
HRI lacking most of the NT-HBD does not purify as a hemoprotein, its kinase activity 
responds to the presence of heme, suggesting the existence of a second heme-binding site 
(276, 277).
The sequence alignment of the NT-HBD to globins and preliminary spectroscopic 
analysis have suggested that histidine is the axial ligand of the heme-binding site in the 
NT-HBD (278).  The heme bound NT-HBD forms a six-coordinate NO complex (278, 
280).  The formation of this six-coordinate NO-Fe-His complex differs from the complex 
formed in the prototypical NO-responsive sensor protein, soluble guanylate cyclase.  In 
soluble guanylate cyclase, NO-binding to the heme iron induces cleavage of the iron-
histidyl bond (281).  The formation of a five-coordinate NO complex is thought to trigger 
for the activation of guanylate cyclase (281).   Since the iron-histidyl bond is retained in 
the NO adduct of the NT-HBD of HRI, we have proposed that changes in the 
conformation of amino acid residues adjacent to the NO binding site (the distal-heme 
ligand), not cleavage of the axial histidine ligand at the proximal side of the heme-
binding site, may be crucial for the NO-induced activation mechanism in HRI (280).
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Recently, we prepared point mutants substituting Ala for His at each of the seven 
histidine residues present in the NT-HBD of rabbit HRI.  Sequence alignments indicated 
that two of the residues (His78 and His123) were invariant from zebrafish to human (282).  
UV-visible absorption, CD, EPR and resonance Raman spectroscopy of purified 
recombinant wild-type and mutant NT-HBDs expressed in E. coli, indicated that His78
and His123 are likely the two crucial residues for the ligation of heme within the NTD of 
HRI (282).  On the other hand, studies with recombinant full length HRI suggest that Cys 
may be an axial heme ligand, and that NO activation may involve the formation of a five-
coordinate NO-heme (283).  However, there are limitations to the conclusions one can 
draw from studies utilizing recombinant HRI, as the protein appears to be a 
heterogeneous mixture of molecules in different states of phosphorylation, and the 
phosphorylation state of HRI is known to alter its heme-binding affinity (284 -287).
In this study, we examined the effect of heme deficiency, NO and CO on the 
interaction between the NT-HBD and the catalytic domain of HRI from which the entire 
NT-HBD was deleted (HRI/∆HBD).  The results indicate that stimuli, such as heme 
deficiency and NO that activate HRI, disrupt the interaction between the NT-HBD and 
HRI/∆HBD, while the interaction between the two domains is retained in heme-replete 
lysate and in the presence of CO.  Thus, we propose that HRI activation is regulated by 
interdomain interactions between the NT-HBD and the catalytic domain, and that 
effectors of HRI activation induce a conformational change within the NT-HBD of HRI 




Construction of mutants. Mutant HRI (HRI/∆HBD), representing sequences 
starting at residue 158 to its C-terminus, was cloned into a modified pSp64T plasmid 
using a StyI restriction site, and mutant HRI (∆H-HRI), representing sequences from HRI 
lacking the deleted region (residues 116 to 158 from N-terminus of HRI, ∆H), was cloned 
by PCR into a modified pSp64T plasmid using StyI and PmeI restriction enzyme sites, as 
described previously (45). Mutant NT-HBD (NT-HBD/∆H) was cloned by PCR into a 
modified pSp64T plasmid using SalI and PmeI restriction enzyme sites. NT-HBD and 
wild type HRI plasmids were described previously (45).  N-terminally His-tagged or non-
His tagged versions of each mutant were made as described previously (45, 278).
Analysis of the interaction between the NT-HBD or NT-HBD/∆H and the 
HRI/∆HBD in reticulocyte lysate.  HRI constructs were synthesized and radiolabeled by 
coupled transcription/translation in nuclease-treated rabbit reticulocyte lysate in the 
presence of [35S]Met for 30 min at 30ºC, followed by a 10-min incubation after the 
addition of aurintricarboxylic acid (60 µM final) to stop further initiation of protein 
synthesis (138, 279) .  Aliquots (3 µl) of each construct were transferred to untreated 
heme-deficient reticulocyte lysate protein synthesis mixtures (22 µl), and then incubated 
for an additional 45 min.  For heme-replete samples, reaction mixtures were 
supplemented with hemin (10 µM) for 15 min and then treated with the NO generator 
NOC-9 (1 mM) for 10 min, or gassing with 100% carbon monoxide (CO) for 5 min on 
ice (279).  His- tagged constructs were immunoadsorbed with anti-His5 monoclonal 
antibody (Qiagen) bound to anti-mouse agarose resin at 4ºC for 1 to 2 h as previously 
described (28, 279).  Samples were then washed 4 times with wash buffer (10 mM PIPES 
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pH 7.2, 150 mM NaCl) and analyzed by SDS-PAGE. All HRI constructs were visualized 
by autoradiography. 
Assay of the kinase activity of wild-type HRI and mutant ∆H-HRI.  HRI was 
synthesized de novo in reticulocyte lysate by coupled transcription/ translation and 
matured in hemin-supplemented (10 µM) or heme-deficient rabbit reticulocyte lysate for 
60 min, or matured in heme- deficient RRL for 45 min followed by incubation in the 
presence 10 µM hemin for 15 min as described above.  His-tagged wild-type and ∆H-
HRI were immunoadsorbed with anti-His-tag antibody resin, and washed as described 
above.  Kinase activity was assayed by incubation of each sample with eIF2 for 5 min at 
30ºC in the presence of [γ-32P]ATP, followed by SDS-PAGE and analysis by 
autoradiography, as described previously (138).
Analysis of the transformation of wild-type and mutant HRIs. [35S]-labeled wild-
type HRI, ∆H-HRI and HRI/∆HBD were synthesized for 30 min as described above.  The 
samples were matured at 30ºC for 0 to 180 min in heme-deficient reticulocyte lysate.  
Proteins were immunoadsorbed with anti-His tagged antibodies and washed as described 
above, and then analyzed by SDS-PAGE on 7% gels, transferred to PVDF membranes 
and visualized by autoradiography (138).
Results and Discussion
Effects of heme deficiency, NO and CO on the interaction of the NT-HBD and the 
catalytic domain (HRI/∆HBD) of HRI.  Although the activation of HRI has been know to 
be regulated by heme for over two decades, almost nothing is known about the physical 
basis behind the mechanism of this phenomenon.  Currently, the binding of hemin is 
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postulated to repress the activity of HRI through the induction of an intermolecular 
disulfide bond between subunits within dimeric HRI (288, 289).  Similarly, while the 
physical characteristics of the coordination complex formed between NO and the NT-
HBD and full length recombinant HRI have been investigated (279, 280, 282, 283), little 
is known about how the binding of NO modulates the activation of HRI.  However, our 
previous studies have shown that the NT-HBD expressed in trans had the capacity to 
modulate NO stimulation of the kinase activity of a HRI mutant (HRI/Met3) from which 
most of the NT-HBD had been deleted (279).  Furthermore, the HRI/Met3 mutant was 
only about 50% as active as wild-type HRI, while being less responsive to inhibition by 
heme (277, 279).  However, the activity of the HRI/Met3 mutant was markedly enhanced 
when the NT-HBD was expressed in trans (279).  These observations suggest that the 
NT-HBD potentially has both positive and negative effector functions with respect to 
regulation of HRI’s kinase activity. 
To test the whether conditions that activate HRI alter interactions between its NT-
HBD of HRI and its catalytic domain, we constructed a HRI mutant from which the 
entire coding sequence of the NT-HBD was deleted (HRI/∆HBD).  His-tagged NT-HBD 
and HRI/∆HBD were then synthesized by coupled transcription/ translation in 
reticulocyte lysate and mixed.  The samples were then diluted into heme-deficient 
reticulocyte lysate to allow the kinase domain to undergo Hsp90-dependent maturation 
(279).  Samples were then left untreated or treated with hemin, the NO-generator NOC-9, 
CO, or hemin in conjunction with NOC-9 or CO, and the ability of anti-His tag antibody 
to co-immunoadsorb HRI/∆HBD with His-tagged NT-HBD was determined.
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Figure 22. Effects of heme, NO, and CO on the interaction between the NT-HBD 
and the catalytic domain (HRI/∆HBD) of HRI.  [35S]-labeled His-tagged NT-HBD and 
untagged HRI/∆HBD were synthesized in reticulocyte lysate, mixed and matured in 
heme-deficient lysate as described under “Experimental Procedures”.  Subsequently, 
samples were incubated in the absence (lanes 1-4) or presence (lanes 5-8) of hemin for 15 
min, and then left untreated treated (lanes 1, 3, 5, and 7), or were treated with 1 mM 
NOC-9 (lanes 2 and 6) for 10 min at 30ºC, or with CO (lanes 4 and 18) for 5 min on ice.  
His-tagged NT-HBD was immunoadsorbed and samples were analyzed for co-adsorbed 
HRI/∆HBD by SDS-PAGE and autoradiography.  NS: Protein non-specifically bound to 
non-immune IgG resin from heme-deficient (left side) and heme-replete (right side) 
lysate. Input: Represents the synthesized protein used in the experiment.
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As shown in Fig 22, addition of hemin markedly enhanced the interaction of NT-
HBD with HRI/∆HBD (lane 1 versus 7).  The presence of NO, on the other hand, 
disrupted the interaction between the NT-HBD and HRI/∆HBD regardless of the 
presence of hemin (lanes 2 and 6).  In contrast, while CO had little further effect on the 
hemin-induced stabilization of the two domains in hemin-supplement lysate (lane 7 
versus 8), the presence of CO caused a perceptible increase in the interaction between the 
two domains in heme-deficient lysate (lane 3 versus 4).  Thus, conditions that cause 
activation of HRI’s kinase activity, heme deficiency and the presence of NO, altered or 
disrupted the interaction between HRI’s NT-HBD and its catalytic domain, while 
conditions that repress HRI activation (heme sufficiency or CO) stabilized the interaction.  
It is likely that the altered interaction between the two domains is a result of a 
conformational change induced by the absence of reversible heme-binding to HRI’s 
second heme-binding site, or the coordination of NO by the NT-HBD, and this altered 
conformation presumably modulates the activation of HRI.  Furthermore, conditions that 
promote the interaction between the NT-HBD and kinase catalytic domain (HRI/∆HBD) 
presumably stabilize a conformation that inhibits HRI’s catalytic activity.
Deletion of the “H-helix” region generates hyperactive HRI.  Sequence analysis 
of HRI indicated that its contains an Erythrocruorin family (globin super-family) 
signature spanning amino acid residues 66 to 89 (278), and that residues 11-118 in the 
NT-HBD of HRI have significant sequence similarity to amino acids 16-120 in 
mammalian α-globins.   However, while the analysis suggest that the NT-HBD of HRI 
may have evolved from the second intron of the α-globin gene (278), the finding that 
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Figure 23.  Comparison of the regulation of the kinase activity of wild type HRI and 
mutant ∆H-HRI.  [35S]-labeled His-tagged HRI and His-tagged ∆H-HRI were 
synthesized in reticulocyte lysate and matured in heme-deficient (lanes 3- 6, 9-12) or 
heme-replete lysate (lanes 1, 2, 7, and 8) for 45 min as described under “Experimental 
Procedures”.  Samples were then matured for an additional 15 min with no additions or 
with the addition (lanes 3, 4, 9, and 10) of 10 µM hemin to the heme-deficient lysate 
(heme-supplemented).  Heme deficient (-), or heme-supplemented (-/+), or heme-replete 
(+) reticulocyte lysates were then treated with 1 mM NOC-9 (lanes 1, 3, 5, 7, 9, and 11) 
or buffer (control: lanes 2, 4, 6, 8, 10, and12) for 10 min at 30ºC.  His-tagged HRI and 
∆H-HRI were immunoadsorbed and assayed for eIF2α and autokinase activity for 5 min 
at 30ºC as described under the “Experimental Procedures”.  Samples were analyzed by 
SDS-PAGE and autoradiography. (A) Autoradiogram of [32P]-eIF2α and [32P]-HRI. (B) 
Autoradiogram of immunoadsorbed [35S]-HRI.  NS: Kinase activity of protein non-
specifically bound to non-immune IgG resin from heme-deficient lysate treated with 1 
mM NOC-9.  WT: wild-type HRI.  MT: mutant ∆H-HRI.  UF:  Sample of unfractionated 
lysate before the immunoadsorption of [35S]-HRI in heme-deficient reticulocyte lysate.
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His123 may be one of the axial heme-binding ligands (282), suggests that the tertiary fold 
of the NT-HBD may be different from that of globin chains, as H123 is predicted to be 
part of what would be equivalent to the H-helix of globins: a helix located outside the 
heme-binding core of globins (278).
To further investigate the relationship between the mechanisms by which HRI’s 
catalytic activity is repressed by heme and activated by NO, we constructed a mutant of 
HRI (∆H-HRI) lacking the putative H-helix and linker region (amino acids 116-157) 
connecting the NT-HBD to the catalytic domain. We hypothesized that the deletion of 
this region, which contains the domain’s putative distal heme-binding ligand, would alter 
the response of HRI’s catalytic domain to NO.  While mutant ∆H-HRI was found to have 
detectable eIF2α kinase activity (Fig. 23A: lane 8) compared of wild-type HRI (Fig. 
23A:lane 2) when the newly synthesized protein was maintained in the presence of 
hemin, the transformation of both wild-type (Fig. 23B: lanes 1 and 2) and ∆H-HRI (Fig. 
23B: lanes 7 and 8) into an NO-activatable kinase was effectively blocked by heme 
(compare to NS in Fig. 23A: activity of non-specifically bound NO-activatable kinase 
activity).  However, after the proteins were incubated in heme-deficient lysate to allow 
them to undergo Hsp90-dependent “transformation” into active kinases (138), the activity 
of wild-type HRI was fully repressed by the addition of hemin (Fig. 23A: lane 4), while 
the activity of ∆H-HRI was not (Fig. 23A: lane 10).  On the other hand, both repressed 
wild-type HRI (Fig. 23A: lane 3) and repressed ∆H-HRI (Fig. 23A. lane 9) were equally 
responsive to activation by NO.
Distinct differences in the properties of ∆H-HRI were also noted in heme-
deficient lysate (Fig. 23).  ∆H-HRI (Fig 23A: lane 12) was hyperactivated in heme-
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deficient lysate compared to wild-type HRI (Fig. 23A: lane 6).  Furthermore, the already 
hyperactivated ∆H-HRI was only marginally simulated by NO in heme-deficient lysate 
(Fig. 23A: lane 11) compared to unstimulated ∆H-HRI (Fig. 23A: lane 12), such that the 
activities of unstimulated and NO-stimulated ∆H-HRI were comparable to the activity of 
wild type HRI that was hyperactivated by NO stimulation in heme-deficient lysate (Fig. 
23A: lanes 5).  Therefore, while ∆H-HRI maintained characteristics of wild type HRI 
relative to the ability of hemin to inhibit its Hsp90-dependent “transformation” into an 
active, regulatable kinase, the activity of “transformed” ∆H-HRI was much less sensitive 
to repression by hemin.  These results suggest that the deleted region is important for 
attenuating activation of HRI in response to heme-deficiency, as the mutant protein is 
hyperactivated to a level comparable to that induced by the presence of NO. 
The “H-helix” and linker region of the NT-HBD are required for the stable 
interdomain interactions induced by the presence of hemin.  The results described above 
suggest that the deletion of amino acids 116-157 (“H-helix” and linker region) impairs 
the ability of hemin to repress the activity of transformed ∆H-HRI.  To test this 
hypothesis, a His-tagged NT-HBD mutant was constructed from which amino acids 116-
157 were deleted (NT-HBD/∆H).  We then examined the ability of the mutant to interact 
with transformed HRI/∆HBD in trans in the presence or absence of hemin.  As 
demonstrated previously in Figure 22, less HRI/∆HBD was co-adsorbed with His-tagged 
NT-HBD from heme-deficient lysate (Fig. 24, lane 1) after its transformation, than from 
lysate where the activity of transformed HRI/∆HBD had been repressed by the addition 
of hemin (Fig. 24,lane 2).  In contrast, little detectable HRI/∆HBD was co-adsorbed with
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Figure 24.  Interaction of the NT-HBD/∆H mutant with the catalytic domain 
(HRI/∆HBD) of HRI.  [35S]-labeled His-tagged NT-HBD, His- tagged NT-HBD/∆H and 
untagged HRI/∆HBD were synthesized in reticulocyte lysate as described under 
“Experimental Procedures”.  The His-tagged constructs were mixed with lysate 
containing HRI/∆HBD and matured in heme-deficient lysate for 45 min.  Subsequently, 
samples were incubated in the absence (lanes 1, 3, and 5) or presence (lanes 2, 4, and 6) 
of 10 µM hemin for 15 min.  His-tagged NT-HBD and NT-HBD/∆H were 
immunoadsorbed, and samples were analyzed for co-adsorbed HRI/∆HBD by SDS-
PAGE and autoradiography.  Protein non-specifically bound to non-immune IgG resin 
from heme-deficient (lanes 5) and heme-supplemented (lanes 6) lysate.  Input: Represents 
the synthesized protein used in the experiment.
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the NT-HBD/∆H mutant in the presence (Fig. 24, lane 4) or absence (Fig. 24, lane 3) of 
hemin.  Thus, amino acids 116-157 appear to either have a direct functional role in the 
mechanism by which hemin modulates the interaction of the NT-HBD with the catalytic 
domain of HRI, or these amino acids are required to maintain the structure of the portion 
of the NT-HBD that mediates the ability of hemin to modulate the interaction between 
these two domains.
The ability to bind hemin also appears to attenuate the “transformation” of HRI in 
heme-deficient lysate (138, 277).  In previous studies, we have observed that the 
transformation of wild type HRI is suppressed in some manner with only about 50% of 
newly synthesized HRI undergoing transformation when incubated for prolonged times in 
heme-deficient lysate (138).  In these lysates [35S]-HRI migrates as a doublet upon SDS-
PAGE with the band exhibiting the fastest migration rate co-migrating with newly 
synthesized untransformed HRI, and the band exhibiting the slowest electrophoretic 
mobility representing transformed HRI.  Little if any hyperphosporylated HRI, which 
exhibits an even slower electrophoretic mobility than transformed HRI (41, 129, 142), is 
observed to be generated during the incubations.  Hyperphosphorylated HRI is refractory 
to inhibition induced upon the addition of hemin (284-287). 
Since the data described above suggested that the NT-HBD likely plays a role in 
the mechanism through which hemin represses the activity of HRI, we examined the 
electrophoretic properties of ∆H-HRI and HRI/∆HBD upon their prolonged 
transformation in heme-deficient lysate.  Wild-type HRI, ∆H-HRI and HRI/∆HBD were 
observed to undergo transformation at distinctly different rates (Fig. 25). After 90 and 
180 min of incubation under heme-deficient conditions, 35 and 75% of wild type HRI 
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Figure 25.  Comparison of the rate of “transformation” of wild type HRI, ∆H-HRI 
and HRI/∆HBD.  [35S]-labeled His-tagged wild type HRI, ∆H-HRI and HRI/∆HBD. 
were synthesized in reticulocyte lysate as described under “Experimental Procedures”, 
and then matured and transformed in heme-deficient lysate for 0 (lanes 1, 4, and 7), 90 
(lanes 2, 5, and 8) or 180 (lanes 3, 6, and 9) min.  Samples were placed on ice at the times 
indicated in the figure, and then immunoadsorbed and analyzed by SDS-PAGE and 
autoradiography.  WT: wild-type HRI (lanes 1, 2, and 3). ∆H-HRI:mutant HRI (lanes 4, 
5, and 6). ∆H-HRI:mutant HRI (lanes 4, 5, and 6). HRI/∆HBD:mutant HRI (lanes 7, 8, 
and 9). Input: Represents the synthesized protein used in the experiment.
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exhibited the slower electrophoretic mobility diagnostic of kinase “transformation” (see 
(138)).  In comparison, 70 and 85% of ∆H-HRI and 85 and 100% of HRI/∆HBD had 
undergone transformation after 90 and 180 min of incubation respectively (Fig. 25).  
These data suggest that an intact and functional NT-HBD is essential for the mechanism 
by which HRI maturation and transformation is attenuated in heme-deficient lysate.
Overall, our data suggests that the mechanism by which HRI is activated by 
heme-deficiency and its mechanism of activation by NO have a feature in common: the 
altered interaction of HRI’s NT-HBD with its catalytic domain.  While the interaction 
between the domains is suppressed in heme-deficient lysate (Fig. 22), it is disrupted by 
NO, which correlates with the enhanced activation of HRI observed in the presence of 
NO.  On the other hand, the deletion of the amino acids 116-157 disrupted the interaction 
between the two domains, and no enhanced activation of the ∆H-HRI mutant was 
observed in heme-deficient lysate in the presence of NO (Fig. 23A).  Thus, the degree of 
activation of HRI or the ∆H-HRI mutant correlates with the interaction, or lack thereof, 
of the NT-HBD with the kinase domain of HRI.  Consistent with this hypothesis the 
ability of CO to suppress the activity of HRI (279) correlates with its ability to stabilize 
the interaction between the two domains (Fig. 22).
The data further implies that after HRI’s transformation and activation in heme-
deficient lysate, HRI activity is regulated by conformational changes that are induced by 
altered interactions between HRI’s NT-HBD and its catalytic domain, and that HRI’s “H-
helix”-linker region plays an important structural or functional role in the regulation of 
this interaction   These changes could be the result of: 1) HRI’s second heme-responsive 
binding site being comprised of the interface between the NT-HBD and elements of 
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HRI’s catalytic domain, possibly elements present in the “H-helix” and in the kinase 
“insertion-sequence” as proposed in earlier studies (277); or 2) the reciprocal interactions 
between the NT-HBD and the second heme-responsive binding site modulating heme-
binding affinity of the site coordinately with the affinity of the interaction between the 
two domains.  Thus, agents (e.g., NO) or mutations (e.g., ∆H-HRI) that activate HRI and 
inhibit the interaction of the NT-HBD with the catalytic domain may coordinately 
suppress the heme-binding affinity of HRI’s second binding site.  Alternately, 
conformational changes induced by dissociation of heme from the second heme-binding 
site may alter the strength of the interaction between the two domains.  Thus the data 
presented in this report give new insight into the mechanism of regulation of HRI, and 
indicate that HRI’s kinase activity is regulated by interdomain interactions, with the NT-





Hsp90 is highly conserved and abundant molecular chaperone that facilitates 
folding of its clients.  In so doing, Hsp90 function plays a key role in the regulation of 
cell physiology.  Recent studies indicate that inhibition of Hsp90 function causes 
destabilization of many cellular proteins that are critically involved in signal transduction 
pathways.  How Hsp90 function may be regulated within a cell is now an active field of 
investigation.
The studies presented in this thesis focused primarily on the role of Hsp90 in 
maintaining the function of signal transduction molecules in differentiating C2C12 
myoblasts, and the effects of novobiocin on the conformation, function, and client 
binding affinity of Hsp90 and its co-chaperones.  In addition, the molecular mechanism 
of the regulation of HRI by heme, and NO and CO, gasses, which are known to be second 
messenger molecules involved in the regulation of signal transduction pathways in the 
cardiovascular and nervous system, was investigated. 
Hsp90 plays a significant role in the regulation of signal transduction pathways 
during muscle cell differentiation. The inhibition of Hsp90 function by geldanamycin in 
differentiating C2C12 myoblasts resulted in the depletion of the protein kinases, ErbB2, 
Akt, and Fyn, and blocked differentiation of myoblasts.  These events subsequently led to 
the induction of apoptosis, as indicated by the cleavage of PARP.  These initial studies 
bring new insights into the essential role for Hsp90 for the proper function of signal
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transduction pathways required for myoblast differentiation. Therefore, these studies 
raise some fundamental questions that need to be answered in the future.
How are the stabilities of Hsp90-dependent kinases differentially regulated in 
response to Hsp90 inhibition?  Both Fyn and c-Src are the members of the Src-family of 
non-receptor protein tyrosine kinases.  They have a similar structure and have 
overlapping functions.  However, the inhibition of Hsp90 function by geldanamycin only 
affected the stability of Fyn, when previous studies have suggested that c-Src is an 
Hsp90-dependent client.  Therefore, it is important to understand what events have 
occurred in C2C12 cells that cause the differences in stability between these two kinases.  
How does the biogenesis of c-Src, a presumptive Hsp90 client, become Hsp90 
independent? 
How is Hsp90 involved in the regulation of myogenin expression?  The 
expression of myogenin was blocked by geldanamycin treatment.  On the other hand, 
MyoD, whose activity is required for myogenin expression, was observed to interact with 
Cdc37, but not Hsp90.  However, while the interaction of Cdc37 with MyoD was 
disrupted by geldanamycin, turnover of the protein was not induced by inhibition of 
Hsp90.  Thus, it is of interest to understand the relationship between MyoD function and 
Hsp90/Cdc37, and why MyoD function is sensitive to geldanamycin.  MyoD is known to 
undergo changes in its phosphorylation state that are thought to regulate its interactions 
with other myogenic transcription factors.  Cdc37 may be acting as a scaffolding protein 
that is required to dock a protein kinase, which phosphorylates MyoD and modulates its 
function.  Alternatively, geldanamycin may simply block the maturation of an Hsp90-
dependent kinase whose function is required for transactivation of MyoD.
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How does Hsp90 function to both enhance and dampen the phosphorylation state 
of a protein client?  It was of interest that we found that phosphorylation of Akt on Ser473
can be increased by geldanamycin, indicating that Hsp90 functions to balance the 
phosphorylation state of Akt during C2C12 myoblast differentiation.  These results 
suggest that PP2A is a major regulator of Akt activity.  However, the mechanism by 
which PP2Ac and thus Akt activity is regulated may be more complex, because there are 
other known and possibly other unidentified Hsp90 clients involved in regulation of Akt 
activity.  Thus, additional work needs to done to study the role of protein phosphatases in 
regulating Hsp90-dependent signal transduction mechanisms.
What is the true mechanism by which novobiocin inhibits Hsp90’s function?  
Novobiocin has been demonstrated to bind to the C-terminal region of Hsp90, as opposed 
to the N-terminal region of Hsp90 which binds geldanamycin.  Our findings demonstrate 
that the C-terminal region of Hsp90 is important for the function of Hsp90 and can be the 
target of action of other drugs.  Work remains to be done in defining the drug-binding site 
within the C-terminal region, which will allow the development of better, higher affinity 
drugs for treatment of diseases.
What is the true nature of the second heme-binding site in HRI.  Our mutagenesis 
studies on HRI indicate that the interaction between two domains of HRI modulates its 
activation.  Furthermore, the N-terminal heme-binding domain appears to have both 
negative and positive effects on the regulation of HRI transformation and activity.  The 
question remains whether the second-heme binding site is defined by the interface 
between the two domains, or whether it is an independent site that is allosterically 
regulated.  However, others have questioned the existence of the site, raising the question 
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of whether there is a single site that undergoes changes in the coordination state of its 
bound heme.  This hypothesis raises additional question about the relationship between 
NO binding and regulation of HRI that occurs in response to changes in heme 
concentrations.  Thus, future work is needed to define the structure of HRI and to 
understand how conformational changes induced by the binding of heme, NO or CO alter 
HRI’s structure between its active and inactive form.
130
BIBLOGRAPHY
1. Anfinsen, C. B. (1973) Principles that govern the folding of protein chains. 
Science 181, 223-30.
2. Dill, K.A. and Chan, H.S. (1997) From Levinthal to pathways to funnels. Nat 
Struct Biol, 4, 10-9.
3. Barral, J.M., Broadley, S.A., Schaffar, G. and Hartl, F.U. (2004) Roles of 
molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol, 15, 17-
29.
4. Bohen, S.P., Kralli, A. and Yamamoto, K.R. (1995) Hold 'em and fold 'em: 
chaperones and signal transduction. Science, 268, 1303-4.
5. Burston, S.G. and Clarke, A.R. (1995) Molecular chaperones: physical and 
mechanistic properties. Essays Biochem, 29, 125-36.
6. Young, J.C., Agashe, V.R., Siegers, K. and Hartl, F.U. (2004) Pathways of 
chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol, 5, 781-
91.
7. Young, J.C., Barral, J.M. and Ulrich Hartl, F. (2003) More than folding: localized 
functions of cytosolic chaperones. Trends Biochem Sci, 28, 541-7.
8. Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z. and Nardai, G. (1998) The 90-
kDa molecular chaperone family:  structure, function, and clinical applications.  A 
comprehensive review. Pharmacol. Ther., 79, 129-168.
9. Minton, A.P. (1997) Influence of excluded volume upon macromolecular 
structure and associations in 'crowded' media. Curr Opin Biotechnol, 8, 65-9.
10. Whitesell, L., Bagatell, R. and Falsey, R. (2003) The stress response: implications 
for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets, 3,
349-58.
11. Ruddock, L.W. and Klappa, P. (1999) Oxidative stress: Protein folding with a 
novel redox switch. Curr Biol, 9, R400-2.
12. Soti, C. and Csermely, P. (2002) Chaperones and aging: role in neurodegeneration 
and in other civilizational diseases. Neurochem Int, 41, 383-9.
13. Pratt, W.B. and Toft, D.O. (2003) Regulation of signaling protein function and 
trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 
(Maywood), 228, 111-33.
14. Young, J.C., Moarefi, I. and Hartl, F.U. (2001) Hsp90: a specialized but essential 
protein-folding tool. J Cell Biol, 154, 267-73.
15. Caplan, A.J., Jackson, S. and Smith, D. (2003) Hsp90 reaches new heights. 
Conference on the Hsp90 chaperone machine. EMBO Rep, 4, 126-30.
16. Sorger, P.K. and Pelham, H.R. (1987) The glucose-regulated protein grp94 is 
related to heat shock protein hsp90. J Mol Biol, 194, 341-4.
131
17. Song, H.Y., Dunbar, J.D., Zhang, Y.X., Guo, D. and Donner, D.B. (1995) 
Identification of a protein with homology to hsp90 that binds the type 1 tumor 
necrosis factor receptor. J Biol Chem, 270, 3574-81.
18. Felts, S.J., Owen, B.A., Nguyen, P., Trepel, J., Donner, D.B. and Toft, D.O. 
(2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct 
functional properties. J Biol Chem, 275, 3305-12.
19. Buchner, J. (1999) Hsp90 & Co. - a holding for folding. Trends Biochem Sci, 24,
136-41.
20. Kampranis, S.C., Bates, A.D. and Maxwell, A. (1999) A model for the 
mechanism of strand passage by DNA gyrase. Proc Natl Acad Sci U S A, 96,
8414-9.
21. Ban, C., Junop, M. and Yang, W. (1999) Transformation of MutL by ATP 
binding and hydrolysis: a switch in DNA mismatch repair. Cell, 97, 85-97.
22. Dutta, R. and Inouye, M. (2000) GHKL, an emergent ATPase/kinase superfamily. 
Trends Biochem Sci, 25, 24-8.
23. Bergerat, A., de Massy, B., Gadelle, D., Varoutas, P.C., Nicolas, A. and Forterre, 
P. (1997) An atypical topoisomerase II from Archaea with implications for 
meiotic recombination. Nature, 386, 414-7.
24. Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, 
J.E., Roe, S.M., Piper, P.W. and Pearl, L.H. (2000) The ATPase cycle of Hsp90
drives a molecular 'clamp' via transient dimerization of the N-terminal domains. 
Embo J, 19, 4383-92.
25. Marcu, M.G., Chadli, A., Bouhouche, I., Catelli, M. and Neckers, L.M. (2000) 
The heat shock protein 90 antagonist novobiocin interacts with a previously 
unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J 
Biol Chem, 275, 37181-6.
26. Marcu, M.G., Schulte, T.W. and Neckers, L. (2000) Novobiocin and related 
coumarins and depletion of heat shock protein 90-dependent signaling proteins. J 
Natl Cancer Inst, 92, 242-8.
27. Soti, C., Racz, A. and Csermely, P. (2002) A Nucleotide-dependent molecular 
switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal 
nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem, 277, 7066-
75.
28. Yun, B.G., Huang, W., Leach, N., Hartson, S.D. and Matts, R.L. (2004) 
Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-
cochaperone-client interactions. Biochemistry, 43, 8217-29.
29. Prodromou, C. and Pearl, L.H. (2003) Structure and functional relationships of 
Hsp90. Curr Cancer Drug Targets, 3, 301-23.
30. Prodromou, C., Siligardi, G., O'Brien, R., Woolfson, D.N., Regan, L., Panaretou, 
B., Ladbury, J.E., Piper, P.W. and Pearl, L.H. (1999) Regulation of Hsp90 
ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. Embo 
J, 18, 754-62.
31. Meyer, P., Prodromou, C., Hu, B., Vaughan, C., Roe, S.M., Panaretou, B., Piper, 
P.W. and Pearl, L.H. (2003) Structural and functional analysis of the middle 
132
segment of hsp90: implications for ATP hydrolysis and client protein and 
cochaperone interactions. Mol Cell, 11, 647-58.
32. Scheibel, T., Siegmund, H.I., Jaenicke, R., Ganz, P., Lilie, H. and Buchner, J. 
(1999) The charged region of Hsp90 modulates the function of the N-terminal 
domain. Proc Natl Acad Sci U S A, 96, 1297-302.
33. Wegele, H., Muschler, P., Bunck, M., Reinstein, J. and Buchner, J. (2003) 
Dissection of the contribution of individual domains to the ATPase mechanism of 
Hsp90. J Biol Chem, 278, 39303-10.
34. Lotz, G.P., Lin, H., Harst, A. and Obermann, W.M. (2003) Aha1 binds to the 
middle domain of Hsp90, contributes to client protein activation, and stimulates 
the ATPase activity of the molecular chaperone. J Biol Chem, 278, 17228-35.
35. MacLean, M. and Picard, D. (2003) Cdc37 goes beyond Hsp90 and kinases. Cell 
Stress Chaperones, 8, 114-9.
36. Gerber, M.R., Farrell, A., Deshaies, R.J., Herskowitz, I. and Morgan, D.O. (1995) 
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic 
cyclins. Proc Natl Acad Sci U S A, 92, 4651-5.
37. Cutforth, T. and Rubin, G.M. (1994) Mutations in Hsp83 and cdc37 impair 
signaling by the sevenless receptor tyrosine kinase in Drosophila. Cell, 77, 1027-
36.
38. Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, 
A., Le Bot, N., Moreno, S., Sohrmann, M. et al. (2003) Systematic functional 
analysis of the Caenorhabditis elegans genome using RNAi. Nature, 421, 231-7.
39. Grammatikakis, N., Lin, J.H., Grammatikakis, A., Tsichlis, P.N. and Cochran, 
B.H. (1999) p50(cdc37) acting in concert with Hsp90 is required for Raf-1 
function. Mol Cell Biol, 19, 1661-72.
40. Stepanova, L., Finegold, M., DeMayo, F., Schmidt, E.V. and Harper, J.W. (2000) 
The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and 
collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. 
Mol Cell Biol, 20, 4462-73.
41. Shao, J., Gramatikakis, N., Scroggins, B., Uma, S., Huang, W., Chen, J.-J., 
Hartson, S.D. and Matts, R.L. (2001) Hsp90 Regulates p50cdc37 Function during 
the Biogenesis of the Active Conformation of the Heme-regulated eIF2α Kinase. 
J. Biol. Chem., 276, 206-214.
42. Shao, J., Irwin, A., Hartson, S.D. and Matts, R.L. (2003) Functional dissection of 
cdc37: characterization of domain structure and amino acid residues critical for 
protein kinase binding. Biochemistry, 42, 12577-88.
43. Siligardi, G., Panaretou, B., Meyer, P., Singh, S., Woolfson, D.N., Piper, P.W., 
Pearl, L.H. and Prodromou, C. (2002) Regulation of Hsp90 ATPase activity by 
the co-chaperone Cdc37p/p50cdc37. J Biol Chem, 277, 20151-9.
44. Roe, S.M., Ali, M.M., Meyer, P., Vaughan, C.K., Panaretou, B., Piper, P.W., 
Prodromou, C. and Pearl, L.H. (2004) The Mechanism of Hsp90 regulation by the 
protein kinase-specific cochaperone p50(cdc37). Cell, 116, 87-98.
45. Scroggins, B.T., Prince, T., Shao, J., Uma, S., Huang, W., Guo, Y., Yun, B.G., 
Hedman, K., Matts, R.L. and Hartson, S.D. (2003) High affinity binding of Hsp90 
is triggered by multiple discrete segments of its kinase clients. Biochemistry, 42,
12550-61.
133
46. Kimura, Y., Rutherford, S.L., Miyata, Y., Yahara, I., Freeman, B.C., Yue, L., 
Morimoto, R.I. and Lindquist, S. (1997) Cdc37 is a molecular chaperone with 
specific functions in signal transduction. Genes Dev, 11, 1775-85.
47. Chang, H.C. and Lindquist, S. (1994) Conservation of Hsp90 macromolecular 
complexes in Saccharomyces cerevisiae. J Biol Chem, 269, 24983-8.
48. Basso, A.D., Solit, D.B., Chiosis, G., Giri, B., Tsichlis, P. and Rosen, N. (2002) 
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 
and is destabilized by inhibitors of Hsp90 function. J Biol Chem, 277, 39858-66.
49. Das, A.K., Cohen, P.W. and Barford, D. (1998) The structure of the 
tetratricopeptide repeats of protein phosphatase 5: implications for TPR-mediated 
protein-protein interactions. Embo J, 17, 1192-9.
50. Pratt, W.B. and Toft, D.O. (1997) Steroid receptor interactions with heat shock 
protein and immunophilin chaperones. Endocr Rev, 18, 306-60.
51. Ratajczak, T., Carrello, A., Mark, P.J., Warner, B.J., Simpson, R.J., Moritz, R.L. 
and House, A.K. (1993) The cyclophilin component of the unactivated estrogen 
receptor contains a tetratricopeptide repeat domain and shares identity with p59 
(FKBP59). J Biol Chem, 268, 13187-92.
52. Hutchison, K.A., Scherrer, L.C., Czar, M.J., Ning, Y., Sanchez, E.R., Leach, K.L., 
Deibel, M.R., Jr. and Pratt, W.B. (1993) FK506 binding to the 56-kilodalton 
immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect 
on receptor folding or function. Biochemistry, 32, 3953-7.
53. Lei, H., Romeo, G. and Kazlauskas, A. (2004) Heat shock protein 90alpha-
dependent translocation of annexin II to the surface of endothelial cells modulates 
plasmin activity in the diabetic rat aorta. Circ Res, 94, 902-9.
54. Tago, K., Tsukahara, F., Naruse, M., Yoshioka, T. and Takano, K. (2004) 
Regulation of nuclear retention of glucocorticoid receptor by nuclear Hsp90. Mol 
Cell Endocrinol, 213, 131-8.
55. Riggs, D.L., Roberts, P.J., Chirillo, S.C., Cheung-Flynn, J., Prapapanich, V., 
Ratajczak, T., Gaber, R., Picard, D. and Smith, D.F. (2003) The Hsp90-binding 
peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. 
Embo J, 22, 1158-67.
56. Galigniana, M.D., Harrell, J.M., O'Hagen, H.M., Ljungman, M. and Pratt, W.B. 
(2004) Hsp90-binding immunophilins link p53 to dynein during p53 transport to 
the nucleus. J Biol Chem, 279, 22483-9.
57. Davies, T.H., Ning, Y.M. and Sanchez, E.R. (2002) A new first step in activation
of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 
immunophilins. J Biol Chem, 277, 4597-600.
58. Chinkers, M. (2001) Protein phosphatase 5 in signal transduction. Trends 
Endocrinol Metab, 12, 28-32.
59. Sinclair, C., Borchers, C., Parker, C., Tomer, K., Charbonneau, H. and Rossie, S. 
(1999) The tetratricopeptide repeat domain and a C-terminal region control the 
activity of Ser/Thr protein phosphatase 5. J Biol Chem, 274, 23666-72.
60. Kang, H., Sayner, S.L., Gross, K.L., Russell, L.C. and Chinkers, M. (2001) 
Identification of amino acids in the tetratricopeptide repeat and C-terminal 
domains of protein phosphatase 5 involved in autoinhibition and lipid activation. 
Biochemistry, 40, 10485-90.
134
61. Russell, L.C., Whitt, S.R., Chen, M.S. and Chinkers, M. (1999) Identification of 
conserved residues required for the binding of a tetratricopeptide repeat domain to 
heat shock protein 90. J Biol Chem, 274, 20060-3.
62. Silverstein, A.M., Galigniana, M.D., Chen, M.S., Owens-Grillo, J.K., Chinkers, 
M. and Pratt, W.B. (1997) Protein phosphatase 5 is a major component of 
glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding 
immunophilin. J Biol Chem, 272, 16224-30.
63. Ollendorff, V. and Donoghue, D.J. (1997) The serine/threonine phosphatase PP5 
interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing 
subunits of the anaphase-promoting complex. J Biol Chem, 272, 32011-8.
64. Chinkers, M. (1994) Targeting of a distinctive protein-serine phosphatase to the 
protein kinase-like domain of the atrial natriuretic peptide receptor. Proc Natl 
Acad Sci U S A, 91, 11075-9.
65. Morita, K., Saitoh, M., Tobiume, K., Matsuura, H., Enomoto, S., Nishitoh, H. and 
Ichijo, H. (2001) Negative feedback regulation of ASK1 by protein phosphatase 5 
(PP5) in response to oxidative stress. Embo J, 20, 6028-36.
66. Ramsey, A.J. and Chinkers, M. (2002) Identification of potential physiological 
activators of protein phosphatase 5. Biochemistry, 41, 5625-32.
67. Chang, H.C., Nathan, D.F. and Lindquist, S. (1997) In vivo analysis of the Hsp90 
cochaperone Sti1 (p60). Mol Cell Biol, 17, 318-25.
68. Chen, S., Prapapanich, V., Rimerman, R.A., Honore, B. and Smith, D.F. (1996) 
Interactions of p60, a mediator of progesterone receptor assembly, with heat 
shock proteins hsp90 and hsp70. Mol Endocrinol, 10, 682-93.
69. Brinker, A., Scheufler, C., Von Der Mulbe, F., Fleckenstein, B., Herrmann, C., 
Jung, G., Moarefi, I. and Hartl, F.U. (2002) Ligand discrimination by TPR 
domains. Relevance and selectivity of EEVD-recognition in Hsp70 x Hop x 
Hsp90 complexes. J Biol Chem, 277, 19265-75.
70. Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, 
H., Hartl, F.U. and Moarefi, I. (2000) Structure of TPR domain-peptide 
complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone 
machine. Cell, 101, 199-210.
71. Hernandez, M.P., Sullivan, W.P. and Toft, D.O. (2002) The assembly and 
intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. 
J Biol Chem, 277, 38294-304.
72. Johnson, B.D., Schumacher, R.J., Ross, E.D. and Toft, D.O. (1998) Hop 
modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem, 273, 3679-
86.
73. Richter, K., Muschler, P., Hainzl, O., Reinstein, J. and Buchner, J. (2003) Sti1 is a 
non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal 
dimerization reaction during the atpase cycle. J Biol Chem, 278, 10328-33.
74. Smith, D.F., Faber, L.E. and Toft, D.O. (1990) Purification of unactivated 
progesterone receptor and identification of novel receptor-associated proteins. J 
Biol Chem, 265, 3996-4003.
75. Bresnick, E.H., Dalman, F.C. and Pratt, W.B. (1990) Direct stoichiometric 
evidence that the untransformed Mr 300,000, 9S, glucocorticoid receptor is a core 
unit derived from a larger heteromeric complex. Biochemistry, 29, 520-7.
135
76. Felts, S.J. and Toft, D.O. (2003) p23, a simple protein with complex activities. 
Cell Stress Chaperones, 8, 108-13.
77. Sullivan, W.P., Owen, B.A. and Toft, D.O. (2002) The Influence of ATP and p23 
on the Conformation of hsp90. J Biol Chem, 277, 45942-8.
78. Young, J.C. and Hartl, F.U. (2000) Polypeptide release by Hsp90 involves ATP 
hydrolysis and is enhanced by the co-chaperone p23. Embo J, 19, 5930-40.
79. Dittmar, K.D., Hutchison, K.A., Owens-Grillo, J.K. and Pratt, W.B. (1996) 
Reconstitution of the steroid receptor.hsp90 heterocomplex assembly system of 
rabbit reticulocyte lysate. J Biol Chem, 271, 12833-9.
80. Bohen, S.P. (1998) Genetic and biochemical analysis of p23 and ansamycin 
antibiotics in the function of Hsp90-dependent signaling proteins. Mol Cell Biol,
18, 3330-9.
81. Freeman, B.C. and Yamamoto, K.R. (2002) Disassembly of transcriptional 
regulatory complexes by molecular chaperones. Science, 296, 2232-5.
82. Richter, K. and Buchner, J. (2001) Hsp90: chaperoning signal transduction. J Cell 
Physiol, 188, 281-90.
83. Citri, A., Kochupurakkal, B.S. and Yarden, Y. (2004) The achilles heel of ErbB-
2/HER2: regulation by the Hsp90 chaperone machine and potential for 
pharmacological intervention. Cell Cycle, 3, 51-60.
84. Zalutsky, M.R. (1997) Growth factor receptors as molecular targets for cancer 
diagnosis and therapy. Q J Nucl Med, 41, 71-7.
85. Menard, S., Casalini, P., Campiglio, M., Pupa, S., Agresti, R. and Tagliabue, E. 
(2001) HER2 overexpression in various tumor types, focussing on its relationship 
to the development of invasive breast cancer. Ann Oncol, 12 Suppl 1, S15-9.
86. Xu, W., Mimnaugh, E., Rosser, M.F., Nicchitta, C., Marcu, M., Yarden, Y. and 
Neckers, L. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by 
its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem,
276, 3702-8.
87. Xu, W., Mimnaugh, E.G., Kim, J.S., Trepel, J.B. and Neckers, L.M. (2002) 
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent 
ErbB2. Cell Stress Chaperones, 7, 91-6.
88. Zhou, P., Fernandes, N., Dodge, I.L., Reddi, A.L., Rao, N., Safran, H., DiPetrillo, 
T.A., Wazer, D.E., Band, V. and Band, H. (2003) ErbB2 degradation mediated by 
the co-chaperone protein CHIP. J Biol Chem, 278, 13829-37.
89. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R.J., 
Johnson, G.L. and Karin, M. (1994) Differential activation of ERK and JNK 
mitogen-activated protein kinases by Raf-1 and MEKK. Science, 266, 1719-23.
90. Steelman, L.S., Pohnert, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E. and 
McCubrey, J.A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in 
cell cycle progression and leukemogenesis. Leukemia, 18, 189-218.
91. Schulte, T.W., Blagosklonny, M.V., Romanova, L., Mushinski, J.F., Monia, B.P., 
Johnston, J.F., Nguyen, P., Trepel, J. and Neckers, L.M. (1996) Destabilization of 
Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated 
protein kinase signalling pathway. Mol Cell Biol, 16, 5839-45.
136
92. Cissel, D.S. and Beaven, M.A. (2000) Disruption of Raf-1/heat shock protein 90 
complex and Raf signaling by dexamethasone in mast cells. J Biol Chem, 275,
7066-70.
93. Chang, F., Lee, J.T., Navolanic, P.M., Steelman, L.S., Shelton, J.G., Blalock, 
W.L., Franklin, R.A. and McCubrey, J.A. (2003) Involvement of PI3K/Akt 
pathway in cell cycle progression, apoptosis, and neoplastic transformation: a 
target for cancer chemotherapy. Leukemia, 17, 590-603.
94. Blalock, W.L., Navolanic, P.M., Steelman, L.S., Shelton, J.G., Moye, P.W., Lee, 
J.T., Franklin, R.A., Mirza, A., McMahon, M., White, M.K. et al. (2003) 
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and 
prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia,
17, 1058-67.
95. Shelton, J.G., Steelman, L.S., Lee, J.T., Knapp, S.L., Blalock, W.L., Moye, P.W., 
Franklin, R.A., Pohnert, S.C., Mirza, A.M., McMahon, M. et al. (2003) Effects of 
the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the 
abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic 
cells. Oncogene, 22, 2478-92.
96. Shelton, J.G., Steelman, L.S., White, E.R. and McCubrey, J.A. (2004) Synergy 
between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle 
progression and prevention of apoptosis in hematopoietic cells. Cell Cycle, 3,
372-9.
97. Mitsiades, C.S., Mitsiades, N. and Koutsilieris, M. (2004) The Akt pathway: 
molecular targets for anti-cancer drug development. Curr Cancer Drug Targets,
4, 235-56.
98. Basso, A.D., Solit, D.B., Munster, P.N. and Rosen, N. (2002) Ansamycin 
antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells 
that overexpress HER2. Oncogene, 21, 1159-66.
99. Sato, S., Fujita, N. and Tsuruo, T. (2000) Modulation of Akt kinase activity by 
binding to Hsp90. Proc Natl Acad Sci U S A, 97, 10832-7.
100. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C. and 
Burrows, F.J. (2003) A high-affinity conformation of Hsp90 confers tumour 
selectivity on Hsp90 inhibitors. Nature, 425, 407-10.
101. Picard, D. (2002) Heat-shock protein 90, a chaperone for folding and regulation. 
Cell Mol Life Sci, 59, 1640-8.
102. Pearl, L.H. and Prodromou, C. (2002) Structure, function, and mechanism of the 
Hsp90 molecular chaperone. Adv. Prot. Chem., 59, 157-185.
103. Schumacher, R.J., Hurst, R., Sullivan, W.P., McMahon, N.J., Toft, D.O. and 
Matts, R.L. (1994) ATP-dependent Chaperoning Activity of Reticulocyte Lysate. 
J. Biol. Chem., 269, 9493-9499.
104. Wiech, H., Buchner, J., Zimmermann, R. and Jakob, U. (1992) Hsp90 chaperones 
protein folding in vitro. Nature, 358, 169-170.
105. Schumacher, R.J., Hansen, W.J., Freeman, B.C., Alnemri, E., Litwack, G. and 
Toft, D.O. (1996) Cooperative action of hsp70, hsp90, and DnaJ proeins in 
protein renaturation. Biochemistry, 35, 14889-14898.
137
106. Thulasiraman, V. and Matts, R.L. (1996) Effect of geldanamycin on the kinetics 
of chaperone-mediated renaturation of firefly luciferase in rabbit reticulocyte 
lysate. Biochemistry, 35, 13443-13450.
107. Freeman, B.C. and Morimoto, R.I. (1996) The human cytosolic molecular 
chaperones in hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of 
a non-native protein and protein refolding. EBMO J., 15, 2969-2979.
108. Rutherford, S.L. and Lindquist, S. (1998) Hsp90 as a capacitor for morphological 
evolution. Nature, 639, 336-342.
109. Queitsch, C., Sangster, T.A. and Lindquist, S. (2002) Hsp90 as a capacitor of 
phenotypic variation. Nature, 417, 618-24.
110. Neckers, L. (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. 
Trends Mol Med, 8, S55-61.
111. Goetz, M.P., Toft, D.O., Ames, M.M. and Erlichman, C. (2003) The Hsp90 
chaperone complex as a novel target for cancer therapy. Ann Oncol, 14, 1169-76.
112. Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W. and Pearl, L.H. 
(1997) Identification and structural characterization of the ATP/ADP-binding site 
in the Hsp90 molecular chaperone. Cell, 90, 65-75.
113. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U. and Pavletich, 
N.P. (1997) Crystal structure of an Hsp90-geldanamycin complex:  Targeting of a 
protein chaperone by an antitumor agent. Cell, 89, 239-250.
114. Richter, K., Muschler, P., Hainzl, O. and Buchner, J. (2001) Coordinated ATP 
hydrolysis by the Hsp90 dimer. J Biol Chem, 276, 33689-96.
115. Weikl, T., Muschler, P., Richter, K., Veit, T., Reinstein, J. and Buchner, J. (2000) 
C-terminal regions of Hsp90 are important for trapping the nucleotide during the 
ATPase cycle. J Mol Biol, 303, 583-92.
116. Chadli, A., Bouhouche, I., Sullivan, W., Stensgard, B., McMahon, N., Catelli, 
M.G. and Toft, D.O. (2000) Dimerization and N-terminal domain proximity 
underlie the function of the molecular chaperone heat shock protein 90. Proc Natl 
Acad Sci U S A, 97, 12524-9.
117. Grenert, J.P., Sullivan, W.P., Fadden, P., Haystead, T.A.J., Clark, J., Mimnaugh, 
E., Krutzsch, H., Ochel, H.-J., Schulte, T.W., Sausville, E. et al. (1997) The 
amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin 
is an ATP-ADP switch that regulates hsp90 conformation. J. Biol. Chem., 272,
23843-23850.
118. Sullivan, W., Stensgard, B., Caucutt, G., Bartha, B., McMahon, N., Alnemri, E.S., 
Litwack, G. and Toft, D. (1997) Nucleotides and two functional states of hsp90. J. 
Biol. Chem., 272, 8007-8012.
119. Smith, D.F., Whitesell, L., Nair, S.C., Chen, S., Prapapanich, V. and Rimerman, 
R.A. (1995) Progesterone receptor structure and function altered by 
geldanamycin, an hsp90-binding agent. Mol. Cell. Biol., 15, 6804-6812.
120. Smith, D.F., Sullivan, W.P., Marion, T.N., Zaitsu, K., Madden, B., McCormick, 
D.J. and Toft, D.O. (1993) Identification of a 60-kilodalton stress-related protein, 
p60, which interacts with hsp90 and hsp70. Mol Cell Biol, 13, 869-76.
121. McLaughlin, S.H., Smith, H.W. and Jackson, S.E. (2002) Stimulation of the weak 
ATPase activity of human hsp90 by a client protein. J Mol Biol, 315, 787-98.
138
122. Yamada, S., Ono, T., Mizuno, A. and Nemoto, T.K. (2003) A hydrophobic 
segment within the C-terminal domain is essential for both client-binding and 
dimer formation of the HSP90-family molecular chaperone. Eur J Biochem, 270,
146-54.
123. Nemoto, T., Ohara-Nemoto, Y., Ota, M., Takagi, T. and Yokoyama, K. (1995) 
Mechanism of dimer formation of the 90-kDa heat-shock protein. Eur J Biochem,
233, 1-8.
124. Garnier, C., Lafitte, D., Tsvetkov, P.O., Barbier, P., Leclerc-Devin, J., Millot, 
J.M., Briand, C., Makarov, A.A., Catelli, M.G. and Peyrot, V. (2002) Binding of 
ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal 
domain. J Biol Chem, 277, 12208-14.
125. Hartson, S.D., Thulasiraman, V., Huang, W., Whitesell, L. and Matts, R.L. (1999) 
Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, 
and alters its interactions with substrates. Biochemistry, 38, 3837-3849.
126. Johnson, B.D., Chadli, A., Felts, S.J., Bouhouche, I., Catelli, M.G. and Toft, D.O. 
(2000) Hsp90 chaperone activity requires the full-length protein and interaction 
among its multiple domains. J Biol Chem, 275, 32499-507.
127. Scheibel, T., Weikl, T. and Buchner, J. (1998) Two chaperone sites in Hsp90 
differing in substrate specificity and ATP dependence. Proc Natl Acad Sci U S A,
95, 1495-9.
128. Owen, B.A., Sullivan, W.P., Felts, S.J. and Toft, D.O. (2002) Regulation of heat 
shock protein 90 (HSP90) ATPase activity by sequences in the carboxyl terminus. 
J Biol Chem, 277, on line.
129. Shao, J., Hartson, S.D. and Matts, R.L. (2002) Evidence that protein phosphatase 
5 functions to negatively modulate the maturation of the Hsp90-dependent heme-
regulated eIF2alpha kinase. Biochemistry, 41, 6770-9.
130. Johnson, J.L. and Toft, D.O. (1995) Binding of p23 and hsp90 during assembly 
with the progesterone receptor. Mol. Endocrinol., 9, 670-678.
131. Grenert, J.P., Johnson, B.D. and Toft, D.O. (1999) The importance of ATP 
binding and hydrolysis by hsp90 in formation and function of protein 
heterocomplexes. J. Biol. Chem., 274, 17525-17533.
132. Obermann, W.M.J., Sondermann, H., Russo, A.A., Pavletich, M.P. and Hartl, 
F.U. (1998) In vivo function of hsp90 is dependent on ATP binding and ATP 
hydrolysis. J. Cell Biol., 143, 901-910.
133. Panaretou, B., Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W. 
and Pearl, L.H. (1998) ATP binding and hydrolysis are essential to the function of 
the hsp90 molecular chaperone in vivo. EMBO J., 17, 4829-4836.
134. Tanioka, T., Nakatani, Y., Kobayashi, T., Tsujimoto, M., Oh-ishi, S., Murakami, 
M. and Kudo, I. (2003) Regulation of cytosolic prostaglandin E2 synthase by 90-
kDa heat shock protein. Biochem Biophys Res Commun, 303, 1018-23.
135. Katschinski, D.M., Le, L., Heinrich, D., Wagner, K.F., Hofer, T., Schindler, S.G. 
and Wenger, R.H. (2002) Heat induction of the unphosphorylated form of 
hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J 
Biol Chem, 277, 9262-7.
139
136. Kanelakis, K.C., Shewach, D.S. and Pratt, W.B. (2002) Nucleotide binding states 
of hsp70 and hsp90 during sequential steps in the process of glucocorticoid 
receptor.hsp90 heterocomplex assembly. J Biol Chem, 277, 33698-703.
137. Haendeler, J., Hoffmann, J., Rahman, S., Zeiher, A.M. and Dimmeler, S. (2003) 
Regulation of telomerase activity and anti-apoptotic function by protein-protein 
interaction and phosphorylation. FEBS Lett, 536, 180-6.
138. Uma, S., Hartson, S.D., Chen, J.J. and Matts, R.L. (1997) Hsp90 is obligatory for 
the heme-regulated eIF-2alpha kinase to acquire and maintain an activable 
conformation. J Biol Chem, 272, 11648-56.
139. Hartson, S.D., Barrett, D.J., Burn, P. and Matts, R.L. (1996) Hsp90-mediated 
folding of the lymphoid cell kinase p56lck. Biochemistry, 35, 13451-13459.
140. Hartson, S.D. and Matts, R.L. (1994) Association of hsp90 with cellular src-
family kinases in a cell-free system correlates with altered kinase structure and 
function. Biochemistry, 33, 8912-8920.
141. Hartson, S.D., Irwin, A.D., Shao, J., Scroggins, B.T., Volk, L., Huang, W. and 
Matts, R.L. (2000) p50cdc37 as a non-exclusive Hsp90 cohort which participates in 
Hsp90-mediated folding of immature kinase molecules. Biochemistry, 39, 7631-
7644.
142. Uma, S., Thulasiraman, V. and Matts, R.L. (1999) Dual role for Hsc70 in the 
biogenesis and regulation of the heme-regulated kinase of the α subunit of 
eukaryotic translation initiation factor 2. Mol. Cell. Biol., 19, 5861-5871.
143. Chen, M.X., McPartlin, A.E., Brown, L., Chen, Y.H., Barker, H.M. and Cohen, 
P.T. (1994) A novel human protein serine/threonine phosphatase, which possesses 
four tetratricopeptide repeat motifs and localizes to the nucleus. Embo J, 13,
4278-90.
144. Blatch, G.L. and Lassle, M. (1999) The tetratricopeptide repeat: a structural motif 
mediating protein-protein interactions. Bioessays, 21, 932-9.
145. Nemoto, T., Sato, N., Iwanari, H., Yamashita, H. and Takagi, T. (1997) Domain 
structures and immunogenic regions of the 90-kDa heat-shock protein (HSP90). 
Probing with a library of anti-HSP90 monoclonal antibodies and limited 
proteolysis. J Biol Chem, 272, 26179-87.
146. Bogatcheva, N.V., Ma, Y., Urosev, D. and Gusev, N.B. (1999) Localization of 
calponin binding sites in the structure of 90 kDa heat shock protein (Hsp90). 
FEBS Lett, 457, 369-74.
147. Riehl, R.M., Sullivan, W.P., Vroman, B.T., Bauer, V.J., Pearson, G.R. and Toft, 
D.O. (1985) Immunological evidence that the nonhormone binding component of 
avian steroid receptors exists in a wide range of tissues and species. Biochemistry,
24, 6586-6591.
148. Bose, S., Weikl, T., Bugl, H. and Buchner, J. (1996) Chaperone function of 
Hsp90-associated proteins. Science, 274, 1715-7.
149. Weaver, A.J., Sullivan, W.P., Felts, S.J., Owen, B.A. and Toft, D.O. (2000) 
Crystal structure and activity of human p23, a heat shock protein 90 co-
chaperone. J Biol Chem, 275, 23045-52.
150. Hu, J., Toft, D.O. and Seeger, C. (1997) Hepadnavirus assembly and reverse 
transcription require a multi-component chaperone complex which is incorporated 
into nucleocapsids. Embo J, 16, 59-68.
140
151. Freeman, B.C., Felts, S.J., Toft, D.O. and Yamamoto, K.R. (2000) The p23 
molecular chaperones act at a late step in intracellular receptor action to 
differentially affect ligand efficacies. Genes Dev, 14, 422-34.
152. Pratt, W.B. (1993) The Role of Heat Shock Proteins in Regulating the Function , 
Folding, and Trafficking of the Glucocorticoid Receptor. J. Biol. Chem., 268,
221455-21458.
153. Hanada, M., Feng, J. and Hemmings, B.A. (2004) Structure, regulation and 
function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta, 1697,
3-16.
154. Ceci, M., Ross, J., Jr. and Condorelli, G. (2004) Molecular determinants of the 
physiological adaptation to stress in the cardiomyocyte: a focus on AKT. J Mol 
Cell Cardiol, 37, 905-12.
155. Glass, D.J. (2003) Molecular mechanisms modulating muscle mass. Trends Mol 
Med, 9, 344-50.
156. Glass, D.J. (2003) Signalling pathways that mediate skeletal muscle hypertrophy 
and atrophy. Nat Cell Biol, 5, 87-90.
157. Latronico, M.V., Costinean, S., Lavitrano, M.L., Peschle, C. and Condorelli, G. 
(2004) Regulation of cell size and contractile function by AKT in 
cardiomyocytes. Ann N Y Acad Sci, 1015, 250-60.
158. Guttridge, D.C. (2004) Signaling pathways weigh in on decisions to make or 
break skeletal muscle. Curr Opin Clin Nutr Metab Care, 7, 443-50.
159. Oudit, G.Y., Sun, H., Kerfant, B.G., Crackower, M.A., Penninger, J.M. and 
Backx, P.H. (2004) The role of phosphoinositide-3 kinase and PTEN in 
cardiovascular physiology and disease. J Mol Cell Cardiol, 37, 449-71.
160. Rochat, A., Fernandez, A., Vandromme, M., Moles, J.P., Bouschet, T., Carnac, G. 
and Lamb, N.J. (2004) Insulin and wnt1 pathways cooperate to induce reserve cell 
activation in differentiation and myotube hypertrophy. Mol Biol Cell, 15, 4544-
55.
161. Peng, X.D., Xu, P.Z., Chen, M.L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., 
Sundararajan, D., Chen, W.S., Crawford, S.E., Coleman, K.G. et al. (2003) 
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone 
development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes 
Dev, 17, 1352-65.
162. Lai, K.M., Gonzalez, M., Poueymirou, W.T., Kline, W.O., Na, E., Zlotchenko, E., 
Stitt, T.N., Economides, A.N., Yancopoulos, G.D. and Glass, D.J. (2004) 
Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. 
Mol Cell Biol, 24, 9295-304.
163. Condorelli, G., Drusco, A., Stassi, G., Bellacosa, A., Roncarati, R., Iaccarino, G., 
Russo, M.A., Gu, Y., Dalton, N., Chung, C. et al. (2002) Akt induces enhanced 
myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad 
Sci U S A, 99, 12333-8.
164. Hayashi, K., Saga, H., Chimori, Y., Kimura, K., Yamanaka, Y. and Sobue, K. 
(1998) Differentiated phenotype of smooth muscle cells depends on signaling 
pathways through insulin-like growth factors and phosphatidylinositol 3-kinase. J 
Biol Chem, 273, 28860-7. 
141
165. Jiang, B.H., Aoki, M., Zheng, J.Z., Li, J. and Vogt, P.K. (1999) Myogenic 
signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase 
Akt/protein kinase B. Proc Natl Acad Sci U S A, 96, 2077-81.
166. Kaneko, S., Feldman, R.I., Yu, L., Wu, Z., Gritsko, T., Shelley, S.A., Nicosia, 
S.V., Nobori, T. and Cheng, J.Q. (2002) Positive feedback regulation between 
Akt2 and MyoD during muscle differentiation. Cloning of Akt2 promoter. J Biol 
Chem, 277, 23230-5.
167. Hayashi, K., Takahashi, M., Kimura, K., Nishida, W., Saga, H. and Sobue, K. 
(1999) Changes in the balance of phosphoinositide 3-kinase/protein kinase B 
(Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a 
phenotype of visceral and vascular smooth muscle cells. J Cell Biol, 145, 727-40.
168. Tiffin, N., Adi, S., Stokoe, D., Wu, N.Y. and Rosenthal, S.M. (2004) Akt 
phosphorylation is not sufficient for insulin-like growth factor-stimulated 
myogenin expression but must be accompanied by down-regulation of mitogen-
activated protein kinase/extracellular signal-regulated kinase phosphorylation. 
Endocrinology, 145, 4991-6.
169. Persad, S., Attwell, S., Gray, V., Mawji, N., Deng, J.T., Leung, D., Yan, J., 
Sanghera, J., Walsh, M.P. and Dedhar, S. (2001) Regulation of protein kinase 
B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for 
kinase activity and amino acids arginine 211 and serine 343. J Biol Chem, 276,
27462-9.
170. Yamada, T., Katagiri, H., Asano, T., Inukai, K., Tsuru, M., Kodama, T., Kikuchi, 
M. and Oka, Y. (2001) 3-phosphoinositide-dependent protein kinase 1, an Akt1 
kinase, is involved in dephosphorylation of Thr-308 of Akt1 in Chinese hamster 
ovary cells. J Biol Chem, 276, 5339-45.
171. Toker, A. and Newton, A.C. (2000) Akt/protein kinase B is regulated by 
autophosphorylation at the hypothetical PDK-2 site. J Biol Chem, 275, 8271-4.
172. Yasuoka, C., Ihara, Y., Ikeda, S., Miyahara, Y., Kondo, T. and Kohno, S. (2004) 
Antiapoptotic activity of Akt is down-regulated by Ca2+ in myocardiac H9c2 
cells Evidence of Ca2+-dependent regulation of protein phosphatase 2Ac. J Biol 
Chem.
173. Xu, W., Yuan, X., Jung, Y.J., Yang, Y., Basso, A., Rosen, N., Chung, E.J., 
Trepel, J. and Neckers, L. (2003) The heat shock protein 90 inhibitor 
geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-
dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. 
Cancer Res, 63, 7777-84.
174. Strack, S., Cribbs, J.T. and Gomez, L. (2004) Critical role for protein phosphatase 
2A heterotrimers in mammalian cell survival. J Biol Chem.
175. Resjo, S., Goransson, O., Harndahl, L., Zolnierowicz, S., Manganiello, V. and 
Degerman, E. (2002) Protein phosphatase 2A is the main phosphatase involved in 
the regulation of protein kinase B in rat adipocytes. Cell Signal, 14, 231-8.
176. Pankov, R., Cukierman, E., Clark, K., Matsumoto, K., Hahn, C., Poulin, B. and 
Yamada, K.M. (2003) Specific beta1 integrin site selectively regulates 
Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J 
Biol Chem, 278, 18671-81.
142
177. Ugi, S., Imamura, T., Maegawa, H., Egawa, K., Yoshizaki, T., Shi, K., Obata, T., 
Ebina, Y., Kashiwagi, A. and Olefsky, J.M. (2004) Protein phosphatase 2A 
negatively regulates insulin's metabolic signaling pathway by inhibiting Akt 
(protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol, 24, 8778-89.
178. Meares, G.P., Zmijewska, A.A. and Jope, R.S. (2004) Heat shock protein-90 
dampens and directs signaling stimulated by insulin-like growth factor-1 and 
insulin. FEBS Lett, 574, 181-6.
179. Ivaska, J., Nissinen, L., Immonen, N., Eriksson, J.E., Kahari, V.M. and Heino, J. 
(2002) Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and 
dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol, 22,
1352-9.
180. Neckers, L. (2003) Development of small molecule Hsp90 inhibitors: utilizing 
both forward and reverse chemical genomics for drug identification. Curr Med 
Chem, 10, 733-9.
181. Kubo, Y. (1991) Comparison of initial stages of muscle differentiation in rat and 
mouse myoblastic and mouse mesodermal stem cell lines. J Physiol, 442, 743-59.
182. Huang, Y., Li, J., Zhang, Y. and Wu, C. (2000) The roles of integrin-linked kinase 
in the regulation of myogenic differentiation. J Cell Biol, 150, 861-72.
183. Garcia, A.J., Vega, M.D. and Boettiger, D. (1999) Modulation of cell proliferation 
and differentiation through substrate-dependent changes in fibronectin 
conformation. Mol Biol Cell, 10, 785-98.
184. Solit, D.B., Basso, A.D., Olshen, A.B., Scher, H.I. and Rosen, N. (2003) 
Inhibition of heat shock protein 90 function down-regulates Akt kinase and 
sensitizes tumors to Taxol. Cancer Res, 63, 2139-44.
185. Fujita, N., Sato, S., Ishida, A. and Tsuruo, T. (2002) Involvement of Hsp90 in 
signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem,
277, 10346-53.
186. Sun, L., Liu, L., Yang, X.J. and Wu, Z. (2004) Akt binds prohibitin 2 and relieves 
its repression of MyoD and muscle differentiation. J Cell Sci, 117, 3021-9.
187. Fujio, Y., Guo, K., Mano, T., Mitsuuchi, Y., Testa, J.R. and Walsh, K. (1999) 
Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator 
of myocyte survival. Mol Cell Biol, 19, 5073-82.
188. Munster, P.N., Marchion, D.C., Basso, A.D. and Rosen, N. (2002) Degradation of 
HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 
overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent 
pathway. Cancer Res, 62, 3132-7.
189. Xu, L., Ouyang, Y.B. and Giffard, R.G. (2003) Geldanamycin reduces necrotic 
and apoptotic injury due to oxygen-glucose deprivation in astrocytes. Neurol Res,
25, 697-700.
190. Hartson, S.D., Ottinger, E.A., Huang, W., Barany, G., Burn, P. and Matts, R.L. 
(1998) Modular folding and evidence for phosphorylation-induced stabilization of 
an hsp90-dependent kinase. J. Biol. Chem., 273, 8475-8482.
191. Scholz, G.M., Hartson, S.D., Cartledge, K., Volk, L., Matts, R.L. and Dunn, A.R. 
(2001) The molecular chaperone Hsp90 is required for signal transduction by 
wild-type Hck and maintenance of its constitutively active counterpart. Cell 
Growth Differ, 12, 409-17.
143
192. Scholz, G., Hartson, S.D., Cartledge, K., Hall, N., Shao, J., Dunn, A.R. and Matts, 
R.L. (2000) p50(Cdc37) can buffer the temperature-sensitive properties of a 
mutant of Hck. Mol Cell Biol, 20, 6984-95.
193. Miyata, Y. and Nishida, E. (2004) CK2 controls multiple protein kinases by 
phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol,
24, 4065-74.
194. Prince, T. and Matts, R.L. (2004) Definition of protein kinase sequence motifs 
that trigger high affinity binding of Hsp90 and Cdc37. J Biol Chem, 279, 39975-
81.
195. Blagosklonny, M.V. (2002) Hsp-90-associated oncoproteins: multiple targets of 
geldanamycin and its analogs. Leukemia, 16, 455-62.
196. Conde, A.G., Lau, S.S., Dillmann, W.H. and Mestril, R. (1997) Induction of heat 
shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic 
cells confers protection against simulated ischemia. J Mol Cell Cardiol, 29, 1927-
38.
197. Lu, A., Ran, R., Parmentier-Batteur, S., Nee, A. and Sharp, F.R. (2002) 
Geldanamycin induces heat shock proteins in brain and protects against focal 
cerebral ischemia. J Neurochem, 81, 355-64.
198. Donze, O., Abbas-Terki, T. and Picard, D. (2001) The Hsp90 chaperone complex 
is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. Embo J,
20, 3771-80.
199. LaFramboise, W.A., Guthrie, R.D., Scalise, D., Elborne, V., Bombach, K.L., 
Armanious, C.S. and Magovern, J.A. (2003) Effect of muscle origin and 
phenotype on satellite cell muscle-specific gene expression. J Mol Cell Cardiol,
35, 1307-18.
200. Kitzmann, M. and Fernandez, A. (2001) Crosstalk between cell cycle regulators 
and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci, 58, 571-
9.
201. McKinsey, T.A., Zhang, C.L. and Olson, E.N. (2002) Signaling chromatin to 
make muscle. Curr Opin Cell Biol, 14, 763-72.
202. Perry, R.L. and Rudnick, M.A. (2000) Molecular mechanisms regulating 
myogenic determination and differentiation. Front Biosci, 5, D750-67.
203. Pownall, M.E., Gustafsson, M.K. and Emerson, C.P., Jr. (2002) Myogenic 
regulatory factors and the specification of muscle progenitors in vertebrate 
embryos. Annu Rev Cell Dev Biol, 18, 747-83.
204. Walsh, K. and Perlman, H. (1997) Cell cycle exit upon myogenic differentiation. 
Curr Opin Genet Dev, 7, 597-602.
205. Garratt, A.N., Ozcelik, C. and Birchmeier, C. (2003) ErbB2 pathways in heart and 
neural diseases. Trends Cardiovasc Med, 13, 80-6.
206. Negro, A., Brar, B.K. and Lee, K.F. (2004) Essential roles of Her2/erbB2 in 
cardiac development and function. Recent Prog Horm Res, 59, 1-12.
207. Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., 
Chien, K.R., Birchmeier, C. and Garratt, A.N. (2002) Conditional mutation of the 
ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc 
Natl Acad Sci U S A, 99, 8880-5.
144
208. Andrechek, E.R., Hardy, W.R., Girgis-Gabardo, A.A., Perry, R.L., Butler, R., 
Graham, F.L., Kahn, R.C., Rudnicki, M.A. and Muller, W.J. (2002) ErbB2 is 
required for muscle spindle and myoblast cell survival. Mol Cell Biol, 22, 4714-
22.
209. Schneider, J.W., Chang, A.Y. and Garratt, A. (2002) Trastuzumab cardiotoxicity: 
Speculations regarding pathophysiology and targets for further study. Semin 
Oncol, 29, 22-8.
210. Xu, Q. and Wu, Z. (2000) The insulin-like growth factor-phosphatidylinositol 3-
kinase-Akt signaling pathway regulates myogenin expression in normal myogenic 
cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem, 275, 36750-7.
211. Ohkawa, Y., Hayashi, K. and Sobue, K. (2003) Calcineurin-mediated pathway 
involved in the differentiated phenotype of smooth muscle cells. Biochem Biophys 
Res Commun, 301, 78-83.
212. Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline, W.O., 
Gonzalez, M., Yancopoulos, G.D. and Glass, D.J. (2004) The IGF-1/PI3K/Akt 
pathway prevents expression of muscle atrophy-induced ubiquitin ligases by 
inhibiting FOXO transcription factors. Mol Cell, 14, 395-403.
213. Grounds, M.D. (2002) Reasons for the degeneration of ageing skeletal muscle: a 
central role for IGF-1 signalling. Biogerontology, 3, 19-24.
214. Goldspink, G. (1999) Changes in muscle mass and phenotype and the expression 
of autocrine and systemic growth factors by muscle in response to stretch and 
overload. J Anat, 194 ( Pt 3), 323-34.
215. Fujio, Y., Mitsuuchi, Y., Testa, J.R. and Walsh, K. (2001) Activation of Akt2 
Inhibits anoikis and apoptosis induced by myogenic differentiation. Cell Death 
Differ, 8, 1207-12.
216. Rosenthal, N. and Musaro, A. (2002) Gene therapy for cardiac cachexia? Int J 
Cardiol, 85, 185-91.
217. Kopple, J.D., Ding, H. and Gao, X.L. (1995) Altered physiology and action of 
insulin-like growth factor 1 in skeletal muscle in chronic renal failure. Am J 
Kidney Dis, 26, 248-55.
218. Burkin, D.J., Kim, J.E., Gu, M. and Kaufman, S.J. (2000) Laminin and 
alpha7beta1 integrin regulate agrin-induced clustering of acetylcholine receptors. 
J Cell Sci, 113 ( Pt 16), 2877-86.
219. Burkin, D.J. and Kaufman, S.J. (1999) The alpha7beta1 integrin in muscle 
development and disease. Cell Tissue Res, 296, 183-90.
220. Carson, J.A. and Wei, L. (2000) Integrin signaling's potential for mediating gene 
expression in hypertrophying skeletal muscle. J Appl Physiol, 88, 337-43.
221. Heino, J. (2000) The collagen receptor integrins have distinct ligand recognition 
and signaling functions. Matrix Biol, 19, 319-23.
222. Li, J., Rao, H., Burkin, D., Kaufman, S.J. and Wu, C. (2003) The muscle integrin 
binding protein (MIBP) interacts with alpha7beta1 integrin and regulates cell 
adhesion and laminin matrix deposition. Dev Biol, 261, 209-19.
223. McGrath, M.J., Mitchell, C.A., Coghill, I.D., Robinson, P.A. and Brown, S. 
(2003) Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces alpha 5 beta 1-
integrin-dependent myocyte elongation. Am J Physiol Cell Physiol, 285, C1513-
26.
145
224. Robinson, P.A., Brown, S., McGrath, M.J., Coghill, I.D., Gurung, R. and 
Mitchell, C.A. (2003) Skeletal muscle LIM protein 1 regulates integrin-mediated 
myoblast adhesion, spreading, and migration. Am J Physiol Cell Physiol, 284,
C681-95.
225. Yao, C.C., Ziober, B.L., Sutherland, A.E., Mendrick, D.L. and Kramer, R.H. 
(1996) Laminins promote the locomotion of skeletal myoblasts via the alpha 7 
integrin receptor. J Cell Sci, 109 ( Pt 13), 3139-50.
226. Ferguson, J.W., Thoma, B.S., Mikesh, M.F., Kramer, R.H., Bennett, K.L., 
Purchio, A., Bellard, B.J. and LeBaron, R.G. (2003) The extracellular matrix 
protein betaIG-H3 is expressed at myotendinous junctions and supports muscle 
cell adhesion. Cell Tissue Res, 313, 93-105.
227. Burkin, D.J., Gu, M., Hodges, B.L., Campanelli, J.T. and Kaufman, S.J. (1998) A 
functional role for specific spliced variants of the alpha7beta1 integrin in 
acetylcholine receptor clustering. J Cell Biol, 143, 1067-75.
228. Attwell, S., Mills, J., Troussard, A., Wu, C. and Dedhar, S. (2003) Integration of 
cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase 
(ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell, 14, 4813-25.
229. Persad, S., Attwell, S., Gray, V., Delcommenne, M., Troussard, A., Sanghera, J. 
and Dedhar, S. (2000) Inhibition of integrin-linked kinase (ILK) suppresses 
activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of 
PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A, 97, 3207-12.
230. Troussard, A.A., Mawji, N.M., Ong, C., Mui, A., St -Arnaud, R. and Dedhar, S. 
(2003) Conditional knock-out of integrin-linked kinase demonstrates an essential 
role in protein kinase B/Akt activation. J Biol Chem, 278, 22374-8.
231. Dias, P., Dilling, M. and Houghton, P. (1994) The molecular basis of skeletal 
muscle differentiation. Semin Diagn Pathol, 11, 3-14.
232. Falcone, G., Gauzzi, M.C., Tato, F. and Alema, S. (1990) Differential control of 
muscle-specific gene expression specified by src and myc oncogenes in myogenic 
cells. Ciba Found Symp, 150, 250-8; discussion 258-61.
233. Schneider, M.D. and Olson, E.N. (1988) Control of myogenic differentiation by 
cellular oncogenes. Mol Neurobiol, 2, 1-39.
234. Rosoff, W.J. and Swope, S.L. (2002) Role for cellular Src kinase in myoblast 
proliferation. J Cell Physiol, 193, 328-39.
235. Mohamed, A.S. and Swope, S.L. (1999) Phosphorylation and cytoskeletal 
anchoring of the acetylcholine receptor by Src class protein-tyrosine kinases. 
Activation by rapsyn. J Biol Chem, 274, 20529-39.
236. Mohamed, A.S., Rivas-Plata, K.A., Kraas, J.R., Saleh, S.M. and Swope, S.L. 
(2001) Src-class kinases act within the agrin/MuSK pathway to regulate 
acetylcholine receptor phosphorylation, cytoskeletal anchoring, and clustering. J 
Neurosci, 21, 3806-18.
237. Fuhrer, C. and Hall, Z.W. (1996) Functional interaction of Src family kinases 
with the acetylcholine receptor in C2 myotubes. J Biol Chem, 271, 32474-81.
238. Laprise, P., Poirier, E.M., Vezina, A., Rivard, N. and Vachon, P.H. (2002) 
Merosin-integrin promotion of skeletal myofiber cell survival: Differentiation 
state-distinct involvement of p60Fyn tyrosine kinase and p38alpha stress-
activated MAP kinase. J Cell Physiol, 191, 69-81.
146
239. Epting, C.L., Lopez, J.E., Shen, X., Liu, L., Bristow, J. and Bernstein, H.S. (2004) 
Stem cell antigen-1 is necessary for cell-cycle withdrawal and myoblast 
differentiation in C2C12 cells. J Cell Sci.
240. Wei, Q. and Paterson, B.M. (2001) Regulation of MyoD function in the dividing 
myoblast. FEBS Lett, 490, 171-8.
241. Shaknovich, R., Shue, G. and Kohtz, D.S. (1992) Conformational activation of a 
basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine 
HSP90 (HSP84). Mol Cell Biol, 12, 5059-68.
242. Shue, G. and Kohtz, D.S. (1994) Structural and functional aspects of basic helix-
loop-helix protein folding by heat-shock protein 90. J Biol Chem, 269, 2707-11.
243. Workman, P. (2004) Altered states: selectively drugging the Hsp90 cancer 
chaperone. Trends Mol Med, 10, 47-51.
244. Workman, P. (2003) Overview: translating Hsp90 biology into Hsp90 drugs. Curr 
Cancer Drug Targets, 3, 297-300.
245. Whitesell, L., Shifrin, S.D., Schwab, G. and Neckers, L.M. (1992) 
Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to 
src kinase inhibition. Cancer Res, 52, 1721-8.
246. Burrows, F., Zhang, H. and Kamal, A. (2004) Hsp90 Activation and Cell Cycle 
Regulation. Cell Cycle, 3.
247. van Wachem, P.B., van Luyn, M.J. and da Costa, M.L. (1996) Myoblast seeding 
in a collagen matrix evaluated in vitro. J Biomed Mater Res, 30, 353-60.
248. Schuhmeier, R.P., Dietze, B., Ursu, D., Lehmann-Horn, F. and Melzer, W. (2003) 
Voltage-activated calcium signals in myotubes loaded with high concentrations of 
EGTA. Biophys J, 84, 1065-78.
249. Sakagami, M., Morrison, P. and Welch, W.J. (1999) Benzoquinoid ansamycins 
(herbimycin A and geldanamycin) interfere with the maturation of growth factor 
receptor tyrosine kinases. Cell Stress Chaperones, 4, 19-28.
250. Lavictoire, S.J., Parolin, D.A., Klimowicz, A.C., Kelly, J.F. and Lorimer, I.A. 
(2003) Interaction of Hsp90 with the nascent form of the mutant epidermal 
growth factor receptor EGFRvIII. J Biol Chem, 278, 5292-9.
251. Tikhomirov, O. and Carpenter, G. (2000) Geldanamycin induces ErbB-2 
degradation by proteolytic fragmentation. J Biol Chem, 275, 26625-31.
252. Mimnaugh, E.G., Chavany, C. and Neckers, L. (1996) Polyubiquitination and 
proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase 
induced by geldanamycin. J Biol Chem, 271, 22796-801.
253. Yorgin, P.D., Hartson, S.D., Fellah, A.M., Scroggins, B.T., Matts, R.M. and 
Whitesell, L. (2000) Effects of geldanamycin, an hsp90-binding agent, on T-cell 
function and T-cell non-receptor protein tyrosine kinases. J. Immunol., 164, 2915-
2923.
254. Lele, Z., Hartson, S.D., Martin, C.C., Whitesell, L., Matts, R.L. and Krone, P.H. 
(1999) Disruption of zebrafish somite development by pharmacologic inhibition 
of Hsp90. Dev Biol, 210, 56-70.
255. Lebrasseur, N.K., Cote, G.M., Miller, T.A., Fielding, R.A. and Sawyer, D.B. 
(2003) Regulation of neuregulin/ErbB signaling by contractile activity in skeletal 
muscle. Am J Physiol Cell Physiol, 284, C1149-55.
147
256. Vlahos, C.J., McDowell, S.A. and Clerk, A. (2003) Kinases as therapeutic targets 
for heart failure. Nat Rev Drug Discov, 2, 99-113.
257. Gerthoffer, W.T. and Gunst, S.J. (2001) Invited review: focal adhesion and small 
heat shock proteins in the regulation of actin remodeling and contractility in 
smooth muscle. J Appl Physiol, 91, 963-72.
258. Iba, H., Takeya, T., Cross, F.R., Hanafusa, T. and Hanafusa, H. (1984) Rous 
sarcoma virus variants that carry the cellular src gene instead of the viral src gene 
cannot transform chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U. S.A., 81,
4424-4428.
259. Brugge, J.S. (1986) Interaction of the Rous sarcoma virus protein pp60src with the 
cellular proteins pp50 and pp90. Curr. Top. Microbiol. and Immunol., 123, 1-22.
260. Hutchison, K.A., Brott, B.K., De Leon, J.H., Perdew, G.H., Jove, R. and Pratt, 
W.B. (1992) Reconstitution of the multiprotein complex of pp60src, hsp90, and 
p50 in a cell-free system. J. Biol. Chem., 267, 2902-2908.
261. Xu, Y., Singer, M.A. and Lindquist, S. (1999) Maturation of the tyrosine kinase c-
src as a kinase and as a substrate depends on the molecular chaperone Hsp90. 
Proc. Natl. Acad. Sci. U.S.A., 96, 109-114.
262. Bijlmakers, M.J. and Marsh, M. (2000) Hsp90 is essential for the synthesis and 
subsequent membrane association, but not the maintenance, of the Src-kinase 
p56(lck). Mol Biol Cell, 11, 1585-95.
263. Miller, J.B. (1990) Myogenic programs of mouse muscle cell lines: expression of 
myosin heavy chain isoforms, MyoD1, and myogenin. J Cell Biol, 111, 1149-59.
264. Dedieu, S., Mazeres, G., Cottin, P. and Brustis, J.J. (2002) Involvement of 
myogenic regulator factors during fusion in the cell line C2C12. Int J Dev Biol,
46, 235-41.
265. Rao, J., Lee, P., Benzeno, S., Cardozo, C., Albertus, J., Robins, D.M. and Caplan, 
A.J. (2001) Functional interaction of human Cdc37 with the androgen receptor 
but not with the glucocorticoid receptor. J Biol Chem, 276, 5814-20.
266. Tintignac, L.A., Sirri, V., Leibovitch, M.P., Lecluse, Y., Castedo, M., Metivier, 
D., Kroemer, G. and Leibovitch, S.A. (2004) Mutant MyoD lacking Cdc2 
phosphorylation sites delays M-phase entry. Mol Cell Biol, 24, 1809-21.
267. Simone, C., Stiegler, P., Bagella, L., Pucci, B., Bellan, C., De Falco, G., De Luca, 
A., Guanti, G., Puri, P.L. and Giordano, A. (2002) Activation of MyoD-dependent 
transcription by cdk9/cyclin T2. Oncogene, 21, 4137-48.
268. Pelpel, K., Leibovitch, M., Fernandez, A. and Leibovitch, S.A. (2000) Mutation 
of MyoD-Ser237 abolishes its up-regulation by c-Mos. FEBS Lett, 474, 233-7.
269. Mitsui, K., Shirakata, M. and Paterson, B.M. (1993) Phosphorylation inhibits the 
DNA-binding activity of MyoD homodimers but not MyoD-E12 heterodimers. J 
Biol Chem, 268, 24415-20.
270. Johnson, S.E., Wang, X., Hardy, S., Taparowsky, E.J. and Konieczny, S.F. (1996) 
Casein kinase II increases the transcriptional activities of MRF4 and MyoD 
independently of their direct phosphorylation. Mol Cell Biol, 16, 1604-13.
271. Lenormand, J.L., Benayoun, B., Guillier, M., Vandromme, M., Leibovitch, M.P. 
and Leibovitch, S.A. (1997) Mos activates myogenic differentiation by promoting 
heterodimerization of MyoD and E12 proteins. Mol Cell Biol, 17, 584-93.
148
272. Shao, J., Prince, T., Hartson, S.D. and Matts, R.L. (2003) Phosphorylation of
serine-13 is required for the proper function of the Hsp90 Co-chaperone, Cdc37. J 
Biol Chem, 278, 38117-20.
273. Bandhakavi, S., McCann, R.O., Hanna, D.E. and Glover, C.V. (2003) A positive 
feedback loop between protein kinase CKII and Cdc37 promotes the activity of 
multiple protein kinases. J Biol Chem, 278, 2829-36.
274. Chen, J.J. and London, I.M. (1995) Regulation of protein synthesis by heme-
regulated eIF-2 alpha kinase. Trends Biochem Sci, 20, 105-8.
275. Dever, T.E. (1999) Translation initiation: adept at adapting. Trends Biochem Sci,
24, 398-403.
276. Chefalo, P.J., Oh, J., Rafie-Kolpin, M., Kan, B. and Chen, J.J. (1998) Heme-
regulated eIF-2alpha kinase purifies as a hemoprotein. Eur J Biochem, 258, 820-
30.
277. Rafie-Kolpin, M., Chefalo, P.J., Hussain, Z., Hahn, J., Uma, S., Matts, R.L. and 
Chen, J.J. (2000) Two heme-binding domains of heme-regulated eukaryotic 
initiation factor-2alpha kinase. N terminus and kinase insertion. J Biol Chem, 275,
5171-8.
278. Uma, S., Matts, R.L., Guo, Y., White, S. and Chen, J.J. (2000) The N-terminal 
region of the heme-regulated eIF2alpha kinase is an autonomous heme binding 
domain. Eur J Biochem, 267, 498-506.
279. Uma, S., Yun, B.G. and Matts, R.L. (2001) The heme-regulated eukaryotic 
initiation factor 2alpha kinase. A potential regulatory target for control of protein 
synthesis by diffusible gases. J Biol Chem, 276, 14875-83.
280. Ishikawa, H., Yun, B.G., Takahashi, S., Hori, H., Matts, R.L., Ishimori, K. and 
Morishima, I. (2002) NO-induced activation mechanism of the heme-regulated 
eIF2alpha kinase. J Am Chem Soc, 124, 13696-7.
281. Deinum, G., Stone, J.R., Babcock, G.T. and Marletta, M.A. (1996) Binding of 
nitric oxide and carbon monoxide to soluble guanylate cyclase as observed with 
Resonance raman spectroscopy. Biochemistry, 35, 1540-7.
282. Inuzuka, T., Yun, B.G., Ishikawa, H., Takahashi, S., Hori, H., Matts, R.L., 
Ishimori, K. and Morishima, I. (2004) Identification of crucial histidines for heme 
binding in the N-terminal domain of the heme-regulated eIF2alpha kinase. J Biol 
Chem, 279, 6778-82.
283. Igarashi, J., Sato, A., Kitagawa, T., Yoshimura, T., Yamauchi, S., Sagami, I. and 
Shimizu, T. (2004) Activation of heme-regulated eukaryotic initiation factor 
2alpha kinase by nitric oxide is induced by the formation of a five-coordinate NO-
heme complex: optical absorption, electron spin resonance, and resonance raman 
spectral studies. J Biol Chem, 279, 15752-62.
284. Mendez, R., Moreno, A. and de Haro, C. (1992) Regulation of heme-controlled 
eukaryotic polypeptide chain initiation factor 2 alpha-subunit kinase of 
reticulocyte lysates. J Biol Chem, 267, 11500-7.
285. Rafie-Kolpin, M., Han, A.P. and Chen, J.J. (2003) Autophosphorylation of 
threonine 485 in the activation loop is essential for attaining eIF2alpha kinase 
activity of HRI. Biochemistry, 42, 6536-44.
149
286. Fagard, R. and London, I.M. (1981) Relationship between phosphorylation and 
activity of heme-regulated eukaryotic initiation factor 2 alpha kinase. Proc Natl 
Acad Sci U S A, 78, 866-70.
287. Bauer, B.N., Rafie-Kolpin, M., Lu, L., Han, A. and Chen, J.J. (2001) Multiple 
autophosphorylation is essential for the formation of the active and stable 
homodimer of heme-regulated eIF2alpha kinase. Biochemistry, 40, 11543-51.
288. Yang, J.M., London, I.M. and Chen, J.J. (1992) Effects of hemin and porphyrin 
compounds on intersubunit disulfide formation of heme-regulated eIF-2 alpha 
kinase and the regulation of protein synthesis in reticulocyte lysates. J Biol Chem,
267, 20519-24.
289. Chen, J.J., Yang, J.M., Petryshyn, R., Kosower, N. and London, I.M. (1989) 




Candidate for the Degree Of 
Doctor of Philosophy
Thesis: STUDIES OF HSP90 FUNCTION ON SIGNAL TRANSDUCTION
            MOLECULES IN C2C12 CELLS AND EFFECTS OF NOVOBIOCIN ON
            HSP90 CONFORMATION AND FUNCTION AND MECHANISM OF
            REGULATION OF HEME-REGULATED eIF2α KINASE BY GAS
            MOLECULES
Major Field: Biochemistry and Molecular Biology
Biographical:
Personal Data: Born in Seoul, Korea, on December 9, 1970, the son of No-oak 
                                    Lee and Dong-Shik Yun.
Education: Graduated from Kangseo High School, Seoul, Korea in February
                  1989; received Bachelor of Science Degree in Biochemistry from
                              Kangwon National University, Kangwon-do, Korea in February 1994;
                              completed requirement for the Doctor of Philosophy Degree with a
                              major in Biochemistry and Molecular Biology at Oklahoma State 
                              University in December 2004.
Experience: Half-time Research Assistant, 1997-2004; Quarter-time Research
                    Assistant, Laboratory of Mass Spectrometry, 2002; Department of
                                Biochemistry and Molecular Biology, and Chemistry, Stillwater, OK.
Honors and Awards: Undergraduate scholarship, 1990, Kangwon National
                                            University; selected for talk presentation, Midwest Heat
          Shock Protein Meeting, 2004.
Name: BO-GEON YUN                             Date of Degree: December, 2004
Institution: Oklahoma State University                               Location: Stillwater, Oklahoma
Title of Study: STUDIES OF HSP90 FUNCTION ON SIGNAL TRANSDUCTION 
MOLECULES IN C2C12 CELLS AND EFFECTS OF NOVOBIOCIN 
ON HSP90 CONFORMATION AND FUNCTION AND MECHANISM 
OF REGULATION OF HEME-REGULATED eIF2α KINASE BY GAS 
MOLECULES
Pages in Study: 149                                Candidate for the Degree of Doctor of Philosophy
Major Field: Biochemistry and Molecular Biology
Scope and Method of Study: The purpose of this study was to investigate: the function of
Hsp90 on signal transduction pathways required for C2C12 myoblast differentiation; 
to characterize the effect of the Hsp90-inhibitor novobiocin on the structure and 
function of Hsp90; and to elucidate the mechanism of regulation of heme-regulated 
eIF2α kinase (HRI) by the gas molecules, nitric oxide (NO) and carbon monoxide 
(CO). Hsp90-dependent signaling pathways were examined in differentiating C2C12 
myoblasts, using the pharmacological agents geldanamycin, novobiocin, and okadaic 
acid, pulse-chase labeling, immunoadsorption of protein kinases, and western 
blotting. The mechanism of inhibition of Hsp90 by novobiocin was analyzed using 
pull-down assays and western blotting, proteolytic fingerprinting, and protein kinase 
assays. Regulation of HRI by NO and CO was studied using coupled 
transcription/translation of site-specific and deletion mutants of HRI in nuclease 
treated reticulocyte lysate, followed by pull-down and kinase assays to analyze 
interdomain interactions and the activity of HRI. 
Findings and Contributions: Inhibition of Hsp90 function induced apoptosis in
differentiating C2C12 myoblasts by depleting ErbB2, Akt(PKB) and Fyn kinases, 
which modulate signal transduction pathways critical for cell differentiation and 
survival, and blocking myogenin expression, which is required for transcriptional 
activation of muscle specific genes. Hsp90 modulated Akt activity via protein 
phosphatase 2A. Novobiocin bound to the C-terminal region of Hsp90, induced 
specific conformational changes in Hsp90’s structure, altered Hsp90’s interaction 
with its co-chaperone partners, and inhibited the maturation of HRI. These results 
verify that novobiocin is an Hsp90 inhibitor. The interaction of the N-terminal heme-
binding domain (NT-HBD) of HRI with the catalytic domain of HRI was disrupted by 
NO, but enhanced by CO or heme. A deletion mutant HRI was hyperactivated in 
heme-deficient lysate, identifying a region within the NT-HBD of HRI that is critical 
for the regulation of HRI activity and modulating inter-domain interactions. 
Adviser’s Approval: ______________________________________________________             
